IMMUNIZATION SUMMARY - UNICEF DATA · IMMUNIZATION SUMMARY A statistical reference containing data...

IMMUNIZATION SUMMARY

A statistical reference containingdata through 2009

(The 2011 Edition)CD-ROM

inside

Version en français sur CD-ROMVersión en español en CD-ROM

3878 UNI UNICEF BOOK_Layout 1 1/13/11 12:54 AM

IMMUNIZATION SUMMARY

A statistical reference containingdata through 2009

See inside back coverfor CD-ROM


Introduction .............................................................................................ivAnnual updates ......................................................................................vii

Indicative prices..................................................................................viiiTrends: Regional progress...................................................................xiMaps: Global indicators......................................................................xvNotes on indicators and data ............................................................xix

Countries and territories ....................................................................xxiii

Afghanistan ................1Albania ........................2Algeria.........................3Andorra.......................4Angola.........................5Antigua and

Barbuda ....................6Argentina ....................7Armenia ......................8Australia......................9Austria.......................10Azerbaijan.................11Bahamas ...................12Bahrain......................13Bangladesh...............14Barbados...................15Belarus ......................16Belgium.....................17Belize .........................18Benin .........................19Bhutan.......................20Bolivia .......................21Bosnia and

Herzegovina ...........22Botswana ..................23Brazil..........................24BruneiDarussalam...............25Bulgaria.....................26Burkina Faso.............27Burundi .....................28Cambodia..................29Cameroon .................30Canada ......................31Cape Verde................32Central African

Republic..................33Chad ..........................34Chile ..........................35China .........................36Colombia...................37Comoros ...................38Congo........................39Congo, Democratic

Republic of the .......40

Cook Islands .............41Costa Rica .................42Côte d’Ivoire .............43Croatia.......................44Cuba ..........................45Cyprus.......................46Czech Republic .........47Denmark....................48Djibouti......................49Dominica...................50Dominican

Republic..................51Ecuador .....................52Egypt .........................53El Salvador................54Equatorial

Guinea ....................55Eritrea........................56Estonia ......................57Ethiopia .....................58Fiji ..............................59Finland ......................60France........................61Gabon........................62Gambia......................63Georgia .....................64Germany ...................65Ghana........................66Greece.......................67Grenada ....................68Guatemala ................69Guinea.......................70Guinea-Bissau ..........71Guyana......................72Haiti ...........................73Honduras ..................74Hungary ....................75Iceland.......................76India...........................77Indonesia ..................78Iran (Islamic

Republic of) ............79Iraq ............................80Ireland .......................81Israel..........................82

Italy............................83Jamaica.....................84Japan.........................85Jordan.......................86Kazakhstan................87Kenya ........................88Kiribati.......................89Korea, Democratic

People’s Republicof .............................90

Korea,Republic of................91Kuwait .......................92Kyrgyzstan ................93Lao People’s

DemocraticRepublic..................94

Latvia.........................95Lebanon ....................96Lesotho .....................97Liberia .......................98Libyan Arab

Jamahiriya..............99Lithuania .................100Luxembourg ...........101Madagascar ............102Malawi.....................103Malaysia..................104Maldives..................105Mali..........................106Malta .......................107Marshall Islands .....108Mauritania...............109Mauritius.................110Mexico.....................111Micronesia (Federated

States of) ..............112Moldova..................113Monaco ...................114Mongolia.................115Montenegro............116Morocco..................117Mozambique...........118Myanmar.................119Namibia...................120

CONTENTS

ii


Nauru ......................121Nepal .......................122Netherlands ............123New Zealand...........124Nicaragua................125Niger........................126Nigeria.....................127Niue.........................128Norway....................129occupied Palestinian

territory.................130Oman.......................131Pakistan...................132Palau........................133Panama ...................134Papua New

Guinea ..................135Paraguay.................136Peru .........................137Philippines ..............138Poland .....................139Portugal...................140Qatar........................141Romania..................142Russian

Federation ............143Rwanda ...................144Saint Kitts

and Nevis..............145Saint Lucia ..............146

Saint Vincent and theGrenadines ...........147

Samoa.....................148San Marino .............149Sao Tome

and Principe .........150Saudi Arabia...........151Senegal ...................152Serbia ......................153Seychelles...............154Sierra Leone ...........155Singapore ...............156Slovakia...................157Slovenia ..................158Solomon Islands ....159Somalia ...................160South Africa............161Spain .......................162Sri Lanka .................163Sudan......................164Suriname ................165Swaziland................166Sweden ...................167Switzerland.............168Syrian Arab

Republic................169Tajikistan .................170Tanzania, UnitedRepublic of............171

Thailand ..................172

The formerYugoslav Republicof Macedonia .......173

Timor-Leste.............174Togo.........................175Tonga.......................176Trinidad andTobago ..................177

Tunisia.....................178Turkey......................179Turkmenistan..........180Tuvalu......................181Uganda....................182Ukraine....................183United Arab

Emirates................184United Kingdom.....185United States..........186Uruguay ..................187Uzbekistan ..............188Vanuatu ...................189Venezuela, Bolivarian

Republic of ...........190Viet Nam .................191Yemen .....................192Zambia ....................193Zimbabwe...............194

Glossary of acronyms..........................................................................195

iii


INTRODUCTION

Tracking, evaluating and sharing information providesa vital tool for understanding immunization coverage.Statistics on levels and trends are used to monitor theperformance of services at local, national andinternational levels. They guide campaigns to eradicatepolio, control measles and eliminate neonatal tetanus.They identify areas of weak system performance andreveal areas where focused attention and extraresources may be required. And, when decidingwhether to introduce a vaccine, immunization levelsand trends are one important consideration.

The numbers for a single vaccine can provide vitalinformation for national and global action. Coveragelevels for the diphtheria and tetanus toxoid withpertussis vaccine (DTP), for example, are considered tobe a good indicator of health system performance. Inaddition, some funding agencies, such as the GlobalAlliance for Vaccines and Immunization (GAVI), oftenconsider immunization coverage levels whenreviewing applications for financial and technicalsupport, although coverage estimates alone areinsufficient to constitute a sole criterion fordetermining whether a national immunizationprogramme has achieved certain performance levels.

This reference book, jointly produced by the UnitedNations Children’s Fund (UNICEF) and the WorldHealth Organization (WHO), presents detailed statisticson the performance of national and district-levelimmunization systems in 194 countries and territories.It provides an overview of key aspects, including:

• Basic indicators from WHO and UNICEF, the United Nations Population Division and the World Bank for each country or territory.

• Trends in national and territorial coverage for eight major antigens.

• District-level performance in achieving coverage with DTP and measles vaccines, maintaining

iv


supplies, and providing autodisable syringes to enhance safety during all routine immunizations.

• The most current immunization schedule reported by each country or territory.

A copy of the most recent data-collection form can befound on the CD-ROM on the inside back coverof this booklet. Further information and copies of theprint documents are available on the followingwebsites:

UNICEF: http://www.childinfo.org/immunization.html

WHO: http://www.who.int/immunization_monitoring/data/en/

v


ANNUAL UPDATES


Table 1: Indicative budget prices for major antigens, 2011The prices listed in the table below are subject to change. UNICEFSupply Division provides this information for preliminary budgetplanning only. Full names of these vaccines appear in the Glossaryof acronyms, p. 195.

viii

BCG BCG-20DT DT-10DTP DTP-10

DTP-20DTPHep DTP-HepB-10 GAVIDTPHepHib DTP-HepB-Hib-1 (Liquid) non-GAVI

DTP-HepB+Hib-2 (Liquid + Lyophilized) non-GAVIDTP-HepB-Hib-1 (Liquid) GAVIDTP-HepB-Hib-10 (Liquid) GAVIDTP-HepB+Hib-2 (Liquid + Lyophilized) GAVI

DTPHib DTP-Hib-10 (Liquid) GAVI/non-GAVIDTP+Hib-1 (Lyophilized) non-GAVIDTP+Hib-10 (Lyophilized) GAVIDTP+Hib-10 (Lyophilized) non-GAVI

HepB HepB-1HepB-2HepB-6HepB-10 HepB-1 adult (1 ml)HepB-10 adult (10 ml)

Hib Hib-1 (Liquid) non-GAVI*Hib-1 (Lyophilized)

Influenza Influenza-10MCV Mea-10MenAC Meningitis AC-10*MenACW Meningitis (ACW)-50*MMR MMR-1 (L-Zagreb strain)

MMR-1 (Urabe strain)MMR-5 (L-Zagreb strain)MMR-10 (Urabe & strain)MMR-10 (L-Zagreb strain)

MR MR-10OPV OPV-10**

OPV-20**bOPV bOPV-20**mOPV mOPV1-20**

mOPV3-20**Pneumococcal Pneumococcal-1*** GAVI (13-val)

Pneumococcal-2*** GAVI (10-val)Rotavirus RotavirusTd Td-10TT TT-10**

TT-20**Yellow fever YF-5

YF-10

*Subject to availability. **Indicative prices are based on weighted average prices. ***Vaccine prices to suppliers are initially US$7.00, however, AMC donors will pay a portionof the price so that countries pay in 2011 a maximum of US$3.50.

Vaccine(doses per vial)


ix

2.121.051.782.826.903.607.003.06

17.505.90

34.003.90

not applicable34.000.400.582.042.100.583.503.653.40

70.002.37

11.5063.001.853.004.50

16.309.305.341.732.592.632.272.503.507.00TBD0.960.770.953.309.80

Recommended budget price, 2011(US$ per vial) (US$ per dose)

0.1060.1050.1780.1410.6903.603.503.061.752.953.403.90

not applicable3.400.400.2900.340.210.580.353.653.407.000.2371.151.261.853.000.901.630.930.530.17340.12940.13160.11340.12523.503.50TBD0.0960.0770.04730.660.984


x

Table 2: Indicative budget prices for immunization devices, 2011

These prices are subject to change. UNICEF Supply Divisionprovides this information for preliminary budget planningonly.

Device (box of 100, unlessotherwise stated)

BCG autodisable syringe, 0.05 ml

BCG autodisable syringe, 0.1 ml

Autodisable syringe, 0.5 ml

Reconstitution syringe, 2 ml, withneedle

Re-use prevention feature syringe, 2 ml, with fixed needle

Reconstitution syringe, 5 ml, withneedle

Re-use prevention feature syringe, 5 ml, with fixed needle

Re-use prevention feature syringe with SIP, 5 ml, with fixed needle

Reconstitution syringe, 10 ml,with needle

Re-use prevention feature syringewith SIP, 10 ml, with fixed needle

Safety box, 5 litre (25 per box)

Recommended budget price, 2011 (US$ per box)

6.105.50

5.10

2.71

5.30

3.35

6.10

14.00

4.70

16.00

13.82


TRENDS: REGIONALPROGRESS TOWARDSMDG4, 1980 - 2009

Note: The list of countries and territories in MDG regions appears online at the United Nations Statistics Division website ‘MillenniumDevelopment Goals Indicators’ <http://mdgs.un.org/unsd/mdg/Host.aspx?Content=Data/regionalGroupings>


xii

MC

V c

ove

rag

e

09

08

07

06

05

04

03

02

01

00

99

98

97

96

95

94

93

92

91

90

89

88

87

86

85

84

83

82

81

80

Glo

bal

8282

8180

7876

7473

7271

7071

7173

7371

7069

6973

6862

5346

4741

3720

1916

MD

G r

egio

ns

Co

mm

on

wea

lth

of

Ind

epen

den

t S

tate

s95

9696

9797

9696

9596

9595

9392

8987

8286

8285

8585

8381

7995

9595

9595

95D

evel

op

ed r

egio

ns

9393

9392

9393

9291

9191

9090

9090

8886

8281

8182

8280

7474

7169

6558

5751

E

aste

rn A

sia

9494

9493

8787

8686

8584

8482

8284

8076

8287

9298

9594

7663

8782

761

11

Lati

n A

mer

ica

and

Car

ibb

ean

9394

9292

9393

9393

9392

9190

8984

8582

8283

8076

7066

6061

6052

4848

4942

No

rth

ern

Afr

ica

9492

9696

9594

9393

9493

9294

9292

8989

8887

8785

8583

7571

6738

3228

2222

Oce

ania

6158

6368

6663

6665

6166

6764

5639

5246

4173

7270

5852

4442

3626

84

54

So

uth

-Eas

tern

Asi

a88

8885

8584

8482

8080

8182

8282

8275

7675

7372

7063

5647

4126

158

20

0S

ou

ther

n A

sia

7576

7574

7065

6361

5856

5456

5865

7067

6155

4957

4635

2716

96

54

32

Su

b-S

ahar

an A

fric

a68

6767

6562

6158

5655

5551

5353

5354

5450

5053

5655

4843

3932

2621

1412

6W

este

rn A

sia

8283

8383

8281

7881

8584

8382

7876

7374

7475

7579

7572

6462

5546

4241

3019

UN

ICE

F re

gio

ns

Cen

tral

an

d E

aste

rn E

uro

pe

and

CIS

9696

9697

9592

9092

9493

9190

8985

8281

8281

7980

7979

7673

8484

8480

7873

Eas

t A

sia

and

Pac

ific

9191

9090

8586

8483

8383

8382

8283

7876

7983

8689

8582

6756

6860

531

11

Eas

tern

an

d S

ou

ther

n A

fric

a76

7575

7269

7068

6868

6564

6566

6764

6660

5859

6259

5452

4943

3934

2118

9In

du

stri

alis

ed C

ou

ntr

ies

9393

9393

9392

9291

9191

9090

9090

8886

8281

8284

8482

7575

7270

6661

6053

Lati

n A

mer

ica

and

th

e C

arib

bea

n93

9492

9293

9393

9393

9291

9089

8485

8282

8380

7670

6660

6160

5248

4849

42M

idd

le E

ast

and

No

rth

Afr

ica

8786

8787

8686

8584

8586

8485

8384

8180

8080

7980

7874

6158

5533

2930

2320

So

uth

Asi

a74

7574

7369

6461

5957

5452

5557

6469

6659

5347

5644

3325

146

53

10

0W

est

and

Cen

tral

Afr

ica

6058

5858

5652

4844

4345

4041

4040

4443

4141

4750

5043

3732

2415

99

84

WH

O r

egio

ns

Afr

ican

6967

6766

6362

5956

5656

5254

5454

5556

5251

5457

5650

4642

3526

2114

126

Am

eric

an93

9392

9293

9393

9293

9291

9190

8686

8483

8382

8076

7466

6968

6259

5959

51E

aste

rn M

edit

erra

nea

n82

8382

8281

7774

7474

7371

7169

6966

6867

6766

6765

6353

5047

3427

2317

15E

uro

pea

n94

9494

9493

9290

9192

9189

8888

8684

8383

8280

8078

7674

7074

7269

6562

56S

ou

th E

ast

Asi

an76

7675

7470

6665

6260

5857

5961

6972

6963

5651

5947

3426

166

31

00

0W

este

rn P

acif

ic93

9392

9287

8886

8686

8585

8483

8481

7780

8589

9490

8873

6178

7366

54

5

2009

2008

2007

2006

2005

2004

2003

2002

2001

2000

1999

1998

1997

1996

1995

1994

1993

1992

1991

1990

1989

1988

1987

1986

1985

1984

1983

1982

1981

1980


xiii

2009

2008

2007

2006

2005

2004

2003

2002

2001

2000

1999

1998

1997

1996

1995

1994

1993

1992

1991

1990

1989

1988

1987

1986

1985

1984

1983

1982

1981

1980

DT

P3

cove

rag

e

Glo

bal

8281

8180

7977

7574

7474

7372

7272

7373

7070

7175

6864

5552

4944

3825

2320

MD

G r

egio

ns

Co

mm

on

wea

lth

of

Ind

epen

den

t S

tate

s95

9595

9696

9594

9595

9595

9391

8985

8373

7979

6868

7275

7985

8989

9295

95D

evel

op

ed r

egio

ns

9595

9595

9696

9595

9493

9492

9194

9191

8788

8787

8887

8785

7978

7271

6959

Eas

tern

Asi

a97

9793

9387

8786

8686

8584

8383

8380

8588

9194

9695

9475

7878

7358

33

1La

tin

Am

eric

a an

d C

arib

bea

n92

9193

9392

9292

9190

9089

8683

8283

8078

7778

6864

6259

5656

5649

4742

37N

ort

her

n A

fric

a97

9797

9796

9594

9496

9593

9190

9189

8685

8481

8788

8682

7573

5043

3730

29O

cean

ia59

5865

6666

6772

6661

6566

6553

6367

6765

6573

7361

5854

4946

4236

3537

37S

ou

th-E

aste

rn A

sia

8886

8482

8282

8276

7980

7981

8179

7776

7473

7575

7061

5449

3825

2118

1816

So

uth

ern

Asi

a73

7273

7373

6966

6464

6463

6464

6569

6560

5759

6850

4031

2320

1714

127

7S

ub

-Sah

aran

Afr

ica

7069

6967

6562

5856

5554

5251

4850

5253

4848

4856

5044

4034

2924

1812

115

Wes

tern

Asi

a83

8383

8181

8073

7883

8280

8178

7674

7978

7876

8682

7773

6256

5141

4141

29U

NIC

EF

reg

ion

sC

entr

al a

nd

Eas

tern

Eu

rop

e an

d C

IS95

9596

9495

9288

9193

9391

9088

8582

8575

8075

7069

7375

7076

7575

7780

75E

ast

Asi

a an

d P

acif

ic93

9389

8985

8584

8283

8382

8282

8179

8283

8587

9087

8468

6965

5746

88

6E

aste

rn a

nd

So

uth

ern

Afr

ica

7777

7775

7473

7069

6966

6565

6666

6766

6157

5863

5653

5245

4138

3218

1810

Ind

ust

rial

ised

Co

un

trie

s95

9595

9596

9696

9594

9394

9291

9491

9187

8889

8990

8989

8880

8276

7573

63La

tin

Am

eric

a an

d t

he

Car

ibb

ean

9291

9393

9292

9291

9090

8986

8382

8380

7877

7868

6462

5956

5656

4947

4237

Mid

dle

Eas

t an

d N

ort

h A

fric

a89

8989

8887

8685

8487

8684

8382

8381

7881

8079

8582

7766

6357

4133

3225

24S

ou

th A

sia

7271

7272

7268

6562

6362

6262

6264

6864

5955

5767

4938

2921

1816

1311

65

Wes

t an

d C

entr

al A

fric

a63

6161

5855

5146

4240

4340

3832

3438

4236

4037

4942

3631

2520

137

65

1W

HO

reg

ion

sA

fric

an71

7070

6765

6359

5655

5553

5250

5154

5550

5049

5751

4643

3732

2418

1211

5A

mer

ican

9292

9493

9393

9392

9191

9188

8685

8684

8179

8074

7272

6965

6465

6057

5450

Eas

tern

Med

iter

ran

ean

8582

8584

8377

7676

7673

7269

6866

6960

6264

6571

6562

5451

4636

2824

1918

Eu

rop

ean

9695

9695

9594

9193

9493

9392

9189

8688

8185

8278

7778

7978

7676

7272

7364

So

uth

Eas

t A

sian

7372

7271

7270

6764

6566

6566

6769

7170

6460

6170

5341

3324

2016

1412

77

Wes

tern

Pac

ific

9595

9292

8888

8785

8685

8483

8383

8084

8688

9294

9290

7274

7367

5512

119


MAPS: GLOBAL INDICATORS


Map

1: I

mm

uniz

atio

n co

vera

ge w

ith m

easl

es-c

onta

inin

g va

ccin

es in

infa

nts,

200

9

Th

e b

ou

nd

arie

s an

d n

ames

sh

ow

n a

nd

th

e d

esig

nat

ion

s u

sed

on

th

is m

ap d

o n

ot

imp

ly t

he

exp

ress

ion

of

any

op

inio

nw

hat

soev

er o

n t

he

par

t o

f U

NIC

EF

con

cern

ing

th

e le

gal

sta

tus

of

any

cou

ntr

y, t

erri

tory

, cit

y o

r ar

ea o

r o

f it

s au

tho

riti

es,

or

con

cern

ing

th

e d

elim

itat

ion

of

its

fro

nti

ers

or

bo

un

dar

ies.

Do

tted

lin

es o

n m

aps

rep

rese

nt

app

roxi

mat

e b

ord

er li

nes

for

wh

ich

th

ere

may

no

t ye

t b

e fu

ll ag

reem

ent.

<50%

(4 c

ou

ntr

ies

or

2%)

50-7

9% (4

5 co

un

trie

s o

r 23

%)

80-8

9%(2

9 co

un

trie

s o

r 15

%)

≥90%

(115

co

un

trie

s o

r 60

%)

So

urc

e: W

HO

/UN

ICE

F co

vera

ge

esti

mat

es, 1

980-

2009

, Ju

ly 2

010

xvi

rev3878 UNI UNICEF BOOK_Layout 1 1/20/11 1:31 AM

Map

2: D

evel

opin

g an

d tr

ansi

tion

coun

trie

s an

d te

rrito

ries

* w

ith a

ll di

stri

cts

achi

evin

g at

leas

t 80%

DTP

3co

vera

ge, 2

009

Th

e b

ou

nd

arie

s an

d n

ames

sh

ow

n a

nd

th

e d

esig

nat

ion

s u

sed

on

th

is m

ap d

o n

ot

imp

ly t

he

exp

ress

ion

of

any

op

inio

nw

hat

soev

er o

n t

he

par

t o

f U

NIC

EF

con

cern

ing

th

e le

gal

sta

tus

of

any

cou

ntr

y, t

erri

tory

, cit

y o

r ar

ea o

r o

f it

s au

tho

riti

es,

or

con

cern

ing

th

e d

elim

itat

ion

of

its

fro

nti

ers

or

bo

un

dar

ies.

Do

tted

lin

es o

n m

aps

rep

rese

nt

app

roxi

mat

e b

ord

er li

nes

for

wh

ich

th

ere

may

no

t ye

t b

e fu

ll ag

reem

ent.

Yes

(45

cou

ntr

ies

or

29%

)

No

(91

cou

ntr

ies

or

59%

)

No

dat

a(1

9 co

un

trie

s o

r 12

%)

(DT

P3

esti

mat

ed c

ove

rag

e fo

r 20

0915

co

un

trie

s ≥9

0%: 4

co

un

trie

s <9

0)

No

t ap

plic

able

(38

cou

ntr

ies)

So

urc

e: W

HO

/UN

ICE

F co

vera

ge

esti

mat

es, 1

980-

2009

, Ju

ly 2

010

* 15

5 d

evel

op

ing

co

un

trie

s an

d e

con

om

ies

in t

ran

siti

on

per

UN

Wo

rld

Eco

no

mic

& S

oci

al S

urv

ey, 2

008

clas

sifi

cati

on

xvii


NOTES ON INDICATORS AND DATA


xx

Basic indicators

Births – The number of children born each year.

Surviving infants – The number of children who have survived beyondtheir first year of life.

For both births and surviving infants, figures are rounded to the nearestthousand. Where populations are small and birth rates are low, the figureshown is ‘0’. In countries or territories where the numbers of births andsurviving infants are very close, rounding to the nearest thousand maycause the figures to appear equal. In places where the birth rate isdeclining, it is possible for the number of surviving infants to exceedbirths because the former were born in the previous year.

Infant mortality rate – The probability of dying between birth and exactlyone year of age. The infant mortality rate is expressed as the number ofinfant deaths per 1,000 live births.

Under-five mortality rate – The probability of dying between birth andexactly five years of age. The under-five mortality rate is expressed as thenumber of deaths of children under age five per 1,000 live births.

Gross national income per capita (PPP, US$) – Gross national income(GNI) is the sum of value added by all resident producers, plus anyproduct taxes (less subsidies) not included in the valuation of output, plusnet receipts of primary income (compensation of employees and propertyincome) from abroad. GNI per capita is gross national income divided bymid-year population. GNI per capita in US dollars is converted using theWorld Bank Atlas method. Purchasing power parity (PPP) is a criterion foran appropriate exchange rate between currencies. It indicates that arepresentative basket of goods in one country would cost the same as inanother country if the currencies are exchanged at that rate. Actualexchange rates vary from the PPP levels for such reasons as the demandfor imports or investments between countries.

Percentage of routine EPI vaccines financed by government – Theimmunizations in the Expanded Programme on Immunization (EPI)include those against tuberculosis, diphtheria, tetanus and pertussis(DTP), polio and measles, as well as protecting newborn children andtheir mothers against tetanus by vaccination of pregnant women. In somecountries, other vaccines (e.g., against hepatitis B, Haemophilusinfluenzae type B or yellow fever) may be included. UNICEF and WHO conduct an annual review of national or territorialimmunization reports to determine the most accurate levels of coverage.

The resulting estimates are based on reported (administrative) data,household surveys and government estimates as reported annually in theWHO/UNICEF Joint Reporting Form on Immunization, as well as datafrom the scientific and technical literature. As an essential part of thisreview, UNICEF and WHO consult and collaborate with national andterritorial authorities. Prior to public release, the draft estimates are sentto the authorities of each country or territory for their review andsubsequent revisions as necessary. The vaccines included in this sectionare:

National coverage rates (WHO/UNICEF estimates)


xxi

District coverage (as reported)

BCG – bacille Calmette-Guérin (vaccine against tuberculosis)DTP1 – first dose of diphtheria and tetanus toxoid with pertussis vaccineDTP3 – third dose of diphtheria and tetanus toxoid with pertussis vaccineHepB3 – third dose of hepatitis B vaccineHib3 – third dose of Haemophilus influenzae type B vaccineMCV – measles-containing vaccinePol3 – third dose of polio vaccinePAB – protection at birth against tetanus

Coverage for DTP1 should be at least as high as DTP3. Cases where DTP1coverage is less than DTP3 coverage reflect deficiencies in data collectionand reporting. UNICEF and WHO are working with national systems toeliminate these discrepancies. Because DTP and Hib vaccines aredispensed on the same schedule, the coverage levels for DTP3 and Hib3should be similar. More information on the estimation method can befound on the following websites:UNICEF: http://www.childinfo.org/immunization.htmlWHO: http://www.who.int/immunization_monitoring/routine/immunization_coverage/en/index4.html

The disaggregation of immunization statistics to the district level assistsefforts to ensure an equitable distribution of immunization for allchildren. The data shown in this section reflect reported (administrative)coverage levels and give an indication of district-level performance. Thedata are reported through the annual WHO/UNICEF Joint Reporting Formon Immunization.

Number of districts in country – The total number of districts in acountry or territory; this figure may vary from year to year.

Percentage of districts reporting – The proportion of districts thatreport data through the annual WHO/UNICEF Joint Reporting Form onImmunization.

DTP3 – The proportion of districts achieving each of three coverageranges for DTP3. In some cases, not all districts are able to reportcoverage levels; consequently, the sum of the three categories may notbe 100 per cent.

MCV – The proportion of districts achieving coverage of 90 per cent orhigher for measles-containing vaccine.

DTP1-DTP3 drop-out rate – The percentage of children who do notreceive all three doses of DTP after receiving an initial dose, comparedwith all children who receive the initial dose of DTP. When a givendistrict’s drop-out rate is less than 10 per cent, children who receive aninitial DTP dose are highly likely to receive all three required doses,indicating a high level of health-care assistance and performance. Thekey indicator given in this reference is the proportion of districtscategorized as high-performing, i.e., those with drop-out rates of lessthan 10 per cent.


Measures such as introducing two rather than one dose of the measlesvaccine into the national immunization schedule and conductingsupplementary immunization activities to fill in the gaps in routinevaccination delivery systems are necessary to prevent measles outbreaks.This section presents data on:

MCV2 routine coverage in 2009: the level of coverage by the seconddose of the measles-containing vaccine, as reported in the annualWHO/UNICEF Joint Reporting Form on Immunization.

Most recent national measles campaign: the year, target age group andcoverage level of the most recent national measles campaign (as opposedto a rollover campaign, implemented in several subnational stages over aperiod of time).

Updated immunization schedules are submitted through the annualWHO/UNICEF Joint Reporting Form on Immunization. The notations usedin each table may vary slightly because there is no standard format forreporting immunization schedules.

Note: In all instances, an ellipsis indicates that data are not available.

DATA SOURCES

• Births, surviving infants, total population: United Nations Population Division.

• Infant mortality rate, under-five mortality rate: The State of the World’s Children 2010, UNICEF, New York, 2009.

• Gross national income per capita: The World Bank.

• National coverage: WHO/UNICEF Review of National Immunization Coverage 1980-2009, July 2010.

• Percentage of routine EPI vaccines financed by government, district coverage, measles control activities and immunization schedules: WHO/UNICEF Joint Reporting Form on Immunization, data collected in 2010.

Measles control activities (as reported)

Immunization schedule

xxii


COUNTRIES ANDTERRITORIES


National coverage rates (WHO/UNICEF estimates, 2009)

District coverage rates (as reported)


2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980BCG 82% 85% 77% 77% 73% 38% 31% 30% 17% ...DTP1 94% 96% 93% 90% 88% 41% 44% 50% 37% 22%

DTP3 83% 85% 83% 77% 76% 31% 20% 25% 15% 4%

HepB3 83% 85% 83% … … … … … … …

Hib3 83% … … … … … … … … …

MCV 76% 75% 70% 68% 64% 35% 41% 20% 14% 11%

Pol3 83% 85% 83% 77% 76% 32% 20% 25% 15% 3%

PAB 89% 83% 84% 95% 96% 32% 13% 13% 13% 1%

Afghanistan

Births........................................................................................................ 1,302,000Surviving infants..................................................................................... 1,101,000Total population ...................................................................................... 28,150,000Infant mortality rate (per 1,000 live births) ........................................... 134Under-five mortality rate (per 1,000 live births) ................................... 199Gross national income per capita (PPP, US$)....................................... 1,110Percentage of routine EPI vaccines financed by government ............ 2%

2009 2008Number of districts in country 329 329Percentage of districts reporting 97% 97%

below 50% 12% 9%DTP3: proportion of districts with coverage between 50-79% 29% 30%

at 80% or above 56% 58%

MCV: proportion of districts with coverage at 90% or above 26% 26%

DTP1–DTP3 drop-out rate: proportion of districts thathave achieved a rate of less than 10% 54% 52%

MCV2 routine coverage in 2009 40%year 2009

Most recent national measles campaign target age group 9-36 mcoverage 110%

BCG birth

DtwPHep 6, 10, 14 weeks

Measles 9, 18 months

OPV birth; 6, 10, 14 weeks; 9

months

TT 1st contact; +1, +6 months; +1, +1 year

Measles control activies (as reported)

1


2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 97% 99% 98% 97% 98% 93% 97% 94% 92% 93%

DTP1 99% 99% 98% 98% 99% 98% 98% 97% 98% 97%

DTP3 98% 99% 98% 97% 98% 97% 97% 94% 96% 94%

HepB3 98% 99% 98% 98% 98% 96% 88% … … …

Hib3 98% … … … … … … … … …

MCV 97% 98% 97% 95% 97% 95% 91% 88% 96% 90%

Pol3 98% 99% 99% 97% 97% 97% 98% 89% 94% 92%

PAB 87% 87% 87% 87% 86% 86% 90% 30% … …

Births........................................................................................................ 47,000Surviving infants..................................................................................... 46,000Total population ...................................................................................... 3,155,000Infant mortality rate (per 1,000 live births) ........................................... 14Under-five mortality rate (per 1,000 live births) ................................... 15Gross national income per capita (PPP, US$)....................................... 8,170Percentage of routine EPI vaccines financed by government ............ 100%


below 50% 0% ...DTP3: proportion of districts with coverage between 50-79% 0% ...

at 80% or above 100% 100%


DTP1–DTP3 drop-out rate: proportion of districts thathave achieved a rate of less than 10% 94% ...


Most recent national measles campaign target age group 12 m-14 ycoverage 99%

BCG birth

DT 6 years

DTwP 2 years

DTwPHibHepB 2, 4, 6 months

HepB birth

MMR 1, 5 years

OPV 2, 4, 6 months; 2, 6 years

Td 14 years

TT 1st contact; +1 month

2009





Albania

2


2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 98% 97% 93% 99% 86% …

DTP1 97% 97% 98% 98% 94% 92% 96% 96% 88% …

DTP3 93% 93% 95% 95% 88% 86% 88% 89% 69% …

HepB3 91% 91% 90% 80% 83% … … … … …

Hib3 93% 93% … … … … … … … …

MCV 88% 88% 92% 91% 83% 80% 89% 83% 68% …

Pol3 92% 92% 95% 95% 88% 86% 88% 89% 69% …

PAB 71% 71% 70% 70% 69% 64% 44% 75% … …

Births........................................................................................................ 723,000Surviving infants..................................................................................... 702,000Total population ...................................................................................... 34,895,000 Infant mortality rate (per 1,000 live births) ........................................... 29 Under-five mortality rate (per 1,000 live births) ................................... 32 Gross national income per capita (PPP, US$)....................................... 8,130 Percentage of routine EPI vaccines financed by government ............ 100%


below 50% … 0%DTP3: proportion of districts with coverage between 50-79% … 0%

at 80% or above … …

MCV: proportion of districts with coverage at 90% or above … …DTP1–DTP3 drop-out rate: proportion of districts thathave achieved a rate of less than 10% … 100%

MCV2 routine coverage in 2009 …year 2007

Most recent national measles campaign target age group unkowncoverage 91%

BCG birth

DT 6 years

DTwPHib 3, 4, 5, 18 months

HepB birth; 1, 5 months

Measles 9 months; 6 years

OPV birth; 3, 4, 5, 18 months; 6,12, 16 years

TD 12, 16 years; +every 10 years

2009





Algeria

3


2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … …

DTP1 98% 98% 98% 97% 98% 98% … … … …

DTP3 99% 99% 96% 93% 98% 98% … … … …

HepB3 96% 94% 91% 84% 79% 84% … … … …

Hib3 97% 98% 95% 93% 97% 90% … … … …

MCV 98% 98% 94% 91% 94% 97% … … … …

Pol3 99% 99% 96% 93% 98% 95% … … … …

PAB … … … … … … … … … …

Births........................................................................................................ …Surviving infants..................................................................................... …Total population ...................................................................................... 86,000 Infant mortality rate (per 1,000 live births) ........................................... 3 Under-five mortality rate (per 1,000 live births) ................................... 4 Gross national income per capita (PPP, US$)....................................... …Percentage of routine EPI vaccines financed by government ............ 100%

2009 2008Number of districts in country 1 1Percentage of districts reporting … …

below 50% … …DTP3: proportion of districts with coverage between 50-79% … …


MCV: proportion of districts with coverage at 90% or above … …

DTP1–DTP3 drop-out rate: proportion of districts thathave achieved a rate of less than 10% … …

MCV2 routine coverage in 2009 …year …

Most recent national measles campaign target age group …coverage …

DTaP 5, 15 years

DTaPHibHepIPV 2, 6 months

DTaPHibIPV 4, 18 months

HepB birth

MenC_conj 2, 4, 18 months

MMR 15 months; 5 years

Pneumo_conj 3, 5, 7, 15 months

2009





Andorra

4


2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 83% 87% 88% 65% 61% 56% 60% 48% 28% …

DTP1 93% 99% 83% 66% 62% 44% 48% 48% 28% …

DTP3 73% 81% 83% 44% 47% 31% 24% 24% 8% …

HepB3 73% 81% 83% … … … … … … …

Hib3 73% 81% 83% … … … … … … …

MCV 77% 79% 88% 48% 45% 41% 46% 38% 44% …

Pol3 73% 75% 83% 44% 46% 33% 28% 23% 13% …

PAB 88% 79% 78% 77% 75% 60% 48% 34% 19% …

Births........................................................................................................ 784,000Surviving infants..................................................................................... 695,000Total population ...................................................................................... 18,498,000 Infant mortality rate (per 1,000 live births) ........................................... 98 Under-five mortality rate (per 1,000 live births) ................................... 161 Gross national income per capita (PPP, US$)....................................... 4,970 Percentage of routine EPI vaccines financed by government ............ 100%



at 80% or above 40% 46%

MCV: proportion of districts with coverage at 90% or above 34% 35%DTP1–DTP3 drop-out rate: proportion of districts thathave achieved a rate of less than 10% 28% 29%



BCG birth

DTwPHibHep 2, 4, 6 months

Measles 9 months

OPV birth; 2, 4, 6 months

TT 1st contact pregnancy; +1, +6 months; +1, +1 year

Vitamin A 6, 9 months

Yellow fever 9 months; travellers

2009





Angola

5


2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … …

DTP1 99% 99% 99% 99% 99% 99% 99% 99% 99% 77%

DTP3 99% 99% 99% 99% 99% 95% 99% 99% 99% 54%

HepB3 98% 98% 97% 99% 99% … … … … …

Hib3 99% 99% 99% 99% 99% … … … … …

MCV 99% 99% 99% 99% 99% 95% 93% 89% 69% …

Pol3 98% 99% 98% 99% 98% 96% 99% 99% 99% 36%

PAB … … … … … … … … … …

Births........................................................................................................ …Surviving infants..................................................................................... …Total population ...................................................................................... 88,000 Infant mortality rate (per 1,000 live births) ........................................... 11 Under-five mortality rate (per 1,000 live births) ................................... 12 Gross national income per capita (PPP, US$)....................................... 17,690 Percentage of routine EPI vaccines financed by government ............ 100%

2009 2008Number of districts in country … 27Percentage of districts reporting … …





MCV2 routine coverage in 2009 91%year …


DT 5 years

DTwP 18 months


HepB 1st dose; +1,

+5 months (adults)

Influenza 6-35 months

MMR 1, 5 years

OPV 2, 4, 6, 18 months; 5 years

Td 15 years

Yellow fever travellers

2009





Antigua and Barbuda

6


2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 99% 99% 99% 99% 90% 62%

DTP1 95% 97% 98% 97% 97% 96% 95% 95% 86% 69%

DTP3 94% 92% 96% 94% 94% 83% 85% 87% 66% 44%

HepB3 90% 89% 92% 90% 85% … … … … …

Hib3 90% 92% 96% 94% 94% 83% … … … …

MCV 99% 97% 98% 97% 99% 91% 99% 93% 54% 61%

Pol3 95% 94% 94% 94% 95% 88% 90% 90% 73% 33%

PAB … … … … … … … … … …

Births........................................................................................................ 691,000Surviving infants..................................................................................... 682,000 Total population ...................................................................................... 40,276,000Infant mortality rate (per 1,000 live births) ........................................... 13Under-five mortality rate (per 1,000 live births) ................................... 14Gross national income per capita (PPP, US$)....................................... 14,120Percentage of routine EPI vaccines financed by government ............ …

2009 2008Number of districts in country 511 547Percentage of districts reporting 99% …

below 50% 7% …DTP3: proportion of districts with coverage between 50-79% 23% …

at 80% or above 70% …

MCV: proportion of districts with coverage at 90% or above 64% …DTP1–DTP3 drop-out rate: proportion of districts thathave achieved a rate of less than 10% … …


Most recent national measles campaign target age group 19-36 ycoverage 77%

BCG birthDTwP 6 yearsDTwPHib 18 monthsHepA 1 yearHepB birth; 11 years (catch up);

high-risk groupsHib high-risk groupsInfluenza high-risk groupsIPV high-risk groupsMenAC (if indicated)MenBC (if indicated)

MenC_conj (if indicated)MMR 1, 6 years or 11 years (catch up)MR post-partum; post-abortus OPV 2, 4, 6, 18 months; 6 yearsPneumo_conj high-risk groupsPneumo_ps high-risk groupsRabies post-exposureTd 16 years; +every 10 yearsYellow fever 1 year (high-risk areas);

travellers

2009





Argentina

7


2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 98% 94% 91% 94% 97% 84% … … …

DTP1 97% 96% 96% 96% 96% 96% 98% … … …

DTP3 93% 89% 88% 87% 90% 93% 98% … … …

HepB3 93% 89% 85% 78% 91% 55% … … … …

Hib3 … … … … … … … … … …

MCV 96% 94% 93% 92% 94% 92% 96% … … …

Pol3 94% 91% 90% 87% 92% 96% 93% … … …

PAB … … … … … … … … … …

Births........................................................................................................ 48,000 Surviving infants..................................................................................... 46,000Total population ...................................................................................... 3,083,000Infant mortality rate (per 1,000 live births) ........................................... 20Under-five mortality rate (per 1,000 live births) ................................... 22Gross national income per capita (PPP, US$)....................................... 5,420 Percentage of routine EPI vaccines financed by government ............ 60%



at 80% or above 98% 94%





BCG birth

DTwP 18 months

DTwPHibHep 1.5, 2.5, 3.5 months

HepB birth

MMR 1, 6 years

OPV 1.5, 2.5, 3.5, 18 months;

6 years

Td 6, 16, 26, 36, 46, 56 years

2009





Armenia

8


2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … …

DTP1 97% 97% 97% 97% 97% 96% 95% 98% 87% 58%

DTP3 92% 92% 92% 92% 92% 90% 86% 95% 68% 33%

HepB3 92% 94% 94% 95% 95% … … … … …

Hib3 92% 94% 94% 95% 94% 90% … … … …

MCV 94% 94% 94% 94% 94% 91% 87% 86% 68% …

Pol3 92% 92% 92% 92% 92% 90% 86% 72% 94% 17%

PAB … … … … … … … … … …

Births........................................................................................................ 270,000Surviving infants..................................................................................... 268,000 Total population ...................................................................................... 21,293,000Infant mortality rate (per 1,000 live births) ........................................... 4Under-five mortality rate (per 1,000 live births) ................................... 5Gross national income per capita (PPP, US$)....................................... 38,210 Percentage of routine EPI vaccines financed by government ............ 100%



at 80% or above 100% 100%

MCV: proportion of districts with coverage at 90% or above 100% 100%DTP1–DTP3 drop-out rate: proportion of districts thathave achieved a rate of less than 10% … …



DTaP 15-17 yearsDTaPHepIPV 2, 4, 6 months

(subnational)DTaPHibHepIPV 2, 4, 6 monthsDTaPIPV 4 yearsHepA 12-24, 18-24 months

(subnational)HepB birth; 2, 4, 6, 12 months;

10-13 years (subnational)Hib 2, 4, 6, 12 months

(subnational)HibHepB 2, 4, 12 months

(subnational)

HPV 12-13 years (females)Influenza ≥65 years (subnational);

high-risk groupsMenC_conj 1 year (subnational)MMR 1, 4 yearsPneumo_conj 2, 4, 6 monthsPneumo_ps 18-24 months; 15-49 years;

≥50 years (subnational)Rotavirus 2, 4, 6 months (subnational)Varicella 18 months; 10-13 years

(subnational)

2009





Australia

9


2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … 90% 90%

DTP1 97% 97% 99% 99% 99% 99% 96% 96% 96% 96%

DTP3 83% 83% 85% 83% 86% 81% 90% 90% 90% 90%

HepB3 83% 83% 85% 83% 86% 33% … … … …

Hib3 83% 83% 85% 83% 86% 72% … … … …

MCV 83% 83% 79% 80% 75% 75% 60% 60% 40% …

Pol3 83% 83% 85% 83% 86% 71% 90% 90% 90% 90%

PAB … … … … … … … … … …

Births........................................................................................................ 76,000Surviving infants..................................................................................... 75,000 Total population ...................................................................................... 8,364,000 Infant mortality rate (per 1,000 live births) ........................................... 3Under-five mortality rate (per 1,000 live births) ................................... 4Gross national income per capita (PPP, US$)....................................... 38,550 Percentage of routine EPI vaccines financed by government ............ …

2009 2008Number of districts in country 121 121Percentage of districts reporting … 0%







DTaPHibHepIPV birth-1 year (3 doses);1-2 years

HepB 12-13 years; school students(booster or catch up)

HPV 9 years (females, 3 doses,private sector)

MMR 1-2 years (2 doses)(catch up at any age)

Pneumo_conj birth-1 year (3 doses);1-2years (high-risk groups)

Rotavirus 7 weeks-6 months (2 or 3doses depending on vaccine)

2009





Austria

10


2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 81% 81% 81% 82% 81% 81% 76% … … …

DTP1 79% 80% 80% 80% 78% 82% 79% … … …

DTP3 73% 74% 74% 74% 72% 75% 74% … … …

HepB3 46% 46% 46% 42% 45% … … … … …

Hib3 … … … … … … … … … …

MCV 67% 66% 66% 65% 67% 67% 64% … … …

Pol3 79% 79% 79% 79% 79% 76% 71% … … …

PAB … … … … … … … … … …

Births........................................................................................................ 169,000 Surviving infants..................................................................................... 162,000 Total population ...................................................................................... 8,832,000 Infant mortality rate (per 1,000 live births) ........................................... 30 Under-five mortality rate (per 1,000 live births) ................................... 34 Gross national income per capita (PPP, US$)....................................... 9,030 Percentage of routine EPI vaccines financed by government ............ 100%



at 80% or above 100% 97%

MCV: proportion of districts with coverage at 90% or above 100% 92%DTP1–DTP3 drop-out rate: proportion of districts thathave achieved a rate of less than 10% 100% …



BCG 4-7 days

DT 5 years

DTwP 2, 3, 4, 18 months


MMR 1, 6 years

OPV 4-7 days; 2, 3, 4, 18 months

Vitamin A 12, 18 months; 6 years

2009





Azerbaijan

11


12

Bahamas





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … …

DTP1 98% 95% 98% 98% 95% 98% 95% 95% 95% 61%

DTP3 96% 93% 95% 95% 93% 99% 87% 86% 86% 36%

HepB3 95% 90% 93% 96% 93% … … … … …

Hib3 96% 94% 95% 95% 93% 90% … … … …

MCV 98% 90% 96% 88% 85% 93% 90% 86% 79% …

Pol3 97% 93% 95% 94% 93% 91% 86% 82% 84% 35%

PAB 90% 90% 90% 92% 90% 85% 79% 71% … …

Births........................................................................................................ 6,000 Surviving infants..................................................................................... 6,000 Total population ...................................................................................... 342,000 Infant mortality rate (per 1,000 live births) ........................................... 9Under-five mortality rate (per 1,000 live births) ................................... 12Gross national income per capita (PPP, US$)....................................... …Percentage of routine EPI vaccines financed by government ............ 100%



at 80% or above 0% …

MCV: proportion of districts with coverage at 90% or above 0% …




DT 4-5 years

DTaPHepBIPV 2, 4, 6 months(subnational)

DTaPHibHepIPV 2, 4, 6 months (subnational)

DTaPHibIPV 2, 4, 6 months (subnational)

DTwP 2, 4, 6 months

DTwPHib 15 months


HepB high-risk groups

Influenza >6 months; 6-65 years (high-risk groups)

IPV 2, 4, 6 months; 4-6 years (subnational)

MMR 1, 4-5 years

OPV 2, 4, 6 months; 4-5 years

Pneumo_conj 2, 4, 6 months; high-risk groups

Td 10 years


13

Bahrain





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … …

DTP1 98% 98% 97% 99% 99% 98% 98% 97% 96% 89%

DTP3 98% 98% 97% 98% 98% 97% 95% 94% 90% 72%

HepB3 98% 98% 97% 98% 98% 97% 95% … … …

Hib3 97% 97% 97% 97% 98% 97% … … … …

MCV 99% 99% 99% 99% 99% 98% 95% 87% 78% 45%

Pol3 97% 97% 97% 98% 98% 97% 95% 94% 90% 72%

PAB 94% 99% 96% 93% 97% 84% 59% 48% 34% 5%

Births........................................................................................................ 14,000 Surviving infants..................................................................................... 14,000 Total population ...................................................................................... 791,000 Infant mortality rate (per 1,000 live births) ........................................... 10 Under-five mortality rate (per 1,000 live births) ................................... 12 Gross national income per capita (PPP, US$)....................................... 33,480 Percentage of routine EPI vaccines financed by government ............ 100%

2009 2008Number of districts in country … 4Percentage of districts reporting … 100%


at 80% or above … 100%

MCV: proportion of districts with coverage at 90% or above … 100%DTP1–DTP3 drop-out rate: proportion of districts thathave achieved a rate of less than 10% … 100%



BCG birth (high-risk groups)DT 2, 4, 6, 18 months; 5 years

(high-risk groups)DTaP 5 yearsDTaPHibHepIPV 2 monthsDTwPHibHep 4, 6, 18 monthsHepA 1, 2 years; school students

(catch up)HepB health workers;

high-risk groupsHib high-risk groupsInfluenza elderly; pilgrims;

health workers

IPV 2, 4, 6, 18 months; 5 years(high-risk groups)

MenACWY 2 years; travellers MMR 1, 5 years; health workersOPV 2, 4, 6, 18 months; 5 yearsPneumo_conj 2, 4, 6 monthsPneumo_ps >65 years; pilgrimsRotavirus 2, 4 monthsTd >12 years (post-trauma

and pregnancy)Tdap >12 years (school students)Typhoid travellersVaricella high-risk groupsYellow fever travellers


2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 98% 98% 98% 96% 95% 93% 86% 2% …

DTP1 99% 98% 98% 97% 95% 88% 87% 86% 20% …

DTP3 94% 94% 94% 94% 93% 81% 69% 69% 2% …

HepB3 95% 95% 95% 83% 44% … … … … …

Hib3 … … … … … … … … … …

MCV 89% 89% 89% 78% 88% 72% 79% 65% 1% …

Pol3 94% 93% 93% 92% 85% 82% 69% 69% 2% …

PAB 93% 91% 91% 92% 89% 89% 85% 70% 3% 2%

Births........................................................................................................ 3,401,000Surviving infants..................................................................................... 3,258,000 Total population ......................................................................................162,221,000 Infant mortality rate (per 1,000 live births) ........................................... 41 Under-five mortality rate (per 1,000 live births) ................................... 52% Gross national income per capita (PPP, US$)....................................... 1,580 Percentage of routine EPI vaccines financed by government ............ 30%


below 50% … 0%DTP3: proportion of districts with coverage between 50-79% 20% 20%

at 80% or above 80% 80%





BCG birth

DTwP 6, 10, 14 weeks

Measles 38 weeks

OPV 6, 10, 14, 38 weeks

TT 15 years; +1, +6 months; +1, +1 year

Vitamin A 38 weeks

2009





Bangladesh

14


2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … …

DTP1 93% 85% 93% 94% 97% 93% 97% 97% 94% 82%

DTP3 93% 85% 93% 84% 92% 93% 93% 91% 83% 60%

HepB3 93% 85% 93% 84% 92% … … … … …

Hib3 93% 85% 93% 84% 92% … … … … …

MCV 94% 94% 75% 92% 93% 94% 92% 87% 88% 41%

Pol3 93% 85% 93% 85% 91% 86% 93% 90% 88% 99%

PAB … … … … … … … … … …

Births........................................................................................................ 3,000Surviving infants..................................................................................... 3,000Total population ...................................................................................... 256,000Infant mortality rate (per 1,000 live births) ........................................... 10 Under-five mortality rate (per 1,000 live births) ................................... 11 Gross national income per capita (PPP, US$)....................................... … Percentage of routine EPI vaccines financed by government ............ 100%



at 80% or above 0% 100%

MCV: proportion of districts with coverage at 90% or above 0% 100%DTP1–DTP3 drop-out rate: proportion of districts thathave achieved a rate of less than 10% 100% …



BCG 5 yearsDT 2, 4, 6, 18 months;

4.5 years (high-risk groups)DTwP 18 months; 4.5 yearsDTwPHibHep 3, 4.5, 6 monthsHepB 2, 4, 6 months

(high-risk groups)Hib 2, 4, 6 months

(high-risk groups)Influenza 18 years

(high-risk groups)

IPV 2, 4, 6, 18 months(high-risk groups)

MMR 1, 3-5 yearsOPV 3, 4.5, 6, 18 months;

4.5, 11 yearsTd 11 yearsVaricella 18 years

(high-risk groups)Yellow fever …

2009





Barbados

15


2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 98% 98% 98% 99% 99% 99% 96% … … …

DTP1 97% 97% 98% 98% 98% 98% 98% … … …

DTP3 96% 97% 95% 99% 99% 99% 96% … … …

HepB3 98% 98% 91% 98% 99% 70% … … … …

Hib3 19% 6% … … … … … … … …

MCV 99% 99% 99% 97% 99% 98% 93% … … …

Pol3 98% 98% 90% 97% 98% 99% 96% … … …

PAB … … … … … … … … … …

Births........................................................................................................ 96,000Surviving infants..................................................................................... 95,000 Total population ...................................................................................... 9,634,000 Infant mortality rate (per 1,000 live births) ........................................... 11Under-five mortality rate (per 1,000 live births) ................................... 12Gross national income per capita (PPP, US$)....................................... 12,380Percentage of routine EPI vaccines financed by government ............ 75%

2009 2008Number of districts in country 119 119Percentage of districts reporting 100% …


at 80% or above 10% 100%





BCG 3-5 days; 7, 14 years

Dip 11 years

DT 6 years


HepB birth; 1-5 months

Hib 3, 4, 16 months (subnational)

Influenza high-risk groups

IPV 3, 4, 5 months

MMR 1, 6 years

OPV 18, 24 months; 7 years

Rubella young children

Td 16 years

TT post-exposure

Yellow fever high-risk groups

2009





Belarus

16


2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … …

DTP1 98% 98% 98% 98% 98% 95% 97% 97% 98% 98%

DTP3 99% 99% 99% 99% 97% 95% 94% 93% 95% 95%

HepB3 97% 98% 94% 94% 77% 60% … … … …

Hib3 97% 98% 98% 98% 95% 86% 13% … … …

MCV 94% 93% 92% 92% 88% 82% 85% 85% 82% …

Pol3 99% 99% 99% 99% 97% 96% 92% 95% 97% 99%

PAB … … … … … … … … … …

Births........................................................................................................ 120,000Surviving infants..................................................................................... 119,000 Total population ...................................................................................... 10,647,000Infant mortality rate (per 1,000 live births) ........................................... 4 Under-five mortality rate (per 1,000 live births) ................................... 5 Gross national income per capita (PPP, US$)....................................... 36,520 Percentage of routine EPI vaccines financed by government ............ …

2009 2008Number of districts in country 43 43Percentage of districts reporting … …



MCV: proportion of districts with coverage at 90% or above … …DTP1–DTP3 drop-out rate: proportion of districts thathave achieved a rate of less than 10% … …



DTaPHibHepIPV 2, 3, 4, 15 months

DTaPIPV 5-7 years

HepB 10-13 years (catch up)

HPV 10-13 years (females)

MenC_conj 15 months

MMR 12 months; 10-13 years

Pneumo_conj 2, 4, 12 months; high-risk groups >2 years

Rotavirus 2, 3 months; 4 monthsif needed

Tdap 14-16 years

2009





Belgium

17


2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 98% 99% 97% 96% 96% 92% 93% 81% 71%

DTP1 99% 98% 98% 98% 98% 96% 94% 97% 81% 72%

DTP3 97% 94% 96% 98% 96% 91% 83% 91% 58% 47%

HepB3 97% 94% 96% 98% 96% 76% … … … …

Hib3 97% 94% 96% 98% 96% … … … … …

MCV 97% 96% 96% 99% 95% 96% 83% 86% 49% 21%

Pol3 98% 94% 97% 98% 96% 91% 83% 86% 61% 44%

PAB 88% 88% 87% 85% 87% 85% 87% 88% 88% …

Births........................................................................................................ 7,000Surviving infants..................................................................................... 7,000 Total population ...................................................................................... 307,000 Infant mortality rate (per 1,000 live births) ........................................... 16Under-five mortality rate (per 1,000 live births) ................................... 18Gross national income per capita (PPP, US$)....................................... 5,950 Percentage of routine EPI vaccines financed by government ............ 100%



at 80% or above 100% 100%





BCG birth

DTwP 2, 4, 6 months; 4 years



Influenza 6-24 months (2 doses); >65 years; health workers;

high-risk groups

IPV 2, 4, 6 months; 4-5 years (HIV-exposed)

MMR 1, 2 years

OPV 2, 4, 6 months; 4 years

Vitamin A 2, 6, 12, 18, 24, 30 months

YF >1 year (travellers)

2009





Belize

18


2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 94% 88% 92% 85% 92% 27% …

DTP1 99% 99% 99% 92% 84% 89% 82% 86% 36% …

DTP3 83% 78% 82% 74% 70% 78% 67% 74% 17% …

HepB3 83% 78% 82% 74% 70% … … … … …

Hib3 83% 78% 82% 74% 35% … … … … …

MCV 72% 66% 70% 66% 61% 70% 65% 79% 23% …

Pol3 83% 79% 82% 76% 73% 78% 68% 74% 16% …

PAB 92% 92% 93% 95% 95% 87% 82% 48% … …

Births........................................................................................................ 349,000Surviving infants..................................................................................... 320,000 Total population ...................................................................................... 8,935,000 Infant mortality rate (per 1,000 live births) ........................................... 75 Under-five mortality rate (per 1,000 live births) ................................... 118Gross national income per capita (PPP, US$)....................................... 1,510 Percentage of routine EPI vaccines financed by government ............ 78%



at 80% or above 91% 87%




BCG birth

DTwPHibHep 6, 10, 14 weeks

Measles 9 months

OPV birth; 6, 10, 14 weeks

TT 1st contact pregnancy; +1, +6months; +1, +1 year

Vitamin A 6 months

Yellow fever 9 months

2009





Benin

19


20

Bhutan





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 96% 99% 94% 92% 92% 97% 98% 99% 54% 43%

DTP1 98% 97% 98% 97% 97% 96% 95% 98% 66% 25%

DTP3 96% 96% 95% 95% 95% 92% 87% 96% 41% 6%

HepB3 96% 96% 95% 95% 95% 98% … … … …

Hib3 … … … … … … … … … …

MCV 98% 99% 95% 90% 93% 78% 85% 93% 44% 21%

Pol3 96% 96% 93% 96% 95% 98% 86% 96% 41% 4%

PAB 89% 89% 84% 85% 85% 85% 78% 63% 3% …

Births........................................................................................................ 15,000 Surviving infants..................................................................................... 14,000 Total population ...................................................................................... 697,000 Infant mortality rate (per 1,000 live births) ........................................... 52Under-five mortality rate (per 1,000 live births) ................................... 79Gross national income per capita (PPP, US$)....................................... 5,300 Percentage of routine EPI vaccines financed by government ............ …



at 80% or above 85% 95%




Most recent national measles campaign target age group 9 m-44 ycoverage 98%

BCG birth

DTwPHep 6, 10, 14 weeks

DTwPHibHepB 6, 10, 14 weeks

HPV 1st contact; +2, +6 months (females)

MR 9, 24 months

OPV 6, 10, 14 weeks

TT 1st contact pregnancy; +1 month; +next pregnancy (up to the 5th)

Vitamin A 6 months


21

Bolivia





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 88% 86% 86% 87% 88% 94% 87% 65% 24% 30%

DTP1 87% 87% 85% 87% 93% 93% 84% 66% 58% 32%

DTP3 85% 83% 82% 83% 85% 77% 64% 41% 33% 11%

HepB3 85% 83% 82% 83% 85% 77% … … … …

Hib3 85% 83% 82% 83% 85% 77% … … … …

MCV 86% 87% 83% 88% 89% 81% 58% 53% 21% 13%

Pol3 84% 82% 82% 82% 84% 78% 64% 50% 30% 14%

PAB 74% 74% 71% 71% 70% 67% 57% 23% … …




at 80% or above 49% 53%




BCG birth


DTwPHibHepIPV 2, 4, 6 months

MMR 12-23 months

OPV 2, 4, 6 months

Rotavirus 2, 4 months

Td 1st contact; +1, +6 months;+1, +1 year

Vitamin A 6-11 months

Yellow fever 12-23 months


22

Bosnia and Herzegovina





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 97% 96% 98% 97% 95% 93% 64% … … …

DTP1 95% 95% 96% 94% 95% 90% 78% … … …

DTP3 90% 91% 95% 87% 93% 85% 55% … … …

HepB3 90% 88% 94% 90% 93% … … … … …

Hib3 80% 83% 83% 82% 50% … … … … …

MCV 93% 84% 96% 85% 90% 80% 53% … … …

Pol3 90% 92% 95% 91% 95% 87% 69% … … …

PAB … … … … … … … … … …

Births........................................................................................................ 34,000Surviving infants..................................................................................... 34,000 Total population ...................................................................................... 3,767,000 Infant mortality rate (per 1,000 live births) ........................................... 13Under-five mortality rate (per 1,000 live births) ................................... 14Gross national income per capita (PPP, US$)....................................... 8,740Percentage of routine EPI vaccines financed by government ............ 95%



at 80% or above 90% 100%





BCG birth

DT 6 years (subnational)

DTaPIPV 2, 4, 6 months (subnational)



Hib 2, 4, 18 months

MMR 1, 6 years

OPV 18 months; 5, 14 years (subnational)

Td 14 years

TT 18 years


23

Botswana





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 99% 99% 96% 93% 97% 92%

DTP1 98% 98% 98% 98% 98% 98% 98% 99% 98% 89%

DTP3 96% 96% 96% 96% 96% 97% 95% 92% 84% 71%

HepB3 93% 93% 93% 93% 92% 86% 73% … … …

Hib3 … … … … … … … … … …

MCV 94% 94% 94% 94% 93% 91% 89% 87% 85% 63%

Pol3 96% 96% 96% 96% 96% 97% 94% 90% 85% 46%

PAB 92% 85% 84% 84% 83% 80% 72% 59% 39% …




at 80% or above 96% 96%



Most recent national measles campaign target age group unknowncoverage 115%

BCG birth

DT 7 years



Measles 9 months



Vitamin A 9-12, 18, 24, 30, 36, 42months; birth-6 months if

not breastfed

Yellow fever …


24

Brazil





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 99% 99% 99% 79% 63% 56%

DTP1 99% 99% 99% 99% 97% 99% 85% 86% 86% 62%

DTP3 99% 98% 99% 99% 96% 98% 81% 66% 66% 37%

HepB3 98% 96% 99% 99% 92% 94% 10% … … …

Hib3 99% 98% 99% 99% 96% 90% … … … …

MCV 99% 99% 99% 99% 99% 99% 87% 78% 67% 57%

Pol3 99% 99% 99% 99% 98% 99% 79% 58% 52% 69%

PAB 92% 92% 92% 92% 67% 92% 78% 63% … …

Births........................................................................................................ 3,026,000Surviving infants..................................................................................... 2,959,000 Total population ......................................................................................193,734,000 Infant mortality rate (per 1,000 live births) ........................................... 17Under-five mortality rate (per 1,000 live births) ................................... 21Gross national income per capita (PPP, US$)....................................... 10,260 Percentage of routine EPI vaccines financed by government ............ 100%

2009 2008Number of districts in country 5,564 5,564Percentage of districts reporting 100% 100%


at 80% or above 92% 88%





BCG birthDT 2, 4, 6 months (high-risk

groups, subnational)DTaP 2, 4, 6 months (high-risk

groups, subnational)DTwP 15 months; 4-6 yearsDTwPHib 2, 4, 6 monthsDTwPHibHep 2, 4, 6 months (high-risk

groups, subnational)HepA 12, 18 months (high-risk

groups, subnational) HepB birth; 1, 6 months;

high-risk groupsHib 2, 4, 6, 15 months (high-risk

groups, subnational)Influenza 6 months-8 years (indigenous

population); ≥60 years; high-risk groups

IPV 2, 4, 6, 15 months (high-risk groups, subnational)

MenAC ≥2 years (subnational)MenC_conj 2, 4, 6 months; high-risk groups

(subnational)MMR CBAW; 1-14 years (2 doses)MR CBAW; >20 years (2 doses) OPV 2, 4, 6, 15 monthsPneumo_conj 2, 4, 6, 12 months (high-risk

groups, subnational)Pneumo_ps ≥2, ≥5 years (high-risk

groups; subnational)Rabies post-exposureRotavirus 35, 97 days Td CBAW; >7 years (4 doses) Typhoid ≥2 years (3 doses); high-risk groups Varicella 12, 14 months (high-risk

groups, subnational)Yellow fever 9 months; 10 years (subnational)


25

Brunei Darussalam





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 98% 97% 96% 99% 99% 91% 95% 99%

DTP1 98% 98% 98% 99% 99% 99% 99% 97% 96% 96%

DTP3 99% 98% 96% 95% 93% 99% 99% 93% 88% 89%

HepB3 99% 99% 99% 99% 99% 99% 99% 96% … …

Hib3 99% 98% 96% 95% 93% … … … … …

MCV 99% 99% 99% 98% 97% 99% 99% 99% 98% 73%

Pol3 99% 98% 97% 95% 94% 99% 99% 92% 88% 89%

PAB 65% 65% 64% 64% 64% 77% 69% 40% 51% …

Births........................................................................................................ 8,000Surviving infants..................................................................................... 8,000 Total population ...................................................................................... 400,000 Infant mortality rate (per 1,000 live births) ........................................... 5 Under-five mortality rate (per 1,000 live births) ................................... 7Gross national income per capita (PPP, US$)....................................... 50,920 Percentage of routine EPI vaccines financed by government ............ …



at 80% or above 100% 100%

MCV: proportion of districts with coverage at 90% or above 100% 100%DTP1–DTP3 drop-out rate: proportion of districts thathave achieved a rate of less than 10% … …



BCG birth

DT 5 years

DTwPHib 2, 3, 4 months


MMR 1, 3 years

OPV 2, 3, 4 months

Rubella subnational

Typhoid subnational


26

Bulgaria





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 98% 98% 98% 98% 98% 98% 99% 99% 99% 99%

DTP1 98% 99% 98% 99% 99% 97% 98% 99% 99% 98%

DTP3 94% 95% 95% 95% 96% 93% 96% 99% 99% 98%

HepB3 96% 96% 95% 96% 96% 94% 95% … … …

Hib3 … … … … … … … … … …

MCV 96% 96% 96% 96% 96% 89% 94% 99% 99% 98%

Pol3 94% 96% 95% 96% 97% 94% 97% 99% 99% 99%

PAB … … … … … … … … … …

Births........................................................................................................ 73,000 Surviving infants..................................................................................... 72,000 Total population ...................................................................................... 7,545,000 Infant mortality rate (per 1,000 live births) ........................................... 8Under-five mortality rate (per 1,000 live births) ................................... 10Gross national income per capita (PPP, US$)....................................... 12,290 Percentage of routine EPI vaccines financed by government ............ 100%



at 80% or above 100% 100%




Most recent national measles campaign target age group 13 m-30 ycoverage …

BCG birth; 7 months; 7, 11, 17 years (after Mantoux test negative)

DT 2, 3, 4, 24 months (pertussis contraindication)

DTaPIPV 6 years



Influenza >65 years; high-risk groups

IPV 2, 3, 4, 16 months


Rabies post-exposure

Td 12, 17, 25, 35, 45, 55 years


27

Burkina Faso





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 92% 92% 92% 92% 92% 77% 72% 95% 33% …

DTP1 89% 89% 89% 89% 89% 77% 79% 92% 35% …

DTP3 82% 82% 82% 82% 82% 57% 34% 66% 9% …

HepB3 81% 81% 81% 76% … … … … … …

Hib3 81% 81% 81% 76% … … … … … …

MCV 75% 75% 75% 75% 75% 51% 43% 79% 38% …

Pol3 84% 84% 84% 84% 84% 62% 35% 66% 10% …

PAB 85% 79% 80% 76% 72% 57% 64% 55% 8% …




at 80% or above 100% 98%




BCG birth


Measles 9 months


TT 1st contact pregnancy; +1, +6 months; +1, +2 years



28

Burundi





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 98% 99% 97% 98% 89% 85% 92% 97% 52% …

DTP1 98% 98% 98% 99% 96% 88% 86% 95% 61% …

DTP3 92% 92% 99% 92% 87% 80% 73% 86% 36% …

HepB3 92% 92% 99% 92% 87% … … … … …

Hib3 92% 92% 99% 92% 87% … … … … …

MCV 91% 84% 88% 92% 87% 76% 80% 74% 32% …

Pol3 96% 89% 93% 88% 82% 71% 73% 97% 58% …

PAB 94% 78% 76% 66% 65% 51% 61% 67% 21% …

Births........................................................................................................ 283,000 Surviving infants..................................................................................... 256,000 Total population ...................................................................................... 8,303,000 Infant mortality rate (per 1,000 live births) ........................................... 101Under-five mortality rate (per 1,000 live births) ................................... 166Gross national income per capita (PPP, US$)....................................... 390Percentage of routine EPI vaccines financed by government ............ 8%



at 80% or above 91% 73%





BCG birth


Measles 9 months


TT 1st contact

Vitamin A 9, 18, 24, 30, 36, 42 months


29

Cambodia





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 98% 98% 90% 87% 87% 81% 69% 52% 33% …

DTP1 99% 95% 87% 85% 85% 78% 55% 63% 47% …

DTP3 94% 91% 82% 80% 82% 59% 39% 38% 23% …

HepB3 91% 91% 82% 80% … … … … … …

Hib3 … … … … … … … … … …

MCV 92% 89% 79% 78% 79% 65% 62% 34% 29% …

Pol3 95% 91% 82% 80% 82% 62% 39% 38% 26% …

PAB 91% 87% 87% 84% 81% 58% 45% 11% 9% …




at 80% or above 88% 81%




BCG birth


HepB 1-7 days

JE 10 months (subnational)

Measles 9-11 months

OPV 6, 10, 14 weeks


Vitamin A 6-59 months (2 doses)


30

Cameroon





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 90% 90% 90% 90% 90% 78% 62% 76% 54% …

DTP1 88% 93% 90% 87% 85% 66% 71% 70% 52% …

DTP3 80% 84% 82% 81% 80% 62% 46% 48% 33% …

HepB3 80% 84% 82% 81% 79% … … … … …

Hib3 80% … … … … … … … … …

MCV 74% 80% 74% 73% 68% 49% 46% 56% 39% …

Pol3 79% 82% 81% 78% 79% 57% 46% 54% 35% …

PAB 91% 86% 83% 81% 76% 54% 20% 19% 10% …

Births........................................................................................................ 711,000Surviving infants..................................................................................... 651,000 Total population ...................................................................................... 19,522,000 Infant mortality rate (per 1,000 live births) ........................................... 95 Under-five mortality rate (per 1,000 live births) ................................... 154Gross national income per capita (PPP, US$)....................................... 2,200Percentage of routine EPI vaccines financed by government ............ 34%



at 80% or above 51% 60%





BCG birth


Measles 9 months


TT 1st contact; +1, +6 months; +1, +2 years

Vitamin A 6 months; +every 6 monthsuntil 59 months; post-partum



31

Canada





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … …

DTP1 93% 93% 97% 97% 97% 97% 97% 96% … …

DTP3 80% 80% 94% 94% 94% 92% 87% 88% … …

HepB3 17% 17% 14% 14% 14% … … … … …

Hib3 80% 80% 87% 94% 90% 86% … … … …

MCV 93% 93% 94% 94% 94% 96% 96% 89% … …

Pol3 80% 80% 90% 94% 92% 88% 89% 88% … …

PAB … … … … … … … … … …

Births........................................................................................................ 358,000Surviving infants..................................................................................... 356,000 Total population ...................................................................................... 33,573,000 Infant mortality rate (per 1,000 live births) ........................................... 5Under-five mortality rate (per 1,000 live births) ................................... 6Gross national income per capita (PPP, US$)....................................... 37,590 Percentage of routine EPI vaccines financed by government ............ …

2009 2008Number of districts in country 13 …Percentage of districts reporting 100% …



MCV: proportion of districts with coverage at 90% or above … …DTP1–DTP3 drop-out rate: proportion of districts thathave achieved a rate of less than 10% … …



BCG high-risk groups

DTaPIPV 4-6 years

DTPHibIPV 2, 4, 6, 18 months

HepA high-risk groups

HepB 1st contact; +1, >+2 months

HPV 1st contact; +2,

+6 months (females)

Influenza 6-23 months;>65 years; high-risk groups

MenC_conj 2, 4, 6 months or 2,4, 12 months

MMR 12, 18 months or 4-6 years

Pneumo_conj 2, 4, 6, 12-15 months

Pneumo_ps ≥65 years

Td every 10 years as booster

Tdap 14-16 years

Varicella 1 year; high-riskgroups (recommended)


32

Cape Verde





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 99% 96% 94% 97% 64% …

DTP1 98% 99% 99% 98% 98% 94% 90% 96% 64% …

DTP3 99% 99% 98% 96% 95% 90% 88% 88% 39% …

HepB3 99% 99% 97% 95% 93% … … … … …

Hib3 … … … … … … … … … …

MCV 96% 96% 95% 94% 92% 86% 85% 79% 54% …

Pol3 99% 99% 98% 97% 95% 90% 89% 87% 39% …

PAB 78% 78% 77% 74% 70% 60% 30% 75% … …

Births........................................................................................................ 12,000Surviving infants..................................................................................... 12,000Total population ...................................................................................... 506,000 Infant mortality rate (per 1,000 live births) ........................................... 23 Under-five mortality rate (per 1,000 live births) ................................... 28Gross national income per capita (PPP, US$)....................................... 3,530Percentage of routine EPI vaccines financed by government ............ 84%


below 50% … 0%DTP3: proportion of districts with coverage between 50-79% 59% 59%

at 80% or above … 41%

MCV: proportion of districts with coverage at 90% or above … 24%

DTP1–DTP3 drop-out rate: proportion of districts thathave achieved a rate of less than 10% … 100%



BCG birth

DTwP 6, 10, 14 weeks; 15 months

HepB birth; 6, 14 weeks

Measles 9 months

OPV birth; 6, 10, 14 weeks;15 months



33

Central African Republic





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 74% 74% 74% 74% 74% 66% 94% 96% 34% 17%

DTP1 64% 64% 64% 64% 64% 60% 77% 95% 44% 35%

DTP3 54% 54% 54% 54% 54% 37% 53% 82% 20% 13%

HepB3 54% … … … … … … … … …

Hib3 54% … … … … … … … … …

MCV 62% 62% 62% 62% 62% 36% 46% 82% 23% 12%

Pol3 47% 47% 47% 47% 47% 38% 51% 82% 20% 13%

PAB 86% 86% 54% 52% 48% 36% 34% 69% 24% 8%

Births........................................................................................................ 154,000Surviving infants..................................................................................... 138,000 Total population ...................................................................................... 4,422,000 Infant mortality rate (per 1,000 live births) ........................................... 112 Under-five mortality rate (per 1,000 live births) ................................... 171 Gross national income per capita (PPP, US$)....................................... 750Percentage of routine EPI vaccines financed by government ............ 74%



at 80% or above 38% 8%

MCV: proportion of districts with coverage at 90% or above 21% 8%DTP1–DTP3 drop-out rate: proportion of districts thathave achieved a rate of less than 10% … 75%



BCG birth


Measles 9 months

OPV 6, 10, 14 weeks





34

Chad





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 40% 40% 40% 40% 40% 49% 43% 59% 15% …

DTP1 45% 45% 45% 45% 45% 45% 41% 44% 21% …

DTP3 23% 23% 23% 23% 23% 26% 18% 20% 3% …

HepB3 22% 17% … … … … … … … …

Hib3 22% 17% … … … … … … … …

MCV 23% 23% 23% 23% 23% 28% 26% 32% 7% …

Pol3 36% 36% 36% 36% 36% 26% 18% 20% 3% …

PAB 60% 58% 60% 60% 61% 39% 65% 14% … …

Births........................................................................................................Surviving infants.....................................................................................Total population ......................................................................................Infant mortality rate (per 1,000 live births) ...........................................Under-five mortality rate (per 1,000 live births) ...................................Gross national income per capita (PPP, US$).......................................Percentage of routine EPI vaccines financed by government ............

Number of districts in countryPercentage of districts reporting

below 50%DTP3: proportion of districts with coverage between 50-79%

at 80% or above

MCV: proportion of districts with coverage at 90% or above

DTP1–DTP3 drop-out rate: proportion of districts thathave achieved a rate of less than 10%

MCV2 routine coverage in 2009year

Most recent national measles campaign target age groupcoverage

BCG birth

DTwPHibHep 6, 10, 14 weeks;

Measles 9 months



Yellow fever …

508,000443,000

11,206,000124209

1,23045%

2009 200861 61

100% 100%21% 92%26% 7%52% 2%

30% 20%

15% 0%

…………


35

Chile





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 98% 98% 95% 93% 97% 94% 96% 96%

DTP1 98% 98% 96% 97% 97% 96% 97% 98% 99% 97%

DTP3 97% 97% 96% 94% 91% 91% 94% 95% 99% 93%

HepB3 97% 97% 96% 94% … … … … … …

Hib3 97% 97% 96% 94% 91% 91% … … … …

MCV 96% 96% 92% 91% 90% 97% 97% 97% 92% 94%

Pol3 97% 97% 95% 94% 92% 91% 94% 95% 99% 93%

PAB … … … … … … … … … …




at 80% or above





BCG birth

DT 7 years

DTwP 4 years

DTwPHibHep 2, 4, 6, 18 months

Influenza adults; high-risk groups

MMR 1, 6 years

OPV 2, 4, 6, 18 months

Pneumo_conj 2, 4, 6 months(high-risk groups)

Pneumo_ps 65 years

252,000250,000

16,970,00079

13,430

…

2009 2008340 346

100% 100%2% 2%

12% 12%86% 86%

62% 71%

90% 92%

89%2007

19-29 y92%


36

China





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 97% 97% 94% 92% 86% 84% 79% 99% 64% …

DTP1 98% 98% 95% 95% 95% 94% 93% 98% 92% …

DTP3 97% 97% 93% 93% 87% 85% 80% 97% 78% …

HepB3 95% 95% 92% 91% 84% 60% … … … …

Hib3 … … … … … … … … … …

MCV 94% 94% 94% 93% 86% 84% 80% 98% 88% …

Pol3 99% 99% 94% 94% 87% 86% 82% 98% 87% …

PAB … … … … … … … … … …

Births ...................................................................................................Surviving infants ................................................................................Total population..................................................................................Infant mortality rate (per 1,000 live births).......................................Under-five mortality rate (per 1,000 live births) ..............................Gross national income per capita (PPP, US$) ..................................Percentage of routine EPI vaccines financed by government ........



at 80% or above





BCG birth

DT 6 years

DTwP 3, 4, 5, 18-24 months

HepA 18, 24-30 months


JE 8 months; 2 years or 8 months (2 doses); 2, 6 years

Measles 8 months (subnational)

MenA 6-18 months (2 doses)

MenAC 3, 6 years

MM 18-24 months (subnational)

MMR 18-24 months

MR 8 months


18,294,00017,890,000

1,345,751,0001719

6,710100%

2009 20083,118 2,85997% 100%0% 0%0% 0%

99% 100%

93% …

100% 87%

98%………


37

Colombia





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 90% 93% 93% 96% 94% 91% 99% 95% 76% 45%

DTP1 97% 97% 97% 97% 97% 94% 95% 96% 82% 39%

DTP3 92% 92% 93% 93% 93% 79% 85% 88% 61% 16%

HepB3 92% 92% 93% 93% 93% 78% 71% … … …

Hib3 92% 92% 93% 93% 93% 65% … … … …

MCV 95% 92% 95% 95% 94% 80% 82% 82% 51% 13%

Pol3 92% 92% 93% 94% 93% 82% 87% 93% 62% 16%

PAB 78% 78% 78% 77% 77% 70% 64% 45% 8% 3%




at 80% or above





BCG birth

DT 2, 4, 6, 18 months; 5 years

DTwP 2, 4, 6, 18 months; 5 years


HepB birthInfluenza 6-23 months;

+1 month; 18-23 months

IPV 2, 4, 6, 18 months; 5 years(immunocompromised)

MMR 1, 5 years


Pneumo_conj 2, 4, 12 months(high-risk groups)


Td 1st contact; +1, +6 months; +1, +1 year (CBAW and pregnancy)

Yellow fever 1 year; high-risk areas;travellers

917,000901,000

45,660,0001619

8,50092%

2009 20081,123 1,119100% 100%

8% 7%34% 36%57% 57%

47% 41%

… 85%

71%2006

14-39 y97%


38

Comoros





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 80% 81% 77% 84% 80% 90% 95% 99% 77% …

DTP1 94% 93% 91% 73% 73% 73% 91% 97% 75% …

DTP3 83% 81% 75% 69% 68% 70% 75% 94% 51% …

HepB3 83% 81% 75% 69% 68% … … … … …

Hib3 38% … … … … … … … … …

MCV 79% 76% 65% 66% 67% 70% 69% 87% 18% …

Pol3 84% 81% 75% 69% 67% 70% 78% 94% 53% …

PAB 83% 83% 89% 88% 91% 57% 67% 78% 13% …




at 80% or above





BCG birth



Measles 9 months



Vitamin A 6, 12, 18, 24, 30, 36 months

22,00021,000

676,00075

1041,300

4%

2009 200817 17

100% 100%0% 12%

35% 24%65% 65%

29% 24%

65% 71%

…2007

9 m-15 y89%


39

Congo





2009Births........................................................................................................Surviving infants.....................................................................................Total population ......................................................................................Infant mortality rate (per 1,000 live births) ...........................................Under-five mortality rate (per 1,000 live births) ...................................Gross national income per capita (PPP, US$).......................................Percentage of routine EPI vaccines financed by government ............



at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 90% 93% 86% 84% 73% 50% 58% 90% 89% 92%

DTP1 92% 93% 80% 81% 73% 45% 74% 92% 77% 67%

DTP3 91% 89% 80% 79% 65% 33% 50% 79% 54% 42%

HepB3 91% 89% 80% … … … … … … …

Hib3 91% … … … … … … … … …

MCV 76% 79% 67% 66% 56% 34% 38% 75% 67% 49%

Pol3 91% 89% 80% 79% 65% 31% 50% 80% 73% 42%

PAB 82% 82% 82% 81% 75% 67% 73% 60% … …

BCG birth


Measles 9 months


TT 1st contact pregnancy;+1 month

Vitamin A 9 months

YF 9-11 months

126,000116,000

3,683,00081

1282,940100%

2009 200830 27

100% 100%0% 0%

20% 11%80% 89%

27% 22%

80% 93%

…2007

9-59 m95%


40

Congo, Democratic Republic of





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 80% 74% 79% 72% 72% 57% 34% 65% 57% 57%

DTP1 91% 75% 79% 71% 68% 49% 47% 60% 62% …

DTP3 77% 68% 72% 62% 60% 40% 23% 35% 37% …

HepB3 77% 68% 72% … … … … … … …

Hib3 77% … … … … … … … … …

MCV 76% 67% 69% 63% 61% 46% 27% 38% 40% 18%

Pol3 74% 61% 71% 62% 60% 42% 24% 34% 34% 15%

PAB 85% 75% 70% 66% 67% 45% 42% 53% 37% …




at 80% or above





BCG birth


Measles 9 months



Vitamin A 6 months; +every 6 monthsuntil 59 months


2,930,0002,593,000

66,020,0001261993001%

2009 2008508 515

100% 99%5% 5%

17% 40%78% 54%

42% 22%

71% 64%

…2007

6-59 m101%


41

Cook Islands








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 99% 99% 96% 99% 99% 29%

DTP1 97% 98% 98% 98% 98% 97% 97% 97% 92% 65%

DTP3 82% 99% 99% 98% 98% 92% 93% 93% 78% 40%

HepB3 82% 99% 99% 97% 96% 98% 85% 71% … …

Hib3 82% … … … … … … … … …

MCV 78% 95% 98% 99% 99% 76% 96% 67% 76% …

Pol3 82% 99% 99% 98% 97% 92% 93% 83% 91% 39%

PAB … … … … … … … … … …

BCG birth

DT 11 years

DTwP 6, 10, 14 weeks; 5-6 years

DTwPHibHep 6 weeks; 3, 5 months

HepB birth


OPV 6, 10, 14 weeks

TT 1, 3, 5 months; 4, 11 years;pregnancy

……

20,0001315…

100%

2009 200839 41

100% 100%0% 0%0% 0%

100% 100%

… 100%

0% 0%

61%

2006

1-35 y

90%


42

Costa Rica





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 81% 90% 91% 87% 88% 92% 99% 92% 82% 80%

DTP1 98% 97% 97% 96% 96% 97% 95% 98% 96% 95%

DTP3 86% 88% 89% 89% 91% 88% 85% 95% 90% 86%

HepB3 87% 89% 89% 88% 90% 89% … … … …

Hib3 87% 87% 88% 88% 89% 92% … … … …

MCV 81% 89% 90% 90% 89% 82% 91% 90% 78% 60%

Pol3 80% 89% 89% 89% 91% 80% 86% 95% 88% 86%

PAB … … … … … … … … … …




at 80% or above





aP post-partum

BCG birth

DTwP 4, 15 months; 4 years

DTwPHibHep 2, 6 months

HepB birth; high-risk groups

Hib 4, 15 months

Influenza seasonal




Pneumo_ps elderly


Td 7 years; +every 10 years

Varicella 15 months

76,00075,000

4,579,0001011

10,940100%

2009 200881 81

100% 100%2% 0%

14% 12%84% 88%

49% 57%

83% 93%

83%20021-4 y86%


43

Côte d’Ivoire








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 95% 91% 94% 77% 85% 84% 69% 62% 29% …

DTP1 95% 89% 93% 95% 83% 82% 64% 77% 50% …

DTP3 81% 74% 76% 77% 76% 67% 52% 54% 25% …

HepB3 81% 74% 76% 77% 79% … … … … …

Hib3 81% … … … … … … … … …

MCV 67% 63% 67% 73% 84% 71% 57% 56% 31% …

Pol3 77% 58% 75% 76% 87% 71% 46% 56% 16% …

PAB 92% 92% 74% 75% 75% 76% 36% 36% … …

BCG birth


Measles 9 months





729,000667,000

21,075,00083

1191,640

5%

2009 200883 72

100% 100%1% 4%

42% 47%57% 49%

7% 4%

25% 6%

…

2008

9-59 m

95%


44

Croatia





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 98% 98% 99% … … …

DTP1 99% 99% 99% 99% 99% 97% 96% … … …

DTP3 96% 96% 96% 96% 96% 93% 90% … … …

HepB3 97% 97% 95% … … … … … … …

Hib3 96% 96% 96% 96% 96% … … … … …

MCV 98% 98% 96% 95% 96% 93% 92% … … …

Pol3 96% 96% 96% 96% 96% 94% 90% … … …

PAB … … … … … … … … … …




at 80% or above





BCG birth; 13 years

DTaP 3 years

DTaPHibIPV 2, 4, 6, 12 months

HepB birth; 2, 6 months; 12 years (3 doses)

MMR 1, 6 years

Td 6, 14, 18 years

TT 60 years

42,00042,000

4,416,00055

19,170…

2009 200821 …… …… …… …… …

… …

… …

…………


45

Cuba








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 99% 99% 99% 98% 98% 99%

DTP1 98% 98% 97% 89% 89% 96% 99% 97% 97% 86%

DTP3 96% 95% 93% 89% 89% 95% 99% 92% 91% 67%

HepB3 96% 95% 93% 89% 95% 98% 99% … … …

Hib3 96% 97% 97% 97% 94% 99% … … … …

MCV 96% 96% 96% 96% 98% 94% 99% 94% 85% 48%

Pol3 99% 99% 99% 99% 99% 99% 95% 94% 88% 99%

PAB … … … … … … … … … …

BCG birth

DT 6 years

DTwP 18 months


HepB birth

Hib 18 months

MenBC 3, 5 months

MMR 1, 6 years

OPV <1, 1, 2, 9 years

TT 15 years

Typhoid 10, 13, 16 years

116,000115,000

11,204,00046

…99%

2009 2008169 169

100% 100%6% 0%3% 2%

91% 98%

93% 97%

100% 100%

95%

2007

12-24 y

97%


46

Cyprus





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … …

DTP1 99% 99% 99% 99% 99% 98% 98% 97% 82% 59%

DTP3 99% 97% 97% 97% 98% 97% 96% 93% 61% 34%

HepB3 96% 93% 93% 93% 88% 89% 68% … … …

Hib3 96% 90% 90% 90% 58% 32% … … … …

MCV 87% 87% 87% 87% 86% 86% 83% 77% 43% 29%

Pol3 99% 97% 97% 97% 98% 97% 96% 94% 61% 35%

PAB … … … … … … … … … …




at 80% or above





BCG children with continuouscontact to contagious TB

DTaPHepIPV 2, 4 monthsDTaPHibHepIPV 2, 4 monthsDTaPHibIPV 2, 4, 6, 15-18 monthsDTaPIPV 2, 4, 6, 15-18 months;

4-6 yearsHepA universal in private sector;

high-risk groupsin public sector

HepB 2, 4, 8-12 monthsHib 2, 4, 6, 12-18 monthsHPV given only by private

sector (females)Influenza seasonal

IPV 2, 4, 6, 15-18 months; 4-6 yearsMenAC military; high-risk groupsMenACWY travellers (high-risk areas)MenC_conj 12-13 months MMR 13-15 months; 4-6 yearsPneumo_conj 2, 4, 6, 12-15 monthsPneumo_ps nationalRabies post-exposureRotavirus given only by private sectorTd 14-16 yearsTyphoid (if indicated)Varicella 13-18 monthsYellow fever travellers (high-risk areas)

10,00010,000

871,00034

28,05040%

2009 20086 6

100% 83%0% 0%0% 0%

83% 83%

17% 33%

100% 100%

…

2009

1st grade

88%


47

Czech Republic








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 98% 99% 99% 99% 99% 98% 95% … … …

DTP1 98% 98% 98% 98% 98% 98% 98% … … …

DTP3 99% 99% 99% 98% 97% 98% 96% … … …

HepB3 99% 99% 99% 98% 99% … … … … …

Hib3 99% 99% 99% 97% 97% … … … … …

MCV 98% 97% 98% 98% 97% 98% 96% … … …

Pol3 99% 99% 99% 98% 96% 98% 98% … … …

PAB … … … … … … … … … …

BCG 4 days

DTaP 5 years

DTaPHibHepIPV 13, 17, 21 weeks; 18 months

DTaPIPV 10 years

HepB 12 years (3 doses)

MMR 15, 21 months

TT 25 years

111,000111,000

10,369,00034

23,610100%

2009 200886 86

100% 100%0% 0%0% 0%

100% 100%

100% 100%

100% 100%

98%

…

…

…


48

Denmark





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … …

DTP1 90% 89% 87% 93% 93% 97% 97% 98% 99% 97%

DTP3 89% 88% 87% 93% 93% 97% 90% 90% 90% 88%

HepB3 … … … … … … … … … …

Hib3 89% 88% 87% 93% 93% 95% 78% … … …

MCV 84% 87% 89% 90% 95% 99% 88% 84% … …

Pol3 89% 88% 87% 93% 93% 97% 97% 99% 99% 99%

PAB … … … … … … … … … …




at 80% or above





DTaPHibIPV 3, 5, 12 months

DTaPIPV 5 years

HepAHepB birth; 1, 2, 12 months(children residing

wih carrier)

HPV 12 years; +2, +6 months(females)

MMR 15 months; 4 years or 15 months; 12 years

Pneumo_conj 3, 5,12 months

62,00061,000

5,470,00034

37,720…

2009 20085 5

100% …… …… …… …

… …

… …

85%………


49

Djibouti








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 90% 90% 90% 88% 80% 34% 51% 81% 37% …

DTP1 90% 90% 92% 76% 73% 66% 66% 95% 46% …

DTP3 89% 89% 88% 72% 71% 46% 41% 85% 22% …

HepB3 89% 88% 25% … … … … … … …

Hib3 89% 89% 25% … … … … … … …

MCV 73% 73% 74% 67% 65% 50% 41% 85% 27% …

Pol3 89% 89% 88% 72% 71% 46% 41% 85% 22% …

PAB 77% 79% 79% 77% 71% 46% 62% 80% 14% …

BCG birth

DTwP 15 months


Measles 9 months

OPV birth; 6, 10, 14 weeks; 15 months

TT 1st contact; +1, +6 months;+1, +1 year

Vitamin A 6, 12, 18, 24, 30, 36 months

24,00022,000

864,0007594

2,480…

2009 20086 6

100% 100%… …

33% 33%67% 67%

… …

… …

…

2008

9 m-15 y

86%


50

Dominca





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 98% 90% 99% 98% 99% 99% 99% 90% 65%

DTP1 98% 97% 97% 97% 98% 98% 99% 97% 97% 84%

DTP3 99% 96% 96% 95% 98% 99% 99% 92% 91% 63%

HepB3 99% 96% 93% 7% … … … … … …

Hib3 99% 96% 93% 7% … … … … … …

MCV 99% 99% 96% 97% 98% 99% 99% 88% 93% …

Pol3 99% 95% 93% 96% 98% 99% 99% 94% 89% 53%

PAB … … … … … … … … … …




at 80% or above





BCG birth-2 months

DT 3 years


HepB >15 years; +1, +6 months

Influenza 6 months-3 years; +1 month; >18 years

MMR 12, 18 months


Td 13 years

……

67,0008

108,470100%

2009 20087 7

100% …0% …0% …

100% …

100% …

100% …

95%………


51

Dominican Republic








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 96% 92% 92% 95% 96% 90% 90% 70% 51% 29%

DTP1 85% 90% 87% 93% 92% 95% 89% 87% 64% 61%

DTP3 82% 85% 87% 89% 87% 78% 72% 69% 39% 36%

HepB3 85% 88% 81% 84% 87% 68% … … … …

Hib3 77% 79% 65% 77% 87% … … … … …

MCV 79% 79% 79% 79% 81% 84% 78% 70% 54% 30%

Pol3 85% 87% 80% 88% 86% 75% 70% 90% 39% 46%

PAB 86% 86% 85% 85% 75% 48% 82% 60% 33% 23%

BCG birth

DTwP 2, 4, 6, 18 months;3, 5 years


HepB birth; 1st contact; +1, +6 months (high-risk groups)

Influenza 6, 12, 24 months; >65 years

MMR 1, 5 years

MR suspected cases

OPV 2, 4, 6, 18 months; 3, 5 years

Pneumo_conj 2, 4, 6, 12 months (high-risk groups,

subnational)

Pneumo_ps 65 years

Td 7, 10, 20, 30, 40, 50 years

Vitamin A 6, 12, 18, 24 months;

Yellow fever ≥6 months (high-risk groups, travellers)

224,000217,000

10,090,0002732

8,10090%

2009 2008155 155

100% 100%19% 17%39% 40%42% 43%

34% 30%

100% 70%

…

2006

7-39 y

99%


52

Ecuador





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 99% 99% 99% 89% 99% 76%

DTP1 93% 93% 93% 93% 93% 93% 94% 87% 66% 31%

DTP3 75% 75% 75% 75% 75% 78% 83% 68% 41% 10%

HepB3 75% 75% 75% 75% 75% 38% … … … …

Hib3 75% 75% 75% 75% 75% … … … … …

MCV 66% 66% 66% 66% 66% 72% 81% 60% 51% 24%

Pol3 72% 72% 72% 72% 72% 76% 82% 67% 39% 19%

PAB 73% 73% 72% 72% 65% 42% 33% 82% 14% 2%




at 80% or above





BCG birth

DT 6 years

DTwP 12-13 months


HepB 1st contact; +1, +6 months (high-risk groups)

Influenza 6-23 months; ≥65 years

MenAC high-risk groups

MMR 1, 6 years


Pneumo_conj 2, 4, 6 months (high-risk groups)

Pneumo_ps >65 years; high-risk groups


Td 1st contact; +1, +6 months;+1 year; +every 10 years

Varicella 6, 11 years

Vitamin A 6, 12, 18, 24, 30, 36 months

Yellow fever 1 year (high-risk areas)

279,000273,000

13,625,0002024

8,040100%

2009 2008170 170

100% 100%1% 2%

10% 19%89% 79%

82% 59%

83% 34%

99%2009

12-23 m7%


53

Egypt








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 98% 98% 98% 99% 98% 98% 93% 89% 80% 50%

DTP1 97% 98% 98% 98% 98% 98% 96% 95% 94% 80%

DTP3 97% 97% 98% 98% 98% 98% 88% 87% 84% 57%

HepB3 97% 97% 98% 98% 98% 98% 74% … … …

Hib3 … … … … … … … … … …

MCV 95% 92% 97% 98% 98% 98% 89% 86% 74% 41%

Pol3 97% 97% 98% 98% 98% 98% 90% 87% 84% 67%

PAB 85% 85% 85% 86% 85% 80% 76% 74% 7% …

BCG birth


DTwPHep 2, 4, 6 months

HepB 2, 4, 6 months

Influenza seasonal

MenAC 3, 6, 12, 15 years

MMR 12, 18 months

OPV birth; 2, 4, 6, 9, 18 months

Td school-age children

TT national


2,029,0001,962,000

82,999,0001821

5,690100%

2009 2008271 265

100% …0% …0% …

100% …

93% …

100% …

96%

2009

2-11 y

104%


54

El Salvador





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 87% 99% 99% 93% 84% 99% 99% 75% 50% 56%

DTP1 99% 99% 98% 98% 93% 98% 99% 93% 78% 69%

DTP3 91% 98% 99% 96% 89% 99% 99% 80% 55% 44%

HepB3 91% 98% 99% 96% 89% 99% … … … …

Hib3 91% 98% 99% 96% 89% … … … … …

MCV 95% 95% 99% 98% 99% 97% 93% 98% 71% 45%

Pol3 91% 98% 99% 96% 89% 98% 94% 80% 54% 42%

PAB 87% 87% 87% 91% 92% 83% 67% 37% 26% 23%




at 80% or above





BCG birth

DT pertussis contraindication

DTwP 15 months; 4 years


Influenza 6-23 months; ≥60 years

IPV 2, 4, 6 months (high-risk groups)

MMR 1, 4 years


Pneumo_conj high-risk groups


Td CBAW and 1st contact pregnancy

125,000122,000

6,163,0001517

6,360…

2009 2008262 262

100% 100%3% 5%

11% 10%85% 85%

65% 60%

96% 90%

83%20071-6 y99%


55

Equatorial Guinea








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 73% 73% 73% 73% 73% 73% 99% 94% 28% …

DTP1 65% 65% 65% 65% 65% 65% 94% 96% 21% …

DTP3 33% 33% 33% 33% 33% 33% 79% 77% 3% …

HepB3 … … … … … … … … … …

Hib3 … … … … … … … … … …

MCV 51% 51% 51% 51% 51% 51% 81% 88% 11% …

Pol3 39% 39% 39% 39% 39% 39% 79% 75% 4% …

PAB 75% 69% 62% 59% 59% 61% 75% 58% 14% …

BCG birth


Measles 9 months


TT 1, 2, 6 months; 1, 2 years; pregnancy

26,00023,000

676,00088

14519,350100%

2009 200818 18

100% 100%17% 33%61% 33%22% 33%

28% 22%

22% 72%

…

2005

9 m-15 y

44%


56

Eritrea





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 99% 95% 68% … … …

DTP1 99% 99% 99% 99% 99% 94% 68% … … …

DTP3 99% 99% 96% 96% 96% 90% 58% … … …

HepB3 99% 99% 97% 97% 97% … … … … …

Hib3 99% 99% … … … … … … … …

MCV 95% 95% 95% 95% 95% 86% 58% … … …

Pol3 99% 99% 96% 96% 96% 91% 58% … … …

PAB 86% 86% 85% 85% 84% 80% 17% … … …




at 80% or above





BCG birth

DTwPHibHep 6, 10, 14 week

Measles 9 months


TT 1st contact pregnancy; +1, +6months; +1, +1 year

185,000175,000

5,073,0003955

640…

2009 20086 6

100% 100%17% 17%67% 67%17% 17%

0% 0%

100% 100%

…

2009

9-47 m

82%


57

Estonia








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 97% 98% 98% 99% 99% 99% 99% … … …

DTP1 97% 97% 98% 98% 99% 96% 94% … … …

DTP3 95% 95% 95% 95% 96% 93% 82% … … …

HepB3 95% 94% 95% 95% 95% … … … … …

Hib3 95% 95% 95% 88% 37% … … … … …

MCV 95% 95% 96% 96% 96% 93% 81% … … …

Pol3 95% 95% 95% 95% 96% 93% 80% … … …

PAB … … … … … … … … … …

BCG 1-5 days

DT 3, 4.5, 6 months; 2, 6-7 years(pertussis contraindication)

DTaPHibIPV 3, 4.5, 6 months; 2 years

DTaPIPV 6-7 years

HepB birth; 1, 6 months or 12 years; +1, +6 months

Hib 3, 4.5 months; 2 years(pertussis contraindication)

IPV 3, 4.5, 6 months; 2, 6-7 years (pertussis contraindication)

MMR 1, 13 years

Rabies post-exposure; +3, +7, +14, +28 days

Td 15-16, 25 years; +every 10 years

16,00016,000

1,340,00046

18,890…

2009 200816 15

… 100%

… 0%

… 0%

… 100%

… 100%

… 100%

96%

…

…

…


58

Ethiopia





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 76% 81% 72% 72% 67% 76% 61% 64% 11% …

DTP1 86% 87% 81% 80% 78% 74% 80% 73% 25% …

DTP3 79% 81% 73% 72% 69% 56% 57% 49% 6% …

HepB3 79% 81% 73% … … … … … … …

Hib3 79% 81% 73% … … … … … … …

MCV 75% 74% 65% 63% 59% 52% 38% 38% 12% 4%

Pol3 76% 75% 71% 69% 66% 57% 65% 49% 6% 3%

PAB 88% 84% 83% 82% 80% 54% 34% 24% 5% …




at 80% or above





BCG birth


Measles 9 months

OPV 6, 10, 14 weeks

TT 1st contact pregnancy; +1, +6 months; +1, +2, +3 years

3,132,0002,893,000

82,825,00067

104930…

2009 200898 103

100% 100%19% 21%38% 33%43% 46%

17% 19%

… 39%

…

…

…

…


59

Fiji








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 98% 96% 99% 99% 99% 95%

DTP1 99% 99% 99% 99% 98% 96% 98% 98% 87% 87%

DTP3 99% 99% 99% 98% 96% 90% 97% 97% 69% 68%

HepB3 99% 99% 99% 99% 99% 98% 82% … … …

Hib3 99% 99% 99% 99% 99% 98% … … … …

MCV 94% 94% 94% 92% 90% 81% 94% 84% 57% 32%

Pol3 99% 99% 99% 98% 97% 91% 99% 96% 68% 55%

PAB 94% 94% 94% 93% 93% 84% 76% 5% … …

BCG birth

DTaPHibHep 6, 10, 14 weeks

HepB birth


MR 1, 6 years


TT 1st contact; +1, +6 months; +1 year

18,00017,000

849,0001518

4,570100%

2009 200819 19

100% …

… …

100% 21%

… …

… 5%

… …

57%

2006

6 m-<6 y

98%


60

Finland





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … 98% 98% 99% 99% 91% 83% 90%

DTP1 99% 99% 99% 99% 99% 99% 99% 96% 98% 97%

DTP3 99% 99% 99% 97% 97% 99% 99% 90% 96% 92%

HepB3 … … … … … … … … … …

Hib3 98% 98% 97% 98% 98% 96% 94% … … …

MCV 98% 97% 98% 97% 97% 96% 98% 97% 85% …

Pol3 99% 97% 97% 97% 97% 95% 99% 90% 89% 90%

PAB … … … … … … … … … …




at 80% or above





BCG <7 years (high-risk groups)


DTaPIPV 4 or 6 years

HepA high-risk groups

HepAHepB high-risk groups



IPV travellers to high-risk areas

MenACWY military

MMR 14-18 months; 6 years

Pneumo_ps 2-4 years (high-risk groups)

TBE >7 years (subnational)

Td every 10 years

Tdap 11-13, 14-15 years (children born after 1997)

59,00059,000

5,326,00033

34,430100%

2009 2008… …… …… …… …… …

… …

… …

…

…

…

…


61

France








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 78% 84% 84% 84% 84% 83% 83% 74% 82% 80%

DTP1 98% 98% 98% 98% 98% 98% 98% 97% 98% 92%

DTP3 99% 98% 98% 98% 98% 97% 96% 94% 95% 79%

HepB3 42% 36% 29% 29% 29% 26% … … … …

Hib3 97% 87% 87% 87% 87% 86% … … … …

MCV 90% 87% 87% 87% 87% 84% 83% 71% 35% …

Pol3 98% 98% 98% 98% 98% 98% 97% 95% 97% 80%

PAB … … … … … … … … … …

aP 26-28 years

BCG birth (high-risk groups)

DT 6, 11-15 years

DTaPHibIPV 2, 3, 4, 16-18 months

DTaPIPV 11-13 years

HepB 2, 3, 16-18 months

HPV 14 years; +2, +6months (females)

IPV 6, 11-13 years

MMR 12, 13-24 months

Pneumo_conj 2, 3, 12 months

Td 16-18, 26-28, 38,48, 58, 68 years

YF 1, 11, 21, 31, 41, 51 years (French Guiana)

745,000742,000

62,343,00034

35,020

10%

2009 2008100 100

… …

… …

… …

… …

… …

… …

…

…

…

…


62

Gabon





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 89% 89% 89% 89% 89% 89% 90% 96% 80% …

DTP1 69% 69% 69% 69% 69% 69% 81% 96% 56% …

DTP3 45% 45% 45% 45% 45% 45% 70% 78% 48% …

HepB3 45% 45% 45% 45% 45% … … … … …

Hib3 … … … … … … … … … …

MCV 55% 55% 55% 55% 55% 55% 57% 76% 58% …

Pol3 44% 44% 44% 44% 44% 44% 70% 78% 48% …

PAB 75% 73% 67% 63% 58% 39% 53% 84% 29% …




at 80% or above





BCG birth


HepB 6, 10, 14 weeks

Measles 9 months




40,00038,000

1,475,0005269

12,460100%

2009 200851 51

100% 100%14% 14%35% 45%51% 41%

4% 10%

47% 53%

…

2007

9-59 m

83%


63

Gambia








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 94% 95% 95% 96% 98% 99% 99% 98% 92% 85%

DTP1 98% 96% 94% 97% 96% 97% 99% 98% 90% 89%

DTP3 98% 96% 94% 93% 89% 89% 96% 92% 78% 63%

HepB3 98% 99% 82% 88% 90% 88% 87% … … …

Hib3 98% 96% 94% 93% 89% 89% … … … …

MCV 96% 91% 85% 89% 81% 92% 91% 86% 75% 69%

Pol3 97% 97% 94% 91% 91% 89% 98% 94% 62% 53%

PAB 91% 91% 90% 94% 89% 92% 92% 85% 85% …

BCG birth

DTwP 12-23 months, as 4th dose (booster)


HepB birth

Measles 9 months

OPV birth; 2, 3, 4, 9, 18 months


TT 1st contact pregnancy; +1, +6 months; +1, +2 years

Vitamin A 6 months; +every 6 months until 59 months


62,00057,000

1,705,00078

1031,33035%

2009 20086 6

100% 100%

0% 0%

0% 17%

0% 83%

100% 50%

100% 100%

…

2007

9-59 m

96%


64

Georgia





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 95% 95% 96% 95% 95% 95% 70% … … …

DTP1 96% 97% 98% 87% 87% 87% 91% … … …

DTP3 88% 92% 98% 87% 84% 80% 79% … … …

HepB3 54% 89% 94% 83% 74% 55% … … … …

Hib3 … … … … … … … … … …

MCV 83% 96% 97% 95% 92% 73% 61% … … …

Pol3 93% 90% 88% 88% 84% 81% 82% … … …

PAB … … … … … … … … … …




at 80% or above





BCG birth-5 days

DT 5 years



MMR 1, 5 years


Td 14 years

52,00050,000

4,260,0002629

4,70088%

2009 200865 66… 97%

0% 0%15% 9%85% 88%

31% 86%

57% 73%

…

2008

1-5 y

…


65

Germany








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … …

DTP1 97% 97% 97% 97% 97% 96% 92% 93% 93% …

DTP3 93% 93% 93% 93% 93% 90% 78% 80% 80% …

HepB3 90% 90% 90% 90% 90% 84% 45% … … …

Hib3 94% 94% 94% 94% 94% 94% 85% … … …

MCV 96% 96% 96% 96% 96% 93% 92% 75% 50% 25%

Pol3 96% 96% 96% 96% 96% 94% 95% 80% 85% 80%

PAB … … … … … … … … … …

DTaPHibHepIPV 2, 3, 4, 11-14 months



HPV 12-17 years (females, 3 doses)

Influenza >60 years

MenC_conj 11-23 months

MMR 11-14, 15-23 months

MMRV 11-14, 15-23 months


Pneumo_ps 60 years

Tdap 5-6 years

TdaPIPV 9-17 years

Varicella 11-14, 15-23 months

659,000657,000

82,167,00044

36,960…

2009 2008423 424

… …

… …

… …

… …

… …

… …

91%

…

…

…


66

Ghana





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 99% 99% 87% 71% 41% …

DTP1 96% 90% 96% 87% 88% 96% 88% 80% 46% 27%

DTP3 94% 87% 94% 84% 84% 88% 70% 58% 22% 7%

HepB3 94% 87% 94% 84% 84% … … … … …

Hib3 94% 87% 94% 84% 84% … … … … …

MCV 93% 86% 95% 85% 83% 90% 70% 61% 21% 16%

Pol3 94% 86% 94% 84% 85% 88% 71% 57% 18% 7%

PAB 86% 86% 86% 85% 83% 69% 68% 60% 34% 3%




at 80% or above





BCG birth


Measles 9 months

OPV 6, 10, 14 weeks

TT 1st contact pregnancy; +1,+6 months; +1, +1 year



766,000711,000

23,837,0004769

1,480…

2009 2008170 138

100% 100%0% 15%

10% 16%90% 85%

69% 56%

… 84%

…

2006

9-59 m

79%


67

Greece








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 91% 91% 91% 91% 90% 88% 50% 86% 65% 95%

DTP1 98% 98% 98% 98% 96% 96% 96% 77% 77% 89%

DTP3 99% 99% 99% 98% 96% 89% 90% 54% 54% 72%

HepB3 95% 95% 95% 94% 93% 89% 12% … … …

Hib3 83% 83% 83% 84% 84% 87% 19% … … …

MCV 99% 99% 99% 98% 96% 89% 70% 76% 77% …

Pol3 99% 99% 99% 98% 96% 89% 95% 96% 96% 90%

PAB … … … … … … … … … …

BCG 6 years

DTaP 2, 4, 6, 15-18 months; 4-6 years

HepA >12 months; +6 months


Hib 2, 4, 6, 12-15 months

HPV 12-15 years (females, 3 doses)

IPV 2, 4, 6-18 months; 4-6 years

MenC_conj 2, 4, 15-18 months

MMR 12-15 months; 4-6 years


Pneumo_ps ≥60 years; high-risk groups

Td 14-16 years; +every 10 years

Tdap 11-12 years

Varicella 12-18 months; 4-6 years

106,000106,000

11,161,00033

28,440…

2009 200854 …

… …

… …

… …

… …

… …

… …

…

…

…

…


68

Grenada





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … …

DTP1 99% 99% 99% 95% 99% 98% 98% 93% 82% 50%

DTP3 99% 99% 96% 91% 99% 97% 95% 80% 61% 25%

HepB3 99% 99% 96% 91% 99% … … … … …

Hib3 99% 99% 96% 91% 99% 33% … … … …

MCV 99% 99% 98% 98% 99% 92% 88% 85% 49% …

Pol3 99% 99% 96% 91% 99% 97% 77% 69% 77% 32%

PAB … … … … … … … … … …




at 80% or above





DT 4-5 years

DTwP 18 months

DTwPHibHep 6, 16-20, 24-28 weeks

HepB >18 years (high-risk groups, 3 doses)


MMR 12, 18 months

OPV 6-8, 16-20, 24-28 weeks; 18 months; 4.5, >14 years

Td >7 years (2 doses)

2,0002,000

104,0001315

7,720100%

2009 20087 7

100% 100%0% 0%0% 0%

100% 100%

43% 100%

… 100%

78%

…

…

…


69

Guatemala








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 93% 99% 97% 96% 97% 95% 79% 62% 30% 36%

DTP1 95% 99% 96% 95% 97% 94% 91% 86% 45% 68%

DTP3 92% 96% 93% 89% 87% 83% 77% 66% 21% 43%

HepB3 92% 96% 93% 89% 87% … … … … …

Hib3 92% 96% 93% 89% 87% … … … … …

MCV 92% 96% 93% 95% 95% 86% 83% 68% 23% 23%

Pol3 92% 96% 93% 90% 87% 80% 80% 74% 42% 43%

PAB 71% 71% 71% 70% 70% 67% 55% 44% 9% 1%

BCG birth



Influenza ≥50 years; health workers

MMR 1 year


Td 1st contact pregnancy; +1,+6 months; +1-10, +1-10 years

Vitamin A 6-59, 12-59 months

456,000444,000

14,027,0003340

4,590100%

2009 2008333 332

100% 100%

0% 1%

20% 5%

79% 94%

62% 81%

84% 78%

…

2007

9-39 y

99%


70

Guinea





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 81% 81% 81% 81% 80% 81% 78% 50% 18% …

DTP1 75% 75% 75% 75% 75% 61% 77% 40% 37% …

DTP3 57% 57% 57% 57% 59% 47% 54% 17% 15% …

HepB3 58% 58% 58% … … … … … … …

Hib3 58% … … … … … … … … …

MCV 51% 51% 51% 51% 51% 42% 61% 35% 29% …

Pol3 53% 53% 53% 53% 59% 47% 54% 18% 16% …

PAB 96% 96% 95% 95% 90% 79% 68% 27% … …




at 80% or above





BCG birth


Measles 9 months


TT 1st contact; +1 month



397,000359,000

10,069,00088

142940

30%

2009 200838 38

100% 100%0% 0%

37% 34%63% 66%

45% 26%

84% 92%

…

2006

9-59 m

97%


71

Guinea-Bissau








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 89% 89% 89% 89% 89% 77% 92% 90% 56% …

DTP1 85% 85% 85% 85% 86% 71% 70% 82% 57% …

DTP3 68% 68% 68% 68% 68% 49% 45% 61% 18% …

HepB3 68% … … … … … … … … …

Hib3 68% … … … … … … … … …

MCV 76% 76% 76% 76% 76% 71% 45% 53% 35% …

Pol3 72% 72% 72% 72% 72% 52% 45% 60% 18% …

PAB 94% 94% 92% 69% 65% 49% 68% 40% 10% …

BCG birth


Measles 9 months



Vitamin A 6 months


66,00059,000

1,611,000115193

1,0600%

2009 200811 11

100% 0%

0% …

45% …

55% …

45% 9%

73% …

…

2009

unknown

101%


72

Guyana





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 98% 96% 97% 96% 96% 93% 93% 85% 98% 68%

DTP1 98% 94% 96% 95% 93% 97% 95% 94% 91% 60%

DTP3 98% 93% 94% 93% 93% 88% 86% 83% 75% 35%

HepB3 98% 93% 94% 93% 93% … … … … …

Hib3 98% 93% 94% 93% 93% … … … … …

MCV 97% 95% 96% 90% 92% 86% 77% 73% 40% …

Pol3 97% 93% 94% 92% 93% 79% 87% 79% 77% 42%

PAB 90% 90% 91% 92% 91% 82% 71% 56% … …




at 80% or above





BCG birth

DT 18, 45 months(pertussis contraindication)

DTwP 18, 45 months



IPV 2, 4, 6, 18, 45 months (high-risk groups)

MenACWY high-risk groups

MMR 12, 45 months

OPV 2, 4, 6, 18, 45 months

Pneumo_conj 2, 4, 6 months(high-risk groups,

subnational)

Td 15-17 years

Tdap adults (subnational)

Yellow fever 1 year

13,00013,000

762,0002935

3,030…

2009 200813 13

100% 100%0% 0%0% 0%

100% 100%

77% 85%

… 85%

84%

2007

0-59 m

95%


73

Haiti








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 75% 75% 75% 75% 75% 72% 74% 72% 71% …

DTP1 83% 83% 83% 83% 83% 77% 75% 66% 42% 21%

DTP3 59% 59% 59% 59% 59% 49% 42% 41% 19% 3%

HepB3 … … … … … … … … … …

Hib3 … … … … … … … … … …

MCV 59% 59% 59% 59% 59% 55% 49% 31% 21% …

Pol3 59% 59% 59% 59% 59% 50% 42% 40% 19% 8%

PAB 70% 50% 43% 31% 37% 41% 41% 39% 36% 14%

BCG birth


MR 9 months

OPV <15 days; 6, 10, 14 weeks

Td 15 years; +1, +6 months;+1, +5 years

Vitamin A 6, 10, 14, 18, 30, 42 months

274,000257,000

10,033,0006487……

2009 2008140 133

100% 100%

29% 44%

26% 28%

44% 29%

2% 1%

76% 100%

…

2006

1-4 y

40%


74

Honduras





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 97% 98% 99% 97% 70% 65% 25%

DTP1 99% 96% 94% 95% 98% 98% 97% 94% 80% 53%

DTP3 98% 93% 94% 95% 98% 94% 94% 84% 58% 28%

HepB3 98% 93% 94% 95% 98% 94% … … … …

Hib3 98% 93% 94% 95% 98% 94% … … … …

MCV 99% 95% 96% 97% 96% 98% 89% 90% 53% 31%

Pol3 98% 93% 94% 94% 98% 88% 94% 87% 58% 31%

PAB 94% 94% 94% 94% 90% 93% 77% 60% 27% 7%




at 80% or above





BCG birth

DT 4, 6, 18 months; 4-5 years(pertussis contraindication)



HepB 1st contact; +1, +6 months

(adults and birth dose)

Influenza 6-35 months; >60 years

IPV 2, 4, 6, 18, months(immunocompromised)

MMR 1 year



Td 11 years; pregnancy

Vitamin A 6, 12, 18, 24, 30, 36 months

Yellow fever >1 year (travellers)

202,000197,000

7,466,0002530

3,73071%

…

2008

1-4 y

97%

2009 2008298 298

100% 100%0% 0%4% 11%

96% 89%

82% 75%

90% 80%


75

Hungary








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 99% 99% 99% 99% 99% 99%

DTP1 99% 99% 99% 99% 99% 99% 99% 99% 99% 99%

DTP3 99% 99% 99% 99% 99% 99% 99% 99% 99% 99%

HepB3 … … … … … … … … … …

Hib3 99% 99% 99% 99% 99% 99% … … … …

MCV 99% 99% 99% 99% 99% 99% 99% 99% 99% 99%

Pol3 99% 99% 99% 99% 99% 99% 99% 99% 99% 98%

PAB … … … … … … … … … …

BCG birth


DTaPIPV 18 months; 6 years

HepB 14 years (2 doses)



99,00098,000

9,993,00056

18,570100%

2009 200881 81

100% 100%

0% 0%

0% 0%

100% 100%

100% 100%

100% 100%

99%

…

…

…


76

Iceland





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … …

DTP1 99% 98% 97% 97% 95% 99% 99% 99% 99% 99%

DTP3 96% 98% 97% 97% 95% 98% 99% 99% 99% 99%

HepB3 … … … … … … … … … …

Hib3 97% 99% 98% 98% 96% 99% 99% … … …

MCV 92% 96% 95% 95% 90% 91% 99% 99% 96% …

Pol3 96% 98% 97% 97% 95% 95% 99% 99% 99% 99%

PAB … … … … … … … … … …




at 80% or above





DTaP 5 years


DTaPIPV 14 years

Influenza ≥60 years

MenC_conj 6, 8 months



5,0005,000

323,00023

33,390100%

93%

…

…

…

2009 200859 1

100% …0% …0% …

100% …

100% …

… …


77

India





2009Births...................................................................................................Surviving infants................................................................................Total population .................................................................................Infant mortality rate (per 1,000 live births) ......................................Under-five mortality rate (per 1,000 live births) ..............................Gross national income per capita (PPP, US$) ..................................Percentage of routine EPI vaccines financed by government........



at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 87% 87% 87% 87% 81% 74% 81% 66% 8% …

DTP1 83% 83% 83% 83% 78% 69% 88% 88% 41% 25%

DTP3 66% 66% 66% 66% 67% 60% 71% 70% 18% 6%

HepB3 21% 21% 6% 6% 8% … … … … …

Hib3 … … … … … … … … … …

MCV 71% 71% 71% 71% 64% 50% 72% 56% 1% …

Pol3 67% 67% 67% 67% 55% 62% 71% 66% 14% 2%

PAB 86% 86% 86% 86% 86% 85% 83% 81% 49% 20%

BCG birth

DT 5 years

DTwP 6, 10, 14 weeks; 16-24 months

HepB birth; 6, 10, 14 weeks(subnational)

JE 16-24 months (subnational)

Measles 9-12 months

OPV birth; 6, 10, 14 weeks; 16-24 months

TT 10, 16 years; pregnancy

Vitamin A 9, 18, 24, 30, 36, 42 months

26,787,00025,371,000

1,198,003,0005066

3,230…

2009 2008… 644

… 99%

… 5%

… 30%

… 64%

… 47%

… 73%

…

…

…

…


78

Indonesia





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 93% 89% 89% 88% 85% 80% 77% 74% 65% 61%

DTP1 89% 86% 86% 86% 85% 85% 87% 82% 52% …

DTP3 82% 77% 75% 72% 72% 71% 69% 60% 27% …

HepB3 82% 78% 72% 66% 65% 65% 50% … … …

Hib3 … … … … … … … … … …

MCV 82% 83% 81% 79% 77% 74% 63% 58% 26% …

Pol3 89% 91% 81% 78% 79% 80% 71% 60% 13% …

PAB 85% 79% 83% 83% 83% 82% 74% 64% 29% 6%




at 80% or above





BCG 1 month

DT 6 years


HepB birth-7 days

IPV 2, 3, 4, 9 months (subnational)



TT 7-8 years


4,174,0004,071,000

229,965,0003039

4,060100%

58%

…

…

…

2009 2008475 464

100% 100%2% 4%

17% 17%80% 79%

55% 52%

87% 83%


79

Iran (Islamic Republic of)








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 99% 99% 96% 95% 79% 7%

DTP1 99% 99% 99% 98% 97% 99% 98% 97% 75% 57%

DTP3 99% 99% 99% 98% 95% 99% 98% 91% 51% 32%

HepB3 99% 99% 97% 98% 94% 99% 59% … … …

Hib3 … … … … … … … … … …

MCV 99% 98% 97% 99% 94% 99% 95% 85% 62% 39%

Pol3 99% 99% 98% 99% 95% 99% 97% 90% 63% 38%

PAB 83% 83% 83% 83% 83% 82% 66% 71% 26% 1%

BCG birth

DTwP 2, 4, 6, 12, 18 months; 6 years

HepB birth; 2, 6 months; high-risk groups

MenAC military

MenACWY pilgrims

MMR 12, 18 months

OPV birth; 2, 4, 6, 18 months; 6 years

Td military; pregnancy; +every 10 years

1,390,0001,352,000

74,196,0002631

11,490100%

2009 2008356 348

100% 100%

0% 0%

0% 0%

100% 100%

100% 99%

100% 100%

99%

2003

5-25 y

102%


80

Iraq





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 92% 92% 92% 92% 92% 93% 97% 96% 94% 76%

DTP1 84% 84% 84% 84% 84% 92% 86% 93% 98% 36%

DTP3 65% 65% 65% 65% 65% 78% 74% 83% 86% 14%

HepB3 58% 58% 58% 58% 58% 67% 57% … … …

Hib3 … … … … … … … … … …

MCV 69% 69% 69% 69% 69% 87% 80% 75% 70% 9%

Pol3 69% 69% 69% 69% 69% 84% 73% 83% 86% 16%

PAB 69% 69% 69% 70% 71% 75% 81% 70% 31% 4%




at 80% or above





BCG birthDT 2, 4, 6, 18 months; 4-6 yearsDTwP 2, 4, 6, 18 months; 4-6 yearsHepA 2, 3 yearsHepB birth; 2, 6 monthsInfluenza pilgrims (subnational)IPV 2, 4, 6, 18 months

(immunocompromised)Measles 9 monthsMenACWY 7, 12 years

(high-risk groups)

MMR 15 months; 4-6 yearsOPV birth; 2, 4, 6, 18 months;

4-6 yearsPneumo_ps 4 years (high-risk groups,

subnational)Td 7, 12 yearsTT 1st contact; +1, +6 months;

+1, +2 yearsTyphoid 4 years (high-risk groups,

subnational)Vitamin A 9, 19 months; 6 yearsYellow fever travellers (subnational)

949,000919,000

30,747,0003544

3,340100%

102%

2009

6-60 m

98%

2009 2008121 115

100% 100%4% 5%

36% 34%60% 61%

53% 47%

31% 32%


81

Ireland








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 94% 94% 93% 93% 93% 90% 87% 84% 80% …

DTP1 97% 97% 97% 97% 96% 95% 90% 85% 70% 59%

DTP3 93% 93% 92% 91% 90% 86% 73% 65% 45% 34%

HepB3 … … … … … … … … … …

Hib3 93% 93% 92% 91% 90% 85% … … … …

MCV 89% 89% 87% 86% 84% 79% 77% 78% 63% …

Pol3 93% 93% 92% 91% 90% 86% 77% 81% 90% 72%

PAB … … … … … … … … … …

BCG birth (subnational)

DTaPHibHepIPV 2, 4, 6 months

DTaPIPV 4-5 years

HepB 1st contact; +1, +6 months (high-risk groups)

Hib 13 months

Influenza ≥50 years; high-risk groups

MenC_conj 4, 6, 13 months

MMR 1, 4-5 years; health workers



Tdap 11-14 years

70,00070,000

4,515,00044

33,280…

2009 20088 8

100% 100%

0% 0%

0% 0%

100% 100%

88% 50%

… …

…

2009

15-18 y

…


82

Israel





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … 75%

DTP1 98% 98% 98% 98% 98% 97% 98% 97% 95% 94%

DTP3 93% 93% 93% 93% 93% 96% 96% 93% 85% 84%

HepB3 96% 96% 96% 96% 96% 97% 93% … … …

Hib3 93% 93% 93% 93% 93% 94% 93% … … …

MCV 96% 96% 96% 96% 94% 97% 93% 91% 85% 81%

Pol3 94% 94% 94% 94% 95% 92% 96% 93% 86% 85%

PAB … … … … … … … … … …




at 80% or above





BCG high-risk groupsDT 2, 4, 6, 12 months

(pertussis contraindication)DTaPHibIPV 2, 4, 6, 12 monthsDTaPIPV 7 yearsHepA 18, 24 months;

high-risk groupsHepAHepB high-risk groupsHepB birth; 1, 6 months;

high-risk groupsHib high-risk groups Influenza high-risk groupsIPV high-risk groups

JE travellersMenACWY high-risk groupsMMR ≥12 years (high-risk groups)MMRV 1, 6 years; high-risk groupsPneumo_conj 2, 4, 12 monthsPneumo_ps ≥65 years; high-risk groupsTBE travellersTd >7 years; +every 10 yearsTdap 14 yearsTyphoid travellersTyphoidHepA travellersVericella high-risk groupsYellow fever travellers

140,000139,000

7,170,00034

27,040…

92%

…

…

…

2009 200815 15

100% 100%0% 0%0% 0%

100% 100%

100% 100%

100% 100%


83

Italy








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … …

DTP1 96% 96% 97% 97% 96% 95% 98% 94% 33% …

DTP3 96% 96% 97% 96% 95% 87% 95% 83% 12% …

HepB3 96% 96% 97% 96% 96% 94% 95% 95% … …

Hib3 96% 96% 96% 96% 95% 55% … … … …

MCV 91% 90% 90% 88% 87% 74% 50% 43% 12% …

Pol3 97% 96% 97% 97% 97% 97% 98% 98% 92% …

PAB … … … … … … … … … …

aP 3, 5, 11-12 monthsBCG high-risk groupsDip 3, 5, 11-12 months;

5-6, 11-15 yearsHepA travellers (2 doses)HepB 3, 5, 11-12 months;

high-risk groupsHib 3, 5, 11-12 monthsHPV 12 years; +1,

+6 months (females)Influenza high-risk groupsIPV 3, 5, 11-12 months;

5-6 years

Measles 12-15 months; 5 or 12 yearsMenC_conj 3, 5, 11-12 months;

high-risk groupsMMR 12-15 months; 5-12 years

(recommended)Pneumo_conj 3, 5, 11-12 months;

high-risk groups (recommended)

Pneumo_ps high-risk groupsRubella females (2 doses)Td 11-15 yearsVaricella high-risk groups (2 doses)

543,000541,000

59,870,00034

31,330100%

2009 200821 21

… …

… …

… …

… …

… …

… …

…

…

…

…


84

Jamaica





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 94% 92% 87% 90% 95% 93% 98% 98% 51% 38%

DTP1 91% 88% 85% 86% 91% 87% 96% 95% 82% 48%

DTP3 90% 87% 85% 85% 88% 86% 90% 86% 60% 24%

HepB3 90% 89% 85% 87% 87% … … … … …

Hib3 90% 87% 85% 87% 89% … … … … …

MCV 88% 88% 76% 87% 84% 88% 90% 74% 64% …

Pol3 90% 87% 85% 86% 83% 86% 91% 87% 58% 34%

PAB 62% 58% 54% 53% 51% 51% … … … …




at 80% or above





BCG birthDT 1.5, 3, 5-6, 18 months;

4-6 years (pertussis contraindication)

DTwP 18 months; 4-6 yearsDTwPHibHep 1.5, 3, 5-6 monthsHepB 1.5, 3, 6 months or

1st contact; +1, +6 months (high-risk groups)

Hib 1.5, 3, 6 months (pertussis contraindication)

Influenza health workers; high-risk groups

IPV 1.5, 3, 5-6, 18 months; 4-6 years (immunocompromsed)

MMR 12-23 months; 4-6 yearsOPV 1.5, 3, 5-6, 18 months; 4-6 yearsTd 4-6 years; pregnancyYellow fever travellers

52,00051,000

2,719,0002631

7,320100%

78%

2006

12-72 m

21%

2009 200813 13

100% 100%0% 0%0% 31%

100% 69%

46% 0%

100% 100%


85

Japan








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … 85% 85% …

DTP1 98% 98% 98% 98% 98% 88% 90% 96% 94% 82%

DTP3 98% 98% 98% 98% 98% 85% 74% 90% 83% 60%

HepB3 … … … … … … … … … …

Hib3 … … … … … … … … … …

MCV 94% 95% 96% 97% 98% 96% 93% 73% 73% 69%

Pol3 99% 98% 97% 95% 95% 99% 97% 90% 95% …

PAB … … … … … … … … … …

BCG 6 months

DT 11 years

DTaP 3, 4.5, 6, 18 months


JE 36, 37 months; 4 years

Measles 1, 5 years

MR 1, 5 years

OPV 6 months; 1 year

Rubella 1, 5 years

1,014,0001,011,000

127,156,00023

33,280…

2009 20081 …

… …

0% …

… …

… …

… …

… …

92%

…

…

…


86

Jordan





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 95% 95% 90% 95% 89% … … … … …

DTP1 98% 98% 99% 99% 98% 91% 99% 97% 95% 55%

DTP3 98% 97% 98% 98% 95% 91% 95% 92% 85% 30%

HepB3 98% 97% 98% 98% 95% 93% 54% … … …

Hib3 98% 97% 98% 98% 95% … … … … …

MCV 95% 95% 95% 99% 95% 94% 92% 87% 73% 29%

Pol3 98% 98% 98% 98% 95% 94% 95% 92% 84% 32%

PAB 87% 87% 87% 86% 67% 44% 47% 49% 52% …




at 80% or above





BCG birth-6 yearsDT 2, 3, 4, 18 months

(high-risk groups)DTaPHibIPV 3, 4 monthsDTwP 18 monthsDTwPHib 5 monthsDTwPHibHep 3, 4 monthsHepB 3, 4, 5 monthsInfluenza health workers;

pilgrims; high-risk groups

Measles 9 monthsMenACWY >2 years (high-risk groups)MMR 12, 18 monthsOPV 4, 5, 9, 18 months; 6 yearsPneumo_conj 3, 5, 9 months

(subnational)Td 6, 16 yearsTT 1st contact; +1, +6 months;

+1 year, +1 yearYellow fever travellers

158,000155,000

6,316,0002225

5,840100%

103%

2005

8-16 y

87%

2009 200821 21

100% 100%0% 0%0% 0%

100% 100%

100% 100%

… 100%


87

Kazakhstan








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 96% 97% 99% 99% 69% 98% 90% … … …

DTP1 98% 99% 97% 99% 99% 97% 97% … … …

DTP3 98% 99% 93% 99% 98% 97% 93% … … …

HepB3 99% 99% 94% 99% 94% 99% … … … …

Hib3 97% 49% … … … … … … … …

MCV 99% 99% 99% 99% 99% 99% 95% … … …

Pol3 99% 99% 94% 99% 99% 97% 94% … … …

PAB … … … … … … … … … …

BCG birth; 6 years

Dip 12 years

DT 6 years

DTwPHib 3, 18 months

DTwPHibHep 2, 4 months

HepA 2 years

HepB birth

Influenza health workers; children (high-risk groups)

MenACWY pilgrims

MMR 1, 6 years


Rubella 15 years


Typhoid adults; high-risk groups

308,000300,000

15,637,0002629

10,270

…

2009 2008204 204

100% 100%

0% 0%

0% 0%

100% 100%

100% 100%

98% …

99%

2005

15-25 y

99%


88

Kenya





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 75% 83% 92% 92% 85% 89% 97% 92% 82% …

DTP1 80% 83% 89% 90% 85% 83% 96% 92% 88% …

DTP3 75% 72% 81% 80% 76% 82% 94% 84% 70% …

HepB3 75% 72% 81% 80% 76% … … … … …

Hib3 75% 72% 81% 80% 76% … … … … …

MCV 74% 76% 80% 77% 69% 78% 83% 78% 63% …

Pol3 71% 74% 76% 77% 70% 80% 94% 84% 70% …

PAB 78% 78% 74% 74% 73% 68% 61% 60% 36% …




at 80% or above





BCG birth


Measles 9 months


TT 1st contact pregnancy; +1 month; +next pregnancy (up to 4th)

Vitamin A 9, 12, 18, 24, 30, 36 months

Yellow fever 9 months (subnational)

1,530,0001,435,000

39,802,0005584

1,570…

0%

2009unknown

…

2009 2008149 78

99% 97%11% 8%46% 49%42% 44%

21% 24%

66% …


89

Kiribati








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 76% 83% 90% 91% 93% 80% 47% 93% 62% 66%

DTP1 92% 99% 99% 99% 95% 97% 82% 98% 62% 68%

DTP3 86% 82% 94% 86% 79% 90% 60% 97% 37% 43%

HepB3 86% 83% 96% 88% 50% 90% 36% 73% … …

Hib3 86% 83% … … … … … … … …

MCV 82% 72% 93% 61% 85% 80% 47% 75% 4% …

Pol3 84% 74% 93% 86% 74% 90% 58% 97% 15% 10%

PAB … … … … … … … … … …

BCG birth

Dip 6 years


HepB birth

MR 1, 6 years

OPV 6, 10, 14 weeks

TT 6, 13 years

……

98,0003746

3,350…

2009 2008204 6

100% …

21% …

33% …

46% …

42% …

63% …

35%

2009

12-59 m

106%


90

Korea, Democratic People’s Republic of





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 98% 97% 96% 96% 94% 76% 82% 99% 51% 50%

DTP1 94% 93% 93% 91% 83% 60% 84% 98% 78% 74%

DTP3 93% 92% 92% 89% 79% 54% 64% 98% 55% 50%

HepB3 92% 92% 92% 96% 92% … … … … …

Hib3 … … … … … … … … … …

MCV 98% 98% 99% 96% 96% 73% 67% 98% 38% 29%

Pol3 98% 98% 99% 98% 97% 92% 88% 99% 65% 50%

PAB 91% 91% 91% 90% 90% 81% 90% 90% … …




at 80% or above





BCG birth


HepB birth


OPV 6, 10, 14 weeks

TT 3, 4 months


327,000311,000

23,906,0002633…

10%

98%

20076 m-45 y

100%

2009 2008208 210

100% 100%0% 0%0% 0%

100% 100%

100% 100%

… …


91

Korea, Republic of








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 96% 96% 96% 98% 97% 73% 93% 72% 47% …

DTP1 97% 97% 91% 98% 98% 98% 99% 90% 91% …

DTP3 94% 94% 91% 98% 96% 97% 99% 74% 76% …

HepB3 94% 94% 91% 99% 99% 93% 99% … … …

Hib3 … … … … … … … … … …

MCV 93% 92% 92% 99% 99% 95% 93% 93% 89% 4%

Pol3 95% 92% 91% 98% 96% 99% 99% 74% 80% …

PAB … … … … … … … … … …

BCG birth-1 month

DTaP 2, 4, 6, 15-18 months;4-6 years



IPV 2, 4, 6-18 months; 4-6 years

JE 1-2 years; +1-2 weeks; +1, +6, +12 years

MMR 12-15 months; 4-6 years

Td 11-12 years

Typhoid high-risk groups (1-4 doses)

Varicella 12-15 months

450,000448,000

48,333,00055

27,31048%

2009 2008270 270

100% 100%

0% 0%

0% 0%

100% 100%

100% 100%

… …

100%

2009

7 y

100%


92

Kuwait





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … …

DTP1 99% 99% 99% 99% 99% 98% 99% 88% 96% 86%

DTP3 98% 98% 98% 98% 98% 98% 99% 71% 90% 67%

HepB3 94% 94% 94% 94% 94% 95% 99% … … …

Hib3 98% 98% 98% 98% 98% 98% … … … …

MCV 97% 97% 97% 97% 97% 99% 98% 66% 91% 48%

Pol3 98% 98% 98% 98% 98% 94% 99% 71% 91% 70%

PAB 84% 84% 83% 82% 81% 77% 37% 51% 13% 6%




at 80% or above





BCG 3.5 years

DT high-risk groups

DTwP 3.5 years

DTwPHib 2, 4, 6, 18 months


Influenza seasonal

MenAC new laborers

MenACWY 2 years; contactswith pilgrims

MMR 1, 3.5 years

OPV birth; 2, 4, 6, 18 months; 3.5 years

Pneumo_ps high-risk groups

Rubella 12 years (females)

Td 10-18 years

TT high-risk groups (subnational)

Typhoid food handlers (subnational)


52,00052,000

2,985,0008

1053,590

…

…………

2009 2008… …… …… …… …… …

… …

… …


93

Kyrgyzstan








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 98% 99% 98% 99% 96% 96% 96% … … …

DTP1 97% 98% 97% 95% 98% 98% 97% … … …

DTP3 95% 95% 94% 92% 98% 99% 93% … … …

HepB3 96% 97% 94% 90% 97% 44% … … … …

Hib3 … … … … … … … … … …

MCV 99% 99% 99% 97% 99% 98% 97% … … …

Pol3 96% 95% 94% 93% 98% 99% 96% … … …

PAB … … … … … … … … … …

BCG birth

DT 6 years

DTwP 2 years

DTwPHibHep 2, 3.5, 5 months

HepB birth

MMR 1 year

MR 6 years

OPV birth; 2, 3.5, 5 months

Td 11, 16, 26, 36, 46, 56 years

122,000117,000

5,482,0003237

2,20064%

2009 200852 52

… …

… …

… …

… …

… …

… …

99%

2001

7-25 y

99%


94

Lao People’s Democratic Republic





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 67% 68% 56% 61% 65% 69% 62% 26% 8% …

DTP1 76% 73% 59% 68% 68% 83% 77% 41% 22% …

DTP3 57% 57% 57% 57% 49% 51% 54% 18% 4% …

HepB3 67% 61% 50% 57% 49% … … … … …

Hib3 … … … … … … … … … …

MCV 59% 52% 40% 48% 41% 42% 68% 32% 6% …

Pol3 67% 60% 46% 56% 50% 57% 64% 26% 4% …

PAB 47% 47% 47% 52% 50% 58% 44% 12% 2% …




at 80% or above





BCG birth


HepB birth

Measles 9 months

OPV 6, 10, 14 weeks

TT 1st contact; +1, +6 months; +1,+1, +1 year

Vitamin A 6, 12, 18, 24, 30, 36 months

172,000164,000

6,320,0004659

2,2107%

…2007

9 m-14 y96%

2009 2008141 140

100% 100%17% 26%53% 63%30% 11%

10% 3%

51% 47%


95

Latvia








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 99% 99% 99% … … …

DTP1 97% 98% 98% 99% 99% 99% 99% … … …

DTP3 95% 97% 98% 98% 99% 96% 98% … … …

HepB3 94% 96% 97% 97% 98% 95% … … … …

Hib3 95% 96% 97% 99% 94% 79% 58% … … …

MCV 96% 97% 97% 95% 95% 97% 81% … … …

Pol3 96% 97% 98% 98% 99% 96% 98% … … …

PAB … … … … … … … … … …

BCG 4-5 days

DT 7 years

DTaPHibIPV 3, 4.5, 6 months

DTaPIPV 18 months

HepB birth; 1, 6-8 months

IPV 7, 14 years

MenAC high-risk groups


OPV 18 months; 7, 14 years

Pneumo_conj high-risk groups


Td 14 years

TdIPV 14 years

Varicella 15 months

23,00023,000

2,249,00078

16,510100%

2009 200833 33

100% …

… …

3% …

97% 100%

… 100%

… …

91%

…

…

…


96

Lebanon





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … …

DTP1 83% 83% 83% 83% 83% 90% 97% 94% 40% 17%

DTP3 74% 74% 74% 74% 74% 83% 93% 82% 17% 0%

HepB3 74% 74% 74% 74% 74% 83% … … … …

Hib3 74% 74% 74% 74% 74% … … … … …

MCV 53% 53% 53% 53% 53% 71% 85% 61% 23% 0%

Pol3 74% 74% 74% 74% 74% 83% 93% 82% 17% 0%

PAB … … … … … … … … … …




at 80% or above





DT <8 years

DTwP 4-5 years

DTwPHib 18 months


HepB birth

Measles 9 months

MenACWY national

MMR 1, 4-5 years

OPV 2, 3, 4, 18 months; 4-5, 10-12 years

Td 10-12 years

66,00065,000

4,224,0001112

13,230100%

88%2000

1-15 y93%

2009 200826 26

96% 100%… 0%… 0%… 100%

96% 73%

… 73%


97

Lesotho








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 96% 96% 96% 96% 96% 88% 96% 89% 91% 81%

DTP1 93% 93% 93% 94% 94% 87% 95% 91% 92% 75%

DTP3 83% 83% 84% 86% 87% 83% 88% 82% 82% 56%

HepB3 83% 83% 84% 86% 87% … … … … …

Hib3 83% … … … … … … … … …

MCV 85% 85% 85% 85% 85% 74% 83% 80% 73% 49%

Pol3 80% 80% 82% 84% 86% 82% 88% 82% 80% 56%

PAB 83% 83% 82% 80% 79% 73% 61% … … …

BCG birth

DT 18 months


HPV 9-18 years (females, 3 doses, subnational)


OPV 6, 10, 14 weeks

TT 1st contact; +1 month; +1 year

Vitamin A 6, 12, 18, 24, 30, 36 months

59,00055,000

2,067,0006184

1,8701%

2009 200810 10

… 50%

20% 0%

50% 50%

30% 50%

0% 0%

100% 100%

…

2007

9-59 m

92%


98

Liberia





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 80% 80% 74% 77% 76% 78% … … … …

DTP1 75% 75% 75% 75% 75% 80% … … … …

DTP3 64% 64% 60% 60% 60% 46% … … … …

HepB3 64% 63% … … … … … … … …

Hib3 64% 63% … … … … … … … …

MCV 64% 64% 64% 63% 62% 63% … … … …

Pol3 74% 74% 64% 66% 66% 56% … … … …

PAB 91% 91% 90% 73% 60% 51% 55% 33% 18% …




at 80% or above





BCG birth


Measles 9 months


TT 15 years; +1, +6 months;+1, +1 year

VitaminA 6, 12 months


149,000135,000

3,955,00080

112290…

…2007

9-59 m97%

2009 200815 15

100% 100%0% 0%

13% 7%87% 93%

67% 87%

60% 60%


99

Libyan Arab Jamahiriya








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 99% 98% 99% 90% 87% 88%

DTP1 98% 98% 98% 98% 98% 98% 98% 94% 93% 82%

DTP3 98% 98% 98% 98% 98% 94% 95% 84% 81% 60%

HepB3 98% 98% 98% 98% 97% 92% 92% … … …

Hib3 98% 98% 56% … … … … … … …

MCV 98% 98% 98% 98% 97% 93% 92% 89% 75% 61%

Pol3 98% 98% 98% 98% 98% 94% 95% 84% 81% 60%

PAB … … … … … … … … … …

BCG birth

DT 6 years

DTwP 18 months


HepB birth

Influenza seasonal

MenACWY 6 years; pilgrims

MMR 12, 18 months

OPV birth; 2, 4, 6, 18 months; 6 years

Td 15 years

TT 15 years


148,000145,000

6,420,0001719

16,430100%

2009 200823 23

100% 100%

0% 0%

0% 0%

100% 100%

100% 100%

100% 100%

94%

2009

1-6 y

98%


100

Lithuania





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 99% 99% 97% … … …

DTP1 98% 96% 99% 98% 98% 99% 96% … … …

DTP3 98% 96% 95% 94% 94% 94% 90% … … …

HepB3 95% 96% 96% 95% 95% 99% … … … …

Hib3 98% 96% 95% 94% 61% 2% … … … …

MCV 96% 97% 97% 97% 97% 97% 94% … … …

Pol3 98% 96% 95% 94% 93% 92% 89% … … …

PAB … … … … … … … … … …




at 80% or above





BCG birth

DTaPHibIPV 3, 4.5, 6, 18 months

DTaPIPV 6 years

HepB birth; 1, 6 months or 12 years (3 doses)


Rabies post-exposure; +3, +7, +14, +28 days

Td 6, 15 years

32,00031,000

3,287,00056

16,740100%

94%

…

…

…

2009 200852 52

100% 100%0% 0%0% 2%

100% 98%

100% 96%

… …


101

Luxembourg








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … …

DTP1 98% 98% 98% 98% 98% 98% 98% 96% 91% …

DTP3 99% 99% 99% 99% 99% 98% 97% 90% 77% …

HepB3 95% 94% 87% 91% 95% 49% … … … …

Hib3 99% 98% 99% 99% 98% 91% … … … …

MCV 96% 96% 96% 96% 95% 91% 88% 80% 58% …

Pol3 99% 99% 99% 99% 99% 98% 96% 90% 90% …

PAB … … … … … … … … … …


DTaPHibIPV 4 months

DTaPIPV 5-6, 15-16 years; +every 10 years

HepB 2-3, 3-4, 11-12 monthsor 12 years (catch up)



IPV every 10 years

MenC_conj ≥13 months


MMRV 12, 15-23 months




Typhoid travellers


6,0005,000

486,00023

57,640100%

2009 2008… …

… …

… …

… …

… …

… …

… …

…

…

…

…


102

Madagascar





2009


2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 73% 83% 94% 90% 80% 72% 72% 67% 31% 21%

DTP1 80% 84% 92% 91% 83% 72% 80% 71% 47% …

DTP3 78% 77% 84% 83% 82% 57% 57% 46% 23% …

HepB3 78% 76% 82% 80% 79% … … … … …

Hib3 78% 52% … … … … … … … …

MCV 64% 70% 81% 65% 61% 55% 55% 47% 6% …

Pol3 76% 77% 83% 78% 72% 60% 56% 46% 21% …

PAB 76% 76% 72% 71% 66% 58% 38% 45% 26% …




at 80% or above





BCG birth


Measles 9 months



Vitamin A 6, 12, 18, 24, 30, 36 months

695,000651,000

19,625,0004158

1,05051%

…

2008

9-59 m

…

2009 2008111 111

100% 100%2% 3%

30% 27%68% 70%

35% 50%

60% 41%


103

Malawi








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 95% 97% 95% 99% 99% 83% 97% 97% 87% …

DTP1 97% 97% 96% 99% 99% 98% 96% 95% 78% 80%

DTP3 93% 91% 87% 99% 93% 75% 89% 87% 55% 58%

HepB3 93% 91% 87% 99% 93% … … … … …

Hib3 93% 91% 87% 99% 93% … … … … …

MCV 92% 88% 83% 85% 82% 73% 90% 81% 49% 49%

Pol3 93% 92% 88% 99% 94% 73% 90% 93% 55% 28%

PAB 87% 87% 86% 88% 86% 84% 87% 81% 26% …

BCG birth


Measles 9 months

OPV 6, 10, 14 weeks


Vitamin A 6, 12, 18, 24, 30, 36 months

608,000559,000

15,263,00069

110760

100%

2009 200828 26

100% 100%

0% 0%

4% 4%

96% 96%

50% 38%

100% 96%

…

2008

9-59 m

98%


104

Malaysia





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 98% 98% 90% 99% 99% 99% 99% 99% 95% 94%

DTP1 95% 96% 90% 96% 96% 95% 93% 95% 68% 86%

DTP3 95% 96% 90% 90% 95% 95% 94% 90% 57% 67%

HepB3 95% 95% 90% 87% 92% 94% 91% 86% … …

Hib3 95% 95% 90% 89% 85% … … … … …

MCV 95% 94% 95% 90% 90% 88% 86% 70% 20% …

Pol3 95% 96% 90% 96% 94% 95% 94% 90% 56% 67%

PAB 87% 87% 87% 88% 88% 88% 84% 82% 52% 20%




at 80% or above





BCG birthDT 7 yearsDTaPHibIPV 2, 3, 5, 18 months

(subnational)DTwP 18 monthsDTwPHibHep 2, 3, 5 months

(subnational)HepB birth; 1, 6 monthsInfluenza high-risk groups

JE 9, 10, 18 months; 5, 8, 11 years (subnational)

Measles 6 months (subnational)

MenACWY pilgrims

MMR 1, 7 years


TT 15 years

Typhoid food handlers


550,000545,000

27,468,00066

13,53080%

…

2004

7-15 y

96%

2009 2008139 139

100% 100%2% …

12% 2%86% 98%

65% 84%

… …


105

Maldives








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 99% 99% 99% 99% 45% 7%

DTP1 98% 98% 98% 98% 98% 98% 99% 97% 53% 22%

DTP3 98% 98% 98% 98% 98% 98% 94% 94% 28% 4%

HepB3 98% 98% 98% 98% 98% 96% 80% … … …

Hib3 … … … … … … … … … …

MCV 98% 97% 97% 97% 97% 99% 96% 96% 47% …

Pol3 98% 98% 98% 98% 98% 98% 97% 94% 28% 4%

PAB 95% 95% 94% 94% 94% 95% 92% 86% 25% 8%

BCG birth

Cholera >18 years (subnational);travellers

DT 5 years(pertussis contraindication)



Influenza >15 years(subnational); pilgrims

Measles 9 months

MenACWY >15 years (subnational);pilgrims

MMR 18 months

OPV birth; 1, 2, 3 months; >15 years (high-risk areas)

TT CBAW; +1, +6 months; +1, +1 year

Vitamin A 6, 12, 18, 24 months

Yellow fever >18 years (subnational); travellers

6,0006,000

309,0001113

5,230100%

2009 200820 20

100% 100%

0% 0%

0% 0%

100% 100%

100% 100%

… 100%

96%

2007

4-6 y

56%


106

Mali





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 86% 86% 86% 86% 83% 69% 76% 82% 33% …

DTP1 85% 85% 86% 86% 87% 61% 73% 67% 28% …

DTP3 74% 74% 74% 77% 77% 43% 49% 42% 8% 8%

HepB3 75% 75% 74% 90% 89% … … … … …

Hib3 74% 74% 44% 16% 3% … … … … …

MCV 71% 71% 72% 72% 73% 55% 52% 43% 19% …

Pol3 74% 74% 74% 77% 78% 54% 49% 42% 8% …

PAB 92% 92% 90% 89% 86% 50% 36% 45% 4% …




at 80% or above





BCG birthDTwPHibHep 6, 10, 14 weeksMeasles 9 months




551,000494,000

13,010,000101191

1,190…

…

2007

9-59 m

101%

2009 200859 59

100% 100%5% 5%

14% 14%81% 81%

69% 68%

98% 22%


107

Malta








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … 92% 77% 65% …

DTP1 91% 88% 84% 85% 94% 97% 97% 84% 62% …

DTP3 73% 72% 74% 85% 92% 94% 92% 63% 37% …

HepB3 86% 86% 82% 86% 85% … … … … …

Hib3 73% 72% 72% 83% 83% 93% … … … …

MCV 82% 78% 79% 94% 86% 74% 51% 80% 10% …

Pol3 73% 72% 76% 83% 94% 94% 92% 86% 84% …

PAB … … … … … … … … … …

BCG 12 years


HepB 15, 16, 21 months

Influenza seasonal (subnational)



Td 3, 16 years

4,0004,000

409,00067

22,640

…

2009 20081 …

… …

… …

… …

… …

… …

… …

85%

…

…

…


108

Marshall Islands





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 92% 92% 92% 92% 93% 89% 71% 49% … …

DTP1 99% 99% 99% 90% 89% 64% 88% 97% … …

DTP3 93% 93% 93% 74% 77% 39% 70% 92% … …

HepB3 93% 93% 93% 97% 89% 38% 47% 10% … …

Hib3 83% 83% 83% 60% 69% 45% … … … …

MCV 94% 94% 94% 96% 86% 94% 57% 52% … …

Pol3 91% 91% 91% 95% 88% 36% 64% 89% … …

PAB … … … … … … … … … …




at 80% or above





BCG birthDTaP 2, 4, 6, 12 monthsHepB birth; 2, 6 months;

adolescentsHib 2, 4, 12 months HPV 11-12 years; +2, +6 months

(females)Influenza seasonal

MMR 12, 13 months

OPV 2, 4, 6 months; 4-6 years


Rotavirus 2, 4, 6 months

TT/Td adolescents; adults


……

62,0002935……

66%

2003

6 m-40 y…

2009 20083 …

100% …0% …0% …

100% …

… …

… …


109

Mauritania








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 81% 89% 92% 86% 89% 75% 80% 79% 74% …

DTP1 79% 88% 92% 85% 85% 70% 93% 69% 52% …

DTP3 64% 74% 75% 68% 71% 53% 55% 33% 27% …

HepB3 64% 74% 74% 68% 42% … … … … …

Hib3 64% … … … … … … … … …

MCV 59% 65% 67% 62% 61% 62% 67% 38% 41% …

Pol3 63% 73% 75% 68% 71% 61% 56% 33% 16% …

PAB 87% 77% 77% 62% 59% 44% 43% 24% 17% …

BCG birth


Measles 9 months


TT 1st contact; +1 month; +1, +1, +1 year; pregnancy

109,000101,000

3,291,00074

1171,960100%

2009 200853 53

100% 100%

25% 13%

64% 64%

11% 23%

2% 6%

28% 62%

…

2004

9 m-14 y

102%


110

Mauritius





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 95% 96% 98% 97% 99% 88% 86% 87% 87% 89%

DTP1 99% 99% 99% 99% 99% 96% 97% 95% 96% 96%

DTP3 99% 99% 97% 97% 97% 88% 93% 85% 88% 89%

HepB3 99% 99% 97% 97% 97% 88% … … … …

Hib3 99% 99% 96% 96% … … … … … …

MCV 99% 98% 98% 99% 98% 84% 89% 76% 67% …

Pol3 99% 99% 96% 98% 97% 88% 93% 86% 91% 90%

PAB 87% 87% 86% 85% 86% 79% 78% 61% 18% 1%




at 80% or above





BCG 1 monthDT 5 yearsDTwPHib 6, 10, 14 weeks; 1 yearHepB 6, 10, 14 weeks;

high-risk groupsInfluenza ≥65 yearsMenACWY travellers

MMR 1, 5 years

OPV 6, 10, 14 weeks; 1 year

TT pregnancy; post-injury; school students

Typhoid travellers


18,00018,000

1,288,0001517

13,270100%

85%

…

…

…

2009 200810 10

100% 100%0% 0%0% 0%

100% 100%

100% 40%

100% 100%


111

Mexico








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 90% 99% 99% 99% 99% 99% 98% 67% 16% 48%

DTP1 97% 97% 98% 98% 98% 98% 97% 77% 65% 69%

DTP3 89% 96% 98% 98% 98% 97% 91% 53% 40% 44%

HepB3 71% 71% 98% 98% 98% 97% … … … …

Hib3 89% 96% 98% 98% 98% 97% … … … …

MCV 95% 96% 96% 96% 96% 96% 90% 75% 64% 35%

Pol3 89% 96% 98% 98% 98% 97% 92% 66% 67% 91%

PAB 87% 87% 87% 87% 86% 81% 71% 59% 36% 5%

BCG birth

DTaP 2, 4 years


HepB birth; 2, 6 months; >12 years (2 doses)

HPV 12 years (females, subnational, 3 doses)

Influenza 6-35 months (2 doses); >60 years

MMR 1, 6 years

MR 11-12 years

OPV >6 months; <5 years (6 doses)


Pneumo_ps 65 years


Td 11-12 years (2 doses); >12 years (4 doses);

pregnancy

Vitamin A <5 years (2 doses,subnational)

2,021,0001,990,000

109,610,0001517

14,110100%

2009 20082,438 2,438

100% 100%

2% 2%

9% 8%

89% 90%

92% 92%

… …

92%

2009

6-7 y

90%


112

Micronesia (Federated States of)





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 75% 79% 82% 55% 70% 24% 50% 12% … …

DTP1 97% 95% 79% 79% 97% 91% 94% 95% … …

DTP3 91% 85% 79% 67% 94% 85% 83% 85% … …

HepB3 88% 89% 90% 84% 91% 87% 82% 56% … …

Hib3 73% 73% 79% 59% 74% 75% … … … …

MCV 86% 86% 92% 83% 96% 85% 90% 81% … …

Pol3 81% 88% 79% 81% 94% 85% 81% 85% … …

PAB … … … … … … … … … …




at 80% or above





BCG birthDTaP 2, 4, 6 months; 1, 4 yearsHepB birth; 2, 6 monthsHib 2, 4, 12 months

MMR 12, 13 months


Pneumo_conj 2, 4, 6 months; 1, 4 years

Td 7, 9 years

3,0003,000

111,0003239

2,8100%

82%

…

…

…

2009 20084 …

… …… …… …… …

… …

0% …


113

Moldova








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 96% 99% 99% 99% 99% 99% 95% … … …

DTP1 88% 96% 97% 97% 98% 98% 98% … … …

DTP3 85% 95% 96% 97% 98% 95% 96% … … …

HepB3 89% 98% 98% 99% 99% 92% 19% … … …

Hib3 47% … … … … … … … … …

MCV 90% 94% 95% 97% 97% 89% 91% … … …

Pol3 87% 97% 97% 98% 99% 97% 97% … … …

PAB … … … … … … … … … …

BCG 2 days; 7 years

DT 7 years

DTwP 22 months



Influenza seasonal

MMR 1, 7 years


Td 15, 20, 25, 30, 35,40, 50, 60 years

45,00044,000

3,604,0001517

3,06054%

2009 200844 43

100% 100%

2% 0%

11% 5%

86% 95%

82% 86%

86% 91%

98%

2002

20-23 y

…


114

Monaco





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 90% 90% 90% 90% 90% 98% 90% 99% … …

DTP1 99% 99% 99% 99% 99% 99% 99% 99% … …

DTP3 99% 99% 99% 99% 99% 99% 99% 99% … …

HepB3 99% 99% 99% 99% 99% 99% … … … …

Hib3 99% 99% 99% 99% 99% 99% … … … …

MCV 99% 99% 99% 99% 99% 99% 99% 99% … …

Pol3 99% 99% 99% 99% 99% 99% 99% 99% … …

PAB … … … … … … … … … …




at 80% or above





BCG birthDTaPHibHepIPV ≥2 monthsHepA 5 months; 1 yearHepB 5 months; 1 year

MenC_conj 2 years

MMR 1, 3-6 years

Pneumo_ps 2 months

…

…

33,000

3

4

…

…

…

…

…

…

2009 2008… …… …… …… …… …

… …

… …


115

Mongolia








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 98% 98% 99% 98% 99% 97% 94% 81% 52% 51%

DTP1 95% 98% 95% 99% 99% 95% 96% 94% 93% 91%

DTP3 95% 96% 95% 99% 99% 95% 88% 84% 80% 76%

HepB3 97% 96% 98% 98% 98% 93% 88% … … …

Hib3 97% 96% 78% 56% 28% … … … … …

MCV 94% 97% 98% 99% 97% 92% 85% 92% 18% 17%

Pol3 96% 95% 99% 98% 99% 94% 86% 87% 86% 86%

PAB … … … … … … … … … …

BCG birth

DT 7, 15 years


HepB birth

MenACWY 2-14 years (subnational)

MMR 9 months: 2 years (subnational)


Rubella 10-16 years (subnational)

50,00048,000

2,671,0002429

3,33064%

2009 2008338 356

100% 97%

0% …

0% …

100% 100%

96% 96%

94% 98%

97%

2007

2-10 y

97%


116

Montenegro





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 95% 98% 98% 98% … … … … … …

DTP1 96% 98% 98% 95% … … … … … …

DTP3 92% 95% 92% 90% … … … … … …

HepB3 87% 93% 90% 90% … … … … … …

Hib3 87% 93% 89% 90% … … … … … …

MCV 86% 89% 90% 90% … … … … … …

Pol3 91% 95% 92% 90% … … … … … …

PAB … … … … … … … … … …




at 80% or above





BCG birthDT 6 yearsDTwP 9, 17, 23 weeks; 18 monthsHepB 9, 13 weeks; 1 yearHib 13, 17, 23 weeks; 18 months

MMR 1, 6, 12 years

OPV 9, 17, 23 weeks; 18 months; 6, 14 years

Td 14 years

TT 18 years

8,000

7,000

624,000

8

9

13,130

100%

97%

…

…

…

2009 200821 21

100% 100%0% 0%0% 0%

100% 100%

43% 76%

… 100%


117

Morocco








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 96% 95% 95% 97% 96% 96% 77% …

DTP1 99% 99% 98% 99% 99% 98% 94% 93% 75% …

DTP3 99% 99% 95% 97% 98% 95% 90% 81% 51% …

HepB3 98% 97% 95% 95% 96% 43% … … … …

Hib3 99% 99% 90% … … … … … … …

MCV 98% 96% 95% 95% 97% 93% 88% 79% 45% …

Pol3 99% 99% 95% 97% 98% 95% 90% 81% 51% …

PAB 86% 86% 85% 85% 85% 86% 80% 66% … …

BCG birth


DTwPHib 6, 10, 14 weeks

HepB birth; 6 weeks; 9 months

Measles 9 months

MR 6 years

OPV birth; 6, 10, 14 weeks;18 months; 5 years


Vitamin A 6, 12, 18 months

651,000633,000

31,993,0003338

4,450100%

2009 200868 68

100% 100%

0% 0%

0% 1%

100% 99%

85% 74%

100% 100%

…

2008

9 m-14 y

99%


118

Mozambique





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 87% 87% 87% 87% 87% 84% 78% 59% 47% …

DTP1 88% 88% 88% 88% 88% 84% 75% 71% 54% …

DTP3 76% 76% 76% 76% 76% 70% 57% 46% 29% …

HepB3 72% 72% 72% 72% 72% … … … … …

Hib3 74% … … … … … … … … …

MCV 77% 77% 77% 77% 77% 71% 71% 59% 39% …

Pol3 75% 75% 75% 75% 75% 68% 57% 46% 25% …

PAB 83% 83% 82% 81% 77% 75% 53% 37% 49% …




at 80% or above





BCG birthDTwPHibHep 6, 10, 14 weeksMeasles 9 monthsOPV birth; 6, 10, 14 weeks


Vitamin A 6 months; +6 months

877,000

801,000

22,894,000

96

142

880

100%

…

2008

9-59 m

103%

2009 2008144 144

100% 100%0% 0%

18% 27%82% 73%

60% 44%

52% 59%


119

Myanmar








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 93% 88% 89% 85% 76% 88% 90% 95% 45% 9%

DTP1 93% 88% 89% 86% 76% 87% 94% 96% 39% 22%

DTP3 90% 85% 86% 82% 73% 82% 84% 88% 16% 4%

HepB3 90% 84% 85% 75% 62% … … … … …

Hib3 … … … … … … … … … …

MCV 87% 82% 81% 78% 72% 84% 82% 68% … …

Pol3 90% 85% 84% 82% 73% 86% 84% 88% 3% …

PAB 93% 93% 93% 92% 89% 79% 80% 62% 24% 3%

BCG 6 weeks


HepB birth; 6, 10, 14 weeks


OPV 6, 10, 14 weeks

TT 1st contact pregnancy;+1 month


1,016,000943,000

50,020,0005471……

2009 2008325 325

99% 99%

1% 4%

9% 26%

89% 69%

49% 38%

93% 92%

65%

2007

9 m-5 y

94%


120

Namibia





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 85% 88% 95% 88% 95% 77% 92% … … …

DTP1 87% 88% 88% 91% 93% 90% 90% … … …

DTP3 83% 83% 86% 86% 86% 79% 74% … … …

HepB3 … … … … … … … … … …

Hib3 … … … … … … … … … …

MCV 76% 73% 69% 63% 73% 69% 68% … … …

Pol3 83% 83% 81% 74% 86% 80% 73% … … …

PAB 82% 82% 82% 81% 80% 74% 40% … … …




at 80% or above





BCG birthDT 5, 10 yearsDTwP 6, 10, 14 weeksMeasles 9 months

OPV birth; 6, 10, 14 weeks; 5, 10 years

TT 15-49 years


59,000

57,000

2,171,000

34

48

6,410

100%

…

2009

9-59 m

104%

2009 200834 34

100% 100%0% 0%

38% 35%62% 65%

15% 21%

… 88%


121

Nauru








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 90% 93% 78% 93% 81% …

DTP1 98% 98% 98% 87% 93% 74% 79% 90% 86% …

DTP3 99% 99% 99% 72% 80% 44% 56% 74% 67% …

HepB3 99% 99% 99% 99% 80% 58% 57% … … …

Hib3 99% … … … … … … … … …

MCV 99% 99% 99% 99% 80% 8% … … … …

Pol3 99% 99% 99% 45% 80% 27% 56% 74% 73% …

PAB … … … … … … … … … …

BCG birth



HepB birth

MR 12, 15 months

OPV 6, 10, 14 weeks; 18 months; 4 years

TT 1st contact; +1 month (pregnancy)

……

10,0003644…

100%

2009 2008… 14

… …

… …

… …

… …

… …

… …

92%

2001

12-59 m…


122

Nepal





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 87% 87% 89% 93% 87% 84% 76% 74% 67% 22%

DTP1 84% 84% 85% 93% 81% 91% 77% 68% 57% 28%

DTP3 82% 82% 82% 89% 75% 80% 54% 43% 32% 8%

HepB3 82% 82% 82% 69% 41% … … … … …

Hib3 … … … … … … … … … …

MCV 79% 79% 81% 85% 74% 77% 56% 57% 34% …

Pol3 82% 82% 82% 91% 78% 72% 50% 42% 20% …

PAB 81% 81% 84% 86% 88% 67% 48% 35% 18% 1%




at 80% or above





BCG birthDTwPHep 6, 10, 14 weeks

(subnational)JE 1 year (subnational)

Measles 9 months

OPV 6, 10, 14 weeks

TT pregnancy


730,000

701,000

29,331,000

39

48

1,180

16%

…

2008

9 m-5 y

93%

2009 200875 75

100% 100%3% 0%

51% 56%47% 44%

8% 11%

95% 95%


123

Netherlands








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … …

DTP1 98% 98% 98% 98% 98% 98% 98% 98% 98% 98%

DTP3 97% 97% 96% 96% 98% 97% 97% 97% 97% 96%

HepB3 … … … … … … … … … …

Hib3 97% 97% 96% 96% 97% 96% … … … …

MCV 96% 96% 96% 95% 96% 96% 94% 94% 92% 91%

Pol3 97% 97% 96% 96% 98% 97% 97% 97% 97% 96%

PAB … … … … … … … … … …

DTaPHibHepIPV 2, 3, 4, 11 months(high-risk groups)


DTaPIPV 4 years

DTIPV 9 years

HepB birth (children of carriers)

Hib <12 years (catch up)

MenC_conj 14 months



183,000182,000

16,592,00044

40,510100%

2009 200812 …

… …

… …

… …

… …

… …

… …

93%

…

…

…


124

New Zealand





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … …

DTP1 99% 97% 97% 98% 98% 95% 96% 96% 89% 91%

DTP3 92% 89% 88% 89% 89% 90% 89% 90% 72% 76%

HepB3 93% 90% 88% 87% 87% 90% 88% … … …

Hib3 98% 86% 78% 80% 80% 90% … … … …

MCV 89% 86% 79% 82% 82% 85% 84% 90% 64% 80%

Pol3 92% 89% 88% 89% 89% 82% 87% 90% 84% …

PAB … … … … … … … … … …




at 80% or above





BCG high-risk groupsDTaPHibHepIPV 6 weeks; 3, 5 weeksDTaPIPV 4 yearsHib 15 monthsHPV 12 years (females)

Influenza >64 years; high-risk groups


Pneumo_conj 6 weeks; 3, 5, 15 months

Td 45, 65 years

Tdap 11 years; high-risk groups

59,000

58,000

4,266,000

5

6

26,430

100%

…

…

…

…

2009 2008… …… …… …… …… …

… …

… …


125

Nicaragua








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 98% 98% 98% 98% 97% 96% 93% 84% 99% 34%

DTP1 98% 98% 94% 94% 92% 97% 93% 88% 64% 39%

DTP3 98% 96% 92% 87% 88% 83% 80% 70% 39% 16%

HepB3 98% 96% 92% 87% 88% 83% … … … …

Hib3 98% 96% 92% 87% 88% 83% … … … …

MCV 99% 99% 99% 99% 96% 86% 85% 82% 59% 15%

Pol3 99% 96% 92% 88% 87% 85% 83% 90% 88% 21%

PAB 80% 80% 80% 85% 87% 83% 68% 39% 21% …

BCG birth

DTwP 18 months


HepB 1st contact; +1, +5months; health workers

Influenza >6-23 months; ≥65 years(high-risk groups)

MMR 1 year

OPV 2, 4, 6 months


Td 6-9, 10-14 years; CBAW; pregnancy

Vitamin A 6 months; 1, 2, 3, 4 years


140,000137,000

5,743,0002226

2,450…

2009 2008153 153

100% 100%

2% 2%

7% 12%

92% 86%

72% 76%

86% 51%

…

2008

1-4 y

100%


126

Niger





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 78% 78% 73% 69% 64% 50% 53% 50% 28% …

DTP1 82% 76% 68% 63% 58% 46% 42% 46% 22% …

DTP3 70% 67% 57% 51% 45% 34% 23% 22% 4% …

HepB3 70% … … … … … … … … …

Hib3 70% … … … … … … … … …

MCV 73% 66% 60% 53% 47% 37% 40% 25% 27% …

Pol3 71% 65% 59% 52% 46% 41% 23% 22% 4% …

PAB 84% 84% 79% 73% 69% 63% 57% 17% 5% …




at 80% or above





BCG birthDTwPHibHep 6, 10, 14 weeksMeasles 9 monthsOPV birth; 6, 10, 14 weeks

TT CBAW and 1st contact pregnancy, +1, +6 months;

+1, +1 years



815,000

746,000

15,290,000

76

160

660

29%

…

2008

9-59 m

100%

2009 200842 42

100% 100%0% 2%5% 12%

95% 86%

43% 29%

74% 95%


127

Nigeria








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 53% 53% 53% 52% 49% 41% 42% 80% 28% …

DTP1 52% 52% 52% 49% 48% 42% 59% 79% 39% …

DTP3 42% 42% 42% 40% 36% 29% 34% 56% 16% …

HepB3 41% 41% 42% 27% 18% … … … … …

Hib3 … … … … … … … … … …

MCV 41% 41% 41% 44% 41% 33% 44% 54% 17% …

Pol3 54% 54% 54% 46% 45% 26% 31% 55% 16% …

PAB 67% 64% 63% 63% 62% 57% 44% 32% 11% …

BCG birth



Measles 9 months

OPV 6, 10, 14 weeks

TT pregnancy


6,081,0005,426,000

154,729,00086

1381,98074%

2009 2008774 774

100% 100%

10% 25%

37% 43%

52% 32%

45% 38%

46% 47%

…

2008

9-59 m

97%


128

Niue





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 97% 99% 92% 99% 41% 85%

DTP1 99% 99% 99% 99% 95% 99% 99% 99% 83% 27%

DTP3 99% 99% 99% 99% 85% 99% 99% 99% 62% 7%

HepB3 99% 99% 99% 99% 86% 99% 90% … … …

Hib3 99% 99% 99% 99% 99% 99% … … … …

MCV 99% 99% 99% 99% 99% 99% 34% 99% 52% 77%

Pol3 99% 99% 99% 99% 86% 99% 99% 99% 62% 76%

PAB … … … … … … … … … …




at 80% or above





BCG birth

DTaPIPV 6 weeks; 3, 5 months;4 years

HepB birth; 3-5 months

Hib 6 weeks; 3, 15 months


Pneumo_conj 6 weeks; 3, 5, 15 months

Td 4, 11 years

……

1,000………

100%

…

2001

12-59 m

…

2009 20081 1

100% 100%0% 0%0% 0%

100% 100%

100% 100%

100% 100%


129

Norway








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … …

DTP1 99% 99% 99% 99% 99% 99% 98% 95% 95% …

DTP3 92% 94% 93% 93% 91% 90% 97% 86% 85% …

HepB3 … … … … … … … … … …

Hib3 94% 94% 95% 94% 93% 93% … … … …

MCV 92% 93% 92% 91% 89% 88% 92% 87% 90% …

Pol3 92% 94% 93% 93% 91% 91% 92% 84% 90% …

PAB … … … … … … … … … …



DTaPIPV 7 years

HepB birth; 1, 2 months(high-risk groups)

HPV 12 years (females, 3 doses)

IPV 15 years



Td 11 years

58,00058,000

4,812,00033

56,05074%

2009 200819 19

95% 100%

0% 0%

0% 0%

95% 100%

89% 100%

… …

96%

…

…

…


130

occupied Palestinian territory





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 99% 92% 91% … … …

DTP1 99% 99% 99% 99% 99% 97% 99% … … …

DTP3 96% 96% 99% 96% 96% 93% 99% … … …

HepB3 96% 96% 99% 97% 99% 95% 93% … … …

Hib3 96% 96% 96% … … … … … … …

MCV 97% 96% 98% 99% 98% 93% 73% … … …

Pol3 97% 97% 99% 97% 99% 93% 96% … … …

PAB … … … … … … … … … …




at 80% or above





BCG birth

DT 6 years

DTwP 18 months




IPV 1, 2 months

Measles 9 months

MenACWY travellers

MMR 12, 18 months



Td 15 years

150,000147,000

4,277,0002530

…

…

126%

…

…

…

2009 200817 17

100% …0% …0% …

100% …

100% …

100% 100%


131

Oman








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 98% 98% 96% 96% 93% 51%

DTP1 98% 98% 99% 99% 99% 99% 99% 98% 82% 41%

DTP3 98% 99% 99% 98% 99% 99% 99% 98% 60% 18%

HepB3 98% 99% 99% 99% 99% 99% 99% … … …

Hib3 98% 99% 99% 98% 99% … … … … …

MCV 97% 97% 97% 96% 98% 99% 98% 98% 65% 22%

Pol3 97% 97% 97% 98% 99% 99% 99% 98% 60% 18%

PAB 91% 91% 95% 94% 94% 94% 80% 93% 82% 35%

BCG birthDT 6 yearsDTwP 18 monthsDTwPHibHep 2, 4, 6 monthsHepB birthInfluenza high-risk groupsIPV 9 weeksMeasles subnationalMenACWY pilgrimsMMR 12, 18 months

OPV 4, 6, 18 months;6, 17 years

Pneumo_conj 2, 4, 6 monthsRabies post-exposureRubella CBAW (15-49)

(post-partum)Td 12, 17 yearsTT pregnancy; post-injuryTyphoid food handlersVitamin A 9, 18 months; post-partumYellow fever travellers

62,00062,000

2,845,0009

1224,370100%

2009 200861 61

100% 100%

0% 0%

0% 0%

100% 100%

100% 100%

100% 100%

99%

…

…

…


132

Pakistan





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 90% 90% 89% 89% 82% 74% 73% 80% 62% 6%

DTP1 90% 85% 90% 90% 82% 72% 73% 77% 55% 20%

DTP3 85% 73% 83% 83% 80% 62% 58% 54% 30% 2%

HepB3 85% 73% 83% 83% 73% … … … … …

Hib3 85% … … … … … … … … …

MCV 80% 85% 80% 80% 78% 59% 47% 50% 38% 1%

Pol3 85% 81% 83% 83% 81% 65% 58% 54% 30% 2%

PAB 84% 80% 78% 80% 78% 71% 63% 50% 12% …




at 80% or above





BCG birth


Measles 9, 12-23 months



5,403,0005,069,000

180,808,0007187

2,71080%

30%

…

…

…

2009 2008135 135

100% 100%11% 10%27% 53%61% 37%

40% 39%

44% 35%


133

Palau








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … …

DTP1 99% 99% 99% 99% 99% 97% 99% 99% … …

DTP3 49% 92% 94% 98% 98% 96% 99% 99% … …

HepB3 69% 92% 91% 98% 98% 96% 99% … … …

Hib3 48% 92% 95% 98% 98% 96% … … … …

MCV 75% 97% 91% 98% 98% 83% 99% 98% … …

Pol3 48% 92% 94% 98% 98% 96% 99% 99% … …

PAB … … … … … … … … … …

DTaP 15 months; 4-6 years

DTaPHepIPV 6 weeks; 4, 6 months

HepB 1 day

Hib 2, 4, 6, 12 months

HPV 11 years; +2, +6 months (females)

Influenza >6 months

IPV 4-6 years

MMR 12, 15 months



…

…20,000

1315

…

…

2009 2008… 1

… 100%

… 0%

… 0%

… 100%

… 100%

… 100%

…

…

…

…


134

Panama





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 99% 99% 99% 97% 94% 99%

DTP1 94% 92% 98% 98% 98% 98% 95% 95% 90% 72%

DTP3 84% 82% 88% 91% 93% 98% 86% 86% 73% 47%

HepB3 84% 83% 88% 91% 93% … … … … …

Hib3 84% 83% 88% 91% 93% … … … … …

MCV 85% 85% 89% 94% 99% 97% 84% 73% 84% 71%

Pol3 84% 82% 88% 98% 90% 99% 86% 86% 71% 70%

PAB … … … … … … … … … …




at 80% or above





BCG birthDT <6 years DTwP 4-5 yearsDTwPHib 15-18 monthsDTwPHibHep 2, 4, 6 monthsHepA 12, 18 monthsHepB birth; health workers;

adolescentsHPV 10 years; +1, +6 months

(females)Influenza 7-9 months; >60 years;

high-risk groupsIPV 2, 4, 6, 15-18 months;

4-5 years (high-risk groups)

MMR 1, 4-5 yearsMR CBAW; health workersOPV 2, 4, 6, 15-18 months;

4-5 yearsPneumo_conj 2, 4, 6, 12-15 months

(subnational); high-risk groups

Pneumo_ps >60 yearsRotavirus 2, 4 monthsTd CBAW; health workersTdap 11 years; high-risk groupsYellow fever 1 year; +every

10 years (high-risk areas)

70,00069,000

3,454,0001623

12,530100%

99%

2008

1-4 y

93%

2009 200877 76

100% 100%… …

26% 20%74% 80%

48% 99%

47% 59%


135

Papua New Guinea








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 80% 68% 67% 75% 73% 81% 91% 92% 66% 62%

DTP1 84% 70% 76% 85% 80% 84% 97% 97% 65% 57%

DTP3 64% 52% 60% 61% 61% 59% 62% 68% 40% 32%

HepB3 64% 56% 59% 70% 63% 57% 23% 20% … …

Hib3 64% … … … … … … … … …

MCV 58% 54% 58% 65% 63% 62% 42% 67% 33% …

Pol3 70% 65% 61% 56% 50% 47% 68% 68% 34% 29%

PAB 61% 61% 60% 57% 53% 24% 60% 78% 25% 45%

BCG birth


HepB birth

Measles 6, 9 months

OPV 1, 2, 3 months

TT 7, 13 years; 1st contact pregnancy;+1, +6 months; +1 year


208,000

198,000

6,732,000

52

68

2,270

61%

2009 200889 89

93% 100%

61% 47%

20% 40%

12% 12%

0% 11%

24% 13%

…

2008

6-83 m

79%


136

Paraguay





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 96% 96% 96% 94% 92% 85% 82% 75% 68% 31%

DTP1 98% 98% 98% 95% 92% 88% 87% 86% 80% 40%

DTP3 92% 92% 92% 91% 89% 86% 68% 67% 57% 17%

HepB3 94% 93% 91% 90% 89% … … … … …

Hib3 94% 93% 92% 90% 89% … … … … …

MCV 91% 91% 91% 91% 91% 92% 75% 69% 48% 19%

Pol3 90% 90% 90% 89% 88% 86% 68% 64% 99% 14%

PAB 74% 74% 74% 81% 78% 47% 75% 66% 42% 26%




at 80% or above





BCG birth



Influenza 6-23 (2 doses); >60 years;high-risk groups

IPV 2, 4, 6 months (high-risk groups)

MMR 1, 4 years

MR 5-8 years (catch up)


Td 1st contact; +1 month; +1, +1, +1 year (CBAW);

>7 years (catch up)

Yellow fever 1 year

154,000149,000

6,349,0001923

4,430100%

63%

2009

1-4 y

79%

2009 2008234 233

100% 100%12% 6%56% 56%32% 38%

15% 23%

86% 89%


137

Peru








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 93% 93% 94% 83% 63% 57%

DTP1 98% 98% 98% 98% 98% 98% 96% 89% 72% 39%

DTP3 93% 99% 97% 94% 89% 98% 90% 72% 48% 16%

HepB3 93% 99% 93% 94% 89% … … … … …

Hib3 93% 99% 93% 94% 89% 38% … … … …

MCV 91% 90% 95% 99% 80% 97% 98% 64% 53% 23%

Pol3 92% 98% 96% 95% 85% 93% 89% 73% 47% 16%

PAB 67% 67% 67% 66% 65% 66% 50% 19% 5% …

BCG birth

DT 4, 6 months(pertussis contraindication)



HepB birth; adults

Hib 2, 4 months(pertussis contraindication)

Influenza ≥7 years; +1 month

IPV 2, 4, 6 months (HIV-exposed)

MMR 1, 4 years

OPV 2, 4, 6 months



Td 1st contact; +2,+6 months (CBAW)

Yellow Fever 15 months

605,000

593,000

29,165,000

19

21

8,140

100%

2009 20081,833 1,833

100% 100%

14% 7%

32% 17%

54% 76%

40% 51%

71% 63%

42%

2009

<5 y

45%


138

Philippines





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 90% 93% 90% 91% 91% 92% 82% 96% 76% 56%

DTP1 89% 94% 90% 90% 91% 92% 76% 96% 81% 72%

DTP3 87% 91% 87% 88% 89% 78% 70% 88% 59% 47%

HepB3 85% 88% 87% 77% 49% 7% 38% … … …

Hib3 … … … … … … … … … …

MCV 88% 92% 92% 92% 92% 81% 72% 85% 49% …

Pol3 86% 91% 87% 88% 90% 74% 67% 88% 58% 50%

PAB 68% 58% 58% 61% 57% 55% 54% 57% 28% 8%




at 80% or above





BCG birth


DTwPHibHep subnational


Measles 9 months

MMR 1 year

OPV 6, 10, 14 weeks

TT pregnancy

Vitamin A 6, 12, 18, 24, 30, 36 months

2,245,0002,196,000

91,983,0002633

3,540100%

58%

2007

9-48 m

95%

2009 2008179 217

98% 86%2% 0%

25% 18%72% 67%

43% 45%

89% 93%


139

Poland








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 93% 93% 93% 94% 94% 96% 98% 97% 95% 93%

DTP1 98% 98% 98% 98% 98% 98% 98% 98% 97% 98%

DTP3 99% 99% 99% 99% 99% 98% 96% 96% 94% 96%

HepB3 98% 98% 98% 98% 98% 99% 23% … … …

Hib3 88% 88% 88% 31% 22% … … … … …

MCV 98% 98% 98% 99% 98% 97% 96% 95% 92% 92%

Pol3 99% 99% 99% 99% 99% 98% 96% 96% 94% 96%

PAB … … … … … … … … … …

BCG birth

DTaP 6 years

DTwP 7-8 weeks; 3-4, 5-6, 16-18 months

HepB birth; 2, 7 months or 14 years; +1, +6 months (catch up)

Hib 2, 3-4, 5-6, 16-18 months

IPV 3-4, 5-6, 16-18 months


OPV 6 years

Td 14, 19 years

375,000372,000

38,074,00067

18,440…

2009 2008379 …

100% …

… …

… …

… …

… …

… …

95%

…

…

…


140

Portugal





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 98% 98% 98% 99% 89% 82% 94% 88% 82% …

DTP1 98% 98% 98% 98% 97% 97% 97% 96% 89% 90%

DTP3 96% 97% 97% 97% 93% 96% 93% 89% 72% 73%

HepB3 96% 97% 97% 97% 94% 58% 6% … … …

Hib3 96% 97% 97% 97% 93% 86% … … … …

MCV 95% 97% 95% 97% 93% 87% 94% 85% 70% 54%

Pol3 96% 97% 96% 97% 93% 96% 96% 89% 29% 18%

PAB … … … … … … … … … …




at 80% or above





BCG birthDTaPHib 18 monthsDTaPHibIPV 2, 4, 6 monthsDTaPIPV 5-6 yearsHepB birth; 2, 4 months;

10-13 years (catch up); high-risk groups

HPV 13 years, +2, +6months (females)

IPV travellers

JE travellersMenACWY travellersMenC_conj 3, 5, 15 monthsMMR 15 months; 5-6 yearsRabies travellersTd 10-13 years; +every 10 yearsTyphoid travellersYellow fever travellers

103,000103,000

10,707,00034

22,870

…

92%

…

…

…

2009 200820 20… 100%… 0%… 0%… 100%

… 100%

100% 100%


141

Qatar








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 98% 97% 96% 99% 99% 99% 96% 97% 76% 4%

DTP1 99% 99% 99% 99% 99% 97% 97% 94% 88% 82%

DTP3 99% 97% 94% 96% 97% 80% 92% 82% 71% 61%

HepB3 99% 97% 94% 96% 97% 89% 90% … … …

Hib3 99% 97% 94% 96% 97% 80% … … … …

MCV 99% 96% 92% 99% 99% 91% 87% 79% 62% 26%

Pol3 98% 98% 97% 95% 98% 91% 92% 82% 71% 61%

PAB … … … … … … … … … …

BCG birthDT 4-6 yearsDTaPHep 2, 4, 6, 18 monthsDTwPHiB 2, 4, 6, 18 months

(subnational)HepB birth, 1st contact; +6-8 weeks;

+5 monthsInfluenza pilgrims; health workersIPV high-risk groupsMenACWY >2 years (+every 3 years);

pilgrims; travellersMMR 12 months; 4-6 years

OPV 2, 4, 6, 18 months; 4-6 years

Pneumo_conj 2, 4, 6, 18 monthsPneumo_ps high-risk groupsRabies 0, 3, 7, 14, 28 days

(post-exposure)Rotavirus 2, 6 monthsTd 13-16 yearsTT 0, 1, 6 months (post-injury)Typhoid food handlers; travellersYellow fever travellers

16,00016,000

1,409,0001011

…95%

2009 20082 …

100% …

0% …

0% …

100% …

100% …

… …

98%

2007

12-59 m

93%


142

Romania





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 98% 99% 99% 90% … …

DTP1 98% 98% 98% 98% 98% 98% 98% 98% 98% …

DTP3 97% 97% 97% 97% 97% 99% 98% 96% 95% …

HepB3 95% 97% 99% 99% 98% 98% … … … …

Hib3 … … … … … … … … … …

MCV 97% 97% 97% 95% 97% 98% 93% 92% 88% …

Pol3 96% 96% 96% 97% 97% 99% 94% 92% 92% …

PAB … … … … … … … … … …




at 80% or above





BCG birth

DTaPIPV 2, 4, 6, 12 months

HepA (if indicated)



Influenza seasonal (subnational)

IPV 9 years

MMR 12 months; 7 years;


TT post-injury (subnational)

Yellow fever subnational

212,000209,000

21,275,0001012

14,460100%

……

…

…

2009 200842 42

100% 100%0% 0%0% 0%

100% 100%

98% 100%

… …


143

Russian Federation








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 96% 98% 96% 97% 97% 97% 92% … … …

DTP1 98% 98% 98% 98% 98% 96% 92% … … …

DTP3 98% 98% 98% 99% 98% 96% 78% … … …

HepB3 98% 98% 98% 98% 97% … … … … …

Hib3 … … … … … … … … … …

MCV 98% 99% 99% 99% 99% 97% 85% … … …

Pol3 98% 98% 99% 99% 98% 97% 77% … … …

PAB … … … … … … … … … …

BCG 3 days; 7, 14 yearsDip every 10 years

(post-tetanus vaccinations)DT 3, 4.5, 6 monthsDTwP 3, 4.5, 6, 18 monthsDTwPHep 3, 6 monthsHepB birth; 1, 6 months Influenza seasonalIPV 3, 4.5, 6 monthsMeasles 1, 6 years

MenAC high-risk groups(subnational)

MenACWY pilgrims

MM 1, 6 years

MMR 1, 6 years (subnational)

Mumps 1, 6 years


Rubella 1, 6 years

Td 6-7, 14 years; +every 10 years

1,559,0001,541,000

140,874,0001112

18,390…

2009 200883 83

100% 100%

0% 0%

0% 0%

100% 100%

100% 100%

100% …

97%

2008

18-35 y

101%


144

Rwanda





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 93% 93% 89% 98% 91% 81% 89% 92% 83% …

DTP1 98% 98% 98% 98% 95% 93% 94% 94% 74% …

DTP3 97% 97% 97% 99% 95% 90% 83% 84% 50% …

HepB3 97% 97% 97% 99% 95% … … … … …

Hib3 97% 97% 96% 99% 95% … … … … …

MCV 92% 92% 94% 95% 89% 74% 84% 83% 52% …

Pol3 97% 97% 98% 99% 95% 90% 84% 83% 56% …

PAB 85% 85% 82% 82% 79% 81% 89% 85% 28% …




at 80% or above





BCG birth


Measles 9 months


Pneumo_conj subnational


413,000372,000

9,998,00070

1111,060

…

…2008

9-11 m

59%

2009 2008… 30… 100%… 0%… 3%… 97%

… 50%

… 97%


145

Saint Kitts and Nevis








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 95% 95% 97% 99% 99% 99% 94% 80% … …

DTP1 98% 98% 99% 99% 99% 99% 99% 99% 97% 79%

DTP3 99% 99% 99% 99% 99% 99% 99% 99% 92% 56%

HepB3 98% 98% 99% 99% 99% 99% … … … …

Hib3 97% 97% 99% 99% 99% 12% … … … …

MCV 99% 99% 99% 99% 99% 99% 99% 99% 91% …

Pol3 98% 98% 99% 99% 99% 99% 99% 99% 89% 76%

PAB … … … … … … … … … …

BCG birth-4 weeks

DT 2, 4, 6 months (high-risk groups)

DTwP 3, 4, 5, 18 months; 4-5 years


HepB 2, 4, 7 months; 1st contact; +1,

+7 months (adults)

IPV 2, 4, 6, 18 months; 4-5, 16 years (high-risk groups)

MMR 1, 2 yearsOPV 2, 4, 6, 18 months; 4-5,

16 years

Td 11, 16, 26 years


……

52,0001315

13,660100%

2009 200817 17

100% 100%

0% …

0% 18%

100% 82%

100% 94%

100% 100%

148%

…

…

…


146

Saint Lucia





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 97% 99% 99% 94% 97% 91% 98% 94% 99% 27%

DTP1 99% 99% 99% 94% 97% 76% 98% 96% 95% 79%

DTP3 95% 96% 99% 85% 95% 70% 98% 89% 87% 56%

HepB3 95% 96% 99% 85% 95% … … … … …

Hib3 95% 96% 99% 85% 95% … … … … …

MCV 99% 99% 94% 94% 94% 88% 94% 82% 68% …

Pol3 95% 96% 99% 85% 95% 70% 98% 90% 44% 58%

PAB … … … … … … … … … …




at 80% or above





BCG 6 weeks

DT 5 years

DTwP 18 months



Influenza seasonal (adults)

IPV 3, 5, 7, 18 months; 4-5, 11-12 years (immunocompromised)

MMR 1, 5 years


Td high-risk groups

Varicella high-risk groups


3,0003,000

172,0001920

8,880100%

63%………

2009 20089 9

100% 89%0% 0%

33% 0%67% 89%

78% 78%

… 78%


147

Saint Vincent and the Grenadines








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 80% 87% 93% 99% 95% 99% 99% 99% 84% …

DTP1 99% 99% 99% 99% 99% 99% 98% 98% 96% 51%

DTP3 99% 99% 99% 99% 99% 99% 97% 98% 90% 26%

HepB3 99% 99% 99% 99% 99% … … … … …

Hib3 99% 99% 99% 99% 99% … … … … …

MCV 99% 99% 99% 99% 97% 96% 99% 96% 74% …

Pol3 99% 99% 99% 99% 93% 99% 97% 92% 89% 26%

PAB … … … … … … … … … …

BCG birth-1 year

DT 4-5, 10-15 years

DTwP 18 months


HepB adults

IPV 2, 4, 6, 18-24 months; 4-5 years (HIV-exposed)

MMR 1, 4-5 years

OPV 2, 4, 6, 18-24 months;4-5 years

Td >15 years


2,0002,000

109,0001112

8,840100%

2009 20089 9

100% 100%

0% …

0% 11%

100% 89%

100% 100%

100% 78%

94%

…

…

…


148

Samoa





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 94% 99% 91% 84% 86% 97% 96% 97% 97% 72%

DTP1 95% 54% 89% 84% 90% 98% 97% 96% 96% 54%

DTP3 72% 46% 71% 56% 64% 99% 94% 90% 89% 29%

HepB3 72% 38% 69% 56% 60% 96% 96% … … …

Hib3 72% 32% … … … … … … … …

MCV 49% 45% 63% 54% 57% 93% 96% 89% 81% …

Pol3 72% 78% 71% 57% 73% 99% 94% 88% 92% 29%

PAB … … … … … … … … … …




at 80% or above





BCG birth

DTaP 5 years

DTwPHipHep 6, 10, 14 weeks

HepB birth

MMR 12, 15 months

OPV 6, 10, 14 weeks

Td 1st contact; +1, +6 months; +1 year

4,0004,000

179,0002125

4,270100%

29%2009

6-59 m76%

2009 20089 3

100% …… …

33% …67% …

22% …

33% …


149

San Marino








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … …

DTP1 95% 89% 92% 98% 98% 97% 99% 99% 99% …

DTP3 92% 87% 92% 95% 95% 96% 99% 99% 99% …

HepB3 92% 87% 92% 95% 95% 94% 98% … … …

Hib3 92% 87% 92% 95% 94% 92% 80% … … …

MCV 92% 73% 92% 94% 94% 74% 97% … … …

Pol3 92% 87% 92% 95% 95% 96% 98% 99% 99% …

PAB … … … … … … … … … …

DT 14-15 years

DTaP 5 years

DTaPHibHepIPV 3, 5, 11-12 months

HPV 12 years (females, 3 doses)


…

…

31,000

1

2

…

…

2009 20080 …

… …

… …

… …

… …

… …

… …

…

…

…

…


150

Sao Tome and Principe





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 98% 98% 98% 81% 95% 99% 75% …

DTP1 98% 99% 99% 99% 99% 89% 92% 97% 72% …

DTP3 98% 99% 97% 97% 97% 82% 79% 92% 48% …

HepB3 98% 99% 87% 75% 96% … … … … …

Hib3 … … … … … … … … … …

MCV 90% 93% 86% 85% 88% 69% 74% 71% 35% …

Pol3 99% 99% 98% 97% 97% 87% 79% 90% 48% …

PAB … … … … … … … … … …




at 80% or above





BCG birth


DTwPHibHep 6, 10, 14 weeks(subnational)


Measles 9 months



Vitamin A 6, 12, 18, 24, 30, 36 months


5,0005,000

163,0005278

1,85025%

…2007

9 m-14 y101%

2009 20087 7

100% 100%0% 0%0% 0%

100% 100%

57% 71%

… 100%


151

Saudi Arabia








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 98% 98% 96% 95% 96% 94% 94% 90% 89% 33%

DTP1 98% 98% 97% 97% 97% 99% 98% 97% 93% 66%

DTP3 98% 98% 96% 96% 96% 95% 96% 92% 81% 41%

HepB3 98% 98% 96% 96% 97% 93% 93% 66% … …

Hib3 98% 98% 96% 96% 96% … … … … …

MCV 98% 97% 96% 95% 97% 94% 94% 88% 79% 8%

Pol3 98% 98% 96% 96% 96% 95% 96% 92% 81% 41%

PAB … … … … … … … … … …

BCG birthDT <7 years

(pertussis contraindication)DTwP 4-6 yearsDTwPHib 18 monthsDTwPHibHep 2, 4, 6 monthsHepA 18 months; 2 yearsHepB birthHib 2, 4, 6 months

(pertussis contraindication)Influenza seasonalIPV 2 months

Measles 9 monthsMenACWY workers in Hadj; pilgrims MMR 1, 4-6 yearsOPV 2, 4, 6, 18 months; 4-6 yearsPneumo_conj 2, 4, 6, 12 monthsPneumo_ps high-risk groupsTd ≥7 yearsTT CBAW and pregnancyTyphoid …Varicella 1, 4-6 yearsYellow fever travellers

593,000

583,000

25,721,000

18

21

24,000

100%

2009 200820 20

100% 100%

0% 0%

0% 0%

100% 100%

100% 100%

100% 100%

…

2007

6 m-18 y

98%


152

Senegal





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 97% 98% 96% 94% 92% 89% 91% 90% … …

DTP1 94% 94% 97% 99% 97% 79% 93% 75% … …

DTP3 86% 88% 94% 89% 84% 52% 80% 51% … …

HepB3 86% 88% 94% 89% 84% … … … … …

Hib3 86% 88% 94% 89% 18% … … … … …

MCV 79% 77% 84% 80% 74% 48% 80% 51% … …

Pol3 83% 87% 93% 89% 84% 49% 80% 53% … …

PAB 88% 88% 85% 86% 80% 62% 54% 45% 7% …




at 80% or above





BCG birth


Measles 9 months


TT CBAW

Vitamin A 6, 12, 18, 24, 30,36 months; post-partum


476,000449,000

12,534,0005193

1,79017%

…2006

9-59 m99%

2009 200865 65

100% 100%2% 0%

28% 32%71% 68%

18% 15%

68% 66%


153

Serbia








at 80% or above





2009 2008 2007 2006* 2005 2000 1995 1990 1985 1980

BCG 98% 99% 98% 99% 98% 85% … … … …

DTP1 96% 96% 96% 96% 98% 98% … … … …

DTP3 95% 95% 94% 92% 98% 95% … … … …

HepB3 93% 93% 99% 93% 65% … … … … …

Hib3 94% 98% 89% 42% … … … … … …

MCV 95% 92% 95% 88% 96% 89% … … … …

Pol3 97% 95% 93% 97% 98% 98% … … … …

PAB … … … … … … … … … …

BCG birthDT 7 yearsDTwP 8, 14, 20 weeks;

18 monthsHepB birth; 1, 5 months;

high-risk groupsHib 8, 14, 20 weeksInfluenza >65 years

(high-risk groups)IPV >12 months

(high-risk groups)

MenAC high-risk groups MMR 1, 7 yearsOPV 8, 14, 20 weeks; 18 months;

7, 14 yearsPneumo_ps high-risk groupsTd 14 yearsTyphoid travellersYellow fever travellers

114,000

112,000

9,850,000

6

7

11,420

100%

2009 200825 25

100% 100%

0% …

0% …

100% 100%

92% 100%

… …

95%

…

…

…

* All data priot to 2006 pertain to the pre-cession Serbia and Montenegro


154

Seychelles





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 96% 99% 99% 99% 99% 99% 99% 98% 92% …

DTP1 98% 98% 98% 98% 98% 98% 98% 99% 95% …

DTP3 99% 99% 99% 99% 99% 98% 97% 99% 86% …

HepB3 99% 99% 99% 99% 99% 98% 99% … … …

Hib3 … … … … … … … … … …

MCV 97% 99% 99% 99% 99% 97% 97% 86% 90% …

Pol3 99% 99% 99% 99% 99% 98% 97% 99% 86% …

PAB … … … … … … … … … …




at 80% or above





BCG birth; 6 years

DTwP 3, 4, 5, 18 month

HepB 3, 4, 9 months



TT 15, 25, 35 years

Yellow fever 1 year; travellers

……

84,0001112

16,820100%

99%………

2009 200816 16… 100%… 0%… 0%… 100%

… 100%

… 100%


155

Sierra Leone








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 95% 88% 82% 83% 85% 74% … … … …

DTP1 87% 84% 77% 79% 80% 64% … … … …

DTP3 75% 72% 64% 64% 65% 44% … … … …

HepB3 75% 71% 63% … … … … … … …

Hib3 75% 71% 63% … … … … … … …

MCV 71% 66% 60% 65% 71% 37% … … … …

Pol3 74% 70% 63% 65% 67% 46% … … … …

PAB 97% 97% 94% 85% 83% 53% 76% 85% 38% 8%

BCG birth


Measles 9 months





227,000

204,000

5,696,000

123

192

790

…

2009 200813 13

100% 100%

0% 0%

14% 43%

86% 57%

71% 14%

43% 21%

…

2009

9-59 m

101%


156

Singapore





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 98% 98% 98% 99% 98% 99% 93% 85%

DTP1 98% 98% 97% 96% 96% 98% 98% 95% 92% 94%

DTP3 97% 97% 96% 95% 96% 98% 98% 85% 78% 84%

HepB3 97% 96% 95% 94% 96% 97% 96% 74% … …

Hib3 … … … … … … … … … …

MCV 95% 95% 95% 93% 96% 96% 97% 84% 75% 47%

Pol3 97% 97% 96% 95% 96% 98% 98% 85% 81% 83%

PAB … … … … … … … … … …




at 80% or above





BCG birth

DTaP 3, 4, 5, 18 months

HepB birth; 1, 5-6 months

Influenza 6 months-5 years (recommended)

MMR 1-2, 6-7 years

OPV 3, 4, 5, 18 months;6-7, 10-11 years

Pneumo_conj 3, 5 months; 1-2 years (subnational)

Td 10-11 years

Tdap 10-11 years

37,00037,000

4,737,00023

49,850…

93%………

2009 2008… …… …… …… …… …

… …

… …


157

Slovakia








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 97% 98% 98% 98% 98% 94% 92% … … …

DTP1 99% 99% 99% 99% 99% 99% 99% … … …

DTP3 99% 99% 99% 99% 99% 99% 99% … … …

HepB3 99% 99% 99% 99% 99% 98% … … … …

Hib3 99% 99% 99% 99% 99% 59% … … … …

MCV 99% 99% 99% 98% 98% 98% 99% … … …

Pol3 99% 99% 99% 99% 99% 98% 98% … … …

PAB … … … … … … … … … …

BCG 3 days; 10 years (if tuberculin negative)


DTaPIPV 5 years

HepB children of carriers; adolescents




Td 12 years

56,00055,000

5,406,00067

21,600…

2009 200879 79

100% 100%

0% …

0% …

100% 100%

100% 100%

… …

99%

…

…

…


158

Slovenia





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … 98% 99% … … …

DTP1 98% 98% 98% 98% 98% 97% 98% … … …

DTP3 96% 97% 97% 97% 95% 91% 98% … … …

HepB3 … … … … … … … … … …

Hib3 95% 97% 98% 97% 95% … … … … …

MCV 95% 96% 96% 96% 94% 95% 93% … … …

Pol3 96% 97% 97% 97% 95% 93% 98% … … …

PAB … … … … … … … … … …




at 80% or above





BCG birth (high-risk groups)Dip (if indicated)DTaP 9 yearsDTaPHibIPV 3, 4.5, 6, 18 monthsHepA (if indicated)HepB 5 (2 doses), 6 yearsHib high-risk groupsHPV 12 years (females)Influenza >65 years

(high-risk groups)IPV (if indicated)

Measles (if indicated)MenACWY high-risk groupsMenC_conj high-risk groupsMMR 1, 5 yearsPneumo_conj high-risk groups Pneumo_ps high-risk groupsRubella (if indicated)Td 9 yearsTT 18 yearsTyphoid (if indicated)Varicella high-risk groups

20,00020,000

2,020,00023

26,34070%

…………

2009 20089 9

100% 100%0% 0%0% 0%

100% 100%

100% 100%

100% 100%


159

Solomon Islands








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 81% 81% 84% 84% 78% 92% 77% 87% 50% 65%

DTP1 83% 83% 89% 99% 86% 89% 87% 91% 63% 71%

DTP3 81% 78% 79% 91% 78% 82% 69% 77% 38% 46%

HepB3 81% 77% 79% 93% 73% 77% 68% … … …

Hib3 77% 77% … … … … … … … …

MCV 60% 60% 78% 84% 70% 87% 68% 70% … …

Pol3 82% 78% 77% 91% 74% 82% 69% 75% 36% 43%

PAB 85% 85% 84% 74% 74% 75% 81% 71% 27% …

BCG birth


HepB birth; 2, 4, 6 months

Measles 1 year

OPV 6, 10, 14 weeks; 5 years

TT 5 years

16,00015,000

523,0003036

1,86063%

2009 200850 10

98% 90%

0% 0%

0% 40%

0% 50%

0% 0%

… 80%

…

2009

1-4 y

90%


160

Somalia





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 29% 36% 52% 50% 50% 69% 46% 31% 30% 6%

DTP1 40% 40% 58% 40% 50% 57% 46% 42% 46% …

DTP3 31% 31% 39% 35% 35% 33% 22% 19% 22% …

HepB3 … … … … … … … … … …

Hib3 … … … … … … … … … …

MCV 24% 24% 34% 35% 35% 35% 34% 30% 35% 9%

Pol3 28% 24% 39% 35% 35% 37% 22% 18% 22% 8%

PAB 64% 49% 50% 51% 47% 47% 48% 49% 16% …




at 80% or above





BCG birth


Measles 9 months



Vitamin A 9 months

402,000

359,000

9,133,000

109

180

…

0%

…2009

9-59 m85%

2009 2008113 113

100% 100%77% 100%23% 0%0% 0%

0% …

0% 0%


161

South Africa








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 81% 81% 81% 81% 81% 89% 95% 57% 70% …

DTP1 77% 77% 77% 77% 77% 85% 89% 89% 91% …

DTP3 69% 69% 69% 69% 69% 73% 72% 72% 75% …

HepB3 67% 67% 67% 67% 67% 71% … … … …

Hib3 67% 67% 67% 67% 67% 71% … … … …

MCV 62% 62% 62% 62% 62% 72% 76% 79% 70% …

Pol3 70% 70% 70% 70% 70% 71% 72% 76% 77% …

PAB 75% 75% 72% 74% 59% 68% 29% … … …

BCG birth

DTaPHibIPV 6, 10, 14 weeks; 18 months

DTwP 18 months

DTwPHib 6, 10, 14 weeks;



OPV birth; 6, 10, 14 weeks;18 months

Pneumo_conj 6, 14 weeks; 9 months

Rotavirus 6, 14 weeks (subnational)

Td 6, 12 years

TT 1st contact pregnancy; +1, +6 months

Vitamin A 6, 12, 18, 34, 30, 36 months

1,085,0001,036,000

50,110,0004362

10,060100%

2009 200852 52

… 81%

… 0%

… 6%

… 75%

… 54%

… 90%

87%

2007

9-59 m

89%


162

Spain





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … …

DTP1 98% 98% 98% 98% 98% 98% 96% 95% 92% …

DTP3 96% 97% 96% 98% 96% 95% 90% 86% 79% …

HepB3 96% 97% 96% 81% 81% 77% … … … …

Hib3 96% 97% 96% 98% 96% 92% … … … …

MCV 98% 98% 97% 97% 97% 94% 90% 99% 79% …

Pol3 96% 97% 96% 98% 96% 95% 88% 94% 73% …

PAB … … … … … … … … … …




at 80% or above





DTaP 4-6 yearsDTaPHibHepIPV 2, 4, 6, 15-18

months (subnational)DTaPHibIPV 2, 4, 6, 15-18 months

(subnational)HepB birth; 1-2, 6 months or

2, 4, 6 months (subnational)HPV 11-14 years (females,

3 doses)Influenza >65 years

MenC_conj 2, 6, 15-18 monthsMMR 12-15 months; 3-6 yearsPneumo_conj 2, 4, 6, 15-18 months

(high-risk groups)Pneumo_ps >65 years

(high-risk groups)Td 14-16 yearsVaricella 10-14 years

499,000

497,000

44,904,000

4

4

31,630

100%

90%………

2009 200819 19

79% 79%… …… …

79% 79%

79% 79%

… …


163

Sri Lanka








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 98% 98% 98% 98% 98% 99% 90% 84% 71% 61%

DTP1 98% 98% 98% 98% 98% 98% 97% 95% 88% 71%

DTP3 97% 98% 98% 98% 99% 99% 93% 86% 70% 46%

HepB3 97% 98% 98% 98% 98% … … … … …

Hib3 … … … … … … … … … …

MCV 96% 97% 97% 98% 99% 98% 87% 80% 20% …

Pol3 97% 98% 98% 98% 99% 99% 92% 86% 71% 46%

PAB 93% 93% 91% 90% 87% 92% 81% 72% 50% 45%

BCG birth

DT 5 years


DTwPHibHep 2, 4, 6 months (suspended)

HepB 2, 4, 6 months

JE 12 months (subnational)

Measles 9 months

MR 3 years


Rubella 13 years

Td 12 years

TT pregnancy (2 doses)

364,000358,000

20,238,0001315

4,720100%

2009 200826 26

92% 100%

… 0%

… 0%

92% 100%

92% 96%

… 100%

88%

…

…

…


164

Sudan





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 82% 83% 83% 77% 72% 56% 63% 77% 12% 2%

DTP1 92% 96% 95% 91% 88% 75% 72% 83% 28% 18%

DTP3 84% 86% 84% 78% 78% 62% 48% 62% 8% 1%

HepB3 76% 78% 78% 60% 22% … … … … …

Hib3 76% 78% … … … … … … … …

MCV 82% 79% 79% 73% 69% 58% 51% 57% 6% …

Pol3 84% 85% 84% 77% 78% 62% 48% 62% 8% 1%

PAB 74% 70% 72% 70% 68% 61% 76% 72% 4% …




at 80% or above





BCG birth


Measles 9 months

OPV 6, 10, 14 weeks

TT 1st contact; +1, +6 month; +1, +1 year

1,300,000

1,213,000

42,272,000

69

108

2,000

3%

…………

2009 2008143 135

99% 99%4% 3%

13% 10%81% 86%

24% 21%

66% 66%


165

Suriname








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … …

DTP1 91% 95% 96% 94% 93% 90% 94% 94% 94% 50%

DTP3 87% 85% 84% 84% 83% 71% 84% 83% 84% 25%

HepB3 87% 84% 84% 84% 83% … … … … …

Hib3 87% 84% 84% 84% 83% … … … … …

MCV 88% 86% 85% 83% 91% 84% 85% 65% 73% …

Pol3 85% 85% 84% 84% 84% 70% 81% 81% 85% 24%

PAB 93% 93% 93% 93% 92% 92% 92% 92% … …

DT 1st contact; +1, +7 months

DTwP 18 months


HepB birth (high-risk groups)

Influenza seasonal (high-risk groups)

MMR 1 year



Td 1st contact; +1, +7 months

Yellow fever 1 year (subnational)

10,00010,000

520,0002426

6,690100%

2009 200810 10

100% 100%

… 0%

… 20%

… 80%

0% 20%

… 90%

…

2001

1-5 y

87%


166

Swaziland





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 99% 90% 99% 96% 79% …

DTP1 97% 97% 97% 97% 97% 95% 94% 96% 82% …

DTP3 95% 95% 95% 95% 95% 87% 82% 89% 61% …

HepB3 95% 93% 93% 93% 93% 82% … … … …

Hib3 95% … … … … … … … … …

MCV 95% 95% 95% 94% 92% 92% 94% 85% 54% …

Pol3 96% 96% 96% 96% 96% 90% 81% 89% 59% …

PAB 86% 86% 85% 85% 82% 80% 77% 63% … …




at 80% or above





BCG birth

DT 5 years



OPV 6, 10, 14 weeks; 18 months;5 years

TT CBAW and 1st contact pregnancy; +1, +6 months; +1, +1, +1 years

Vitamin A 6, 12, 18, 24, 30, 36 months


35,000

33,000

1,185,000

52

73

4,580

100%

…2009

9-47 m96%

2009 20084 4

0% 100%0% 0%

100% 50%0% 50%

0% 0%

75% 0%


167

Sweden








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 21% 21% 21% 20% 20% 16% 14% 13% 16% 3%

DTP1 98% 98% 98% 98% 98% 98% 99% 99% 99% 99%

DTP3 98% 98% 98% 98% 98% 99% 99% 99% 99% 99%

HepB3 … … … … … … … … … …

Hib3 98% 98% 98% 98% 98% 98% 99% … … …

MCV 97% 97% 97% 96% 96% 91% 97% 96% 94% 88%

Pol3 98% 98% 98% 98% 98% 99% 99% 99% 98% 97%

PAB … … … … … … … … … …

BCG birth-6 months(high-risk groups)

DTaP 10 years (catch up)

DTaPHibHepIPV 3, 5, 12 months (high-risk groups)


DTaPIPV 5-6 yearsHepB birth; +1, +2 or 6, +12 months

(children of carriers)

Influenza >65 years; high-risk groups (subnational)

MMR 18 months; 6-8 years or 12 years (catch up)


Pneumo_ps >65 years; high-risk groups(subnational)

Tdap 14-16 years

108,000108,000

9,249,00023

38,560

…

2009 2008290 290

100% 100%

0% 0%

0% 0%

100% 100%

97% 98%

… …

…

…

…

…


168

Switzerland





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … …

DTP1 95% 95% 95% 95% 95% 95% 93% 96% … …

DTP3 95% 95% 94% 94% 94% 88% 89% 90% … …

HepB3 … … … … … … … … … …

Hib3 95% 95% 92% 92% 93% 86% … … … …

MCV 90% 90% 87% 87% 87% 81% 83% 90% … …

Pol3 95% 95% 95% 95% 95% 92% 95% 98% … …

PAB … … … … … … … … … …




at 80% or above






DTaPIPV 4-7 years

HepB 11-15 years; +6 months

HPV 11-14 years; +2, +6 months (females)

Influenza 1 month

MenC_conj 12-15 months; 11-15 years



Pneumo_ps >65 years

Td 11-15 years; +10 years

Varicella >11 years; +1 month

73,000

72,000

7,568,000

4

4

41,830

5%

…………

2009 200826 26

92% 92%0% 0%0% 0%

92% 92%

23% 23%

… …


169

Syrian Arab Republic








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 90% 90% 90% 90% 90% 91% 91% 92% 53% 35%

DTP1 88% 88% 88% 88% 88% 92% 96% 93% 54% 35%

DTP3 80% 80% 80% 80% 80% 84% 89% 91% 29% 13%

HepB3 77% 77% 77% 77% 77% 76% 74% … … …

Hib3 80% 80% 80% 80% 80% … … … … …

MCV 81% 81% 81% 81% 81% 83% 85% 87% 27% 13%

Pol3 83% 83% 83% 83% 83% 86% 89% 91% 29% 13%

PAB 94% 94% 92% 93% 92% 90% 76% 63% 8% 1%

BCG birth

DT 6 years


DTwPHibHepB 3 months

HepB birth; 7 months

IPV 3, 4 months

MenACWY 6 years

MMR 12, 18 months


Td 12 years


Vitamin A 1 year

596,000587,000

21,906,0001416

4,620100%

2009 200871 71

100% 100%

0% 0%

0% 0%

100% 100%

… 100%

100% 100%

99%

2008

11-15 y

100%


170

Tajikistan





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 82% 89% 83% 93% 97% 98% 96% … … …

DTP1 96% 92% 88% 97% 93% 89% 86% … … …

DTP3 93% 86% 86% 86% 86% 83% 80% … … …

HepB3 93% 86% 84% 90% 85% … … … … …

Hib3 93% 92% … … … … … … … …

MCV 89% 86% 85% 94% 91% 88% 70% … … …

Pol3 93% 87% 85% 84% 83% 84% 69% … … …

PAB … … … … … … … … … …




at 80% or above





BCG 3-5 days

DT 6 years

DTwP 16-22 months


HepB birth

Measles 1, 6 years

MR 1, 6 years (subnational)

OPV birth; 2, 3, 4, 12 months

Pneumo_conj >1 year (high-risk groups)

Td 16-17 years


195,000

184,000

6,952,000

52

61

1,950

17%

93%2009

12 m-14 y98%

2009 200865 65

100% 100%0% …0% 9%

100% 91%

100% 20%

100% 97%


171

Tanzania, United Republic of








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 93% 89% 89% 90% 91% 86% 96% 85% 90% 72%

DTP1 90% 88% 89% 94% 95% 96% 93% 92% 86% 81%

DTP3 85% 86% 83% 90% 90% 79% 81% 78% 67% 59%

HepB3 85% 86% 83% 90% 90% … … … … …

Hib3 85% … … … … … … … … …

MCV 91% 88% 90% 93% 91% 78% 78% 80% 66% 46%

Pol3 88% 89% 88% 91% 91% 64% 79% 78% 64% 57%

PAB 90% 81% 81% 81% 81% 79% 85% 77% 51% 37%

BCG birth

DTwPHep 4, 8, 12 weeks or 6, 10, 14 weeks (Zanzibar)

DTwPHibHepB 4, 8, 12 weeks or 6,10, 14 weeks (Zanzibar)

Measles 9 months

OPV birth; 4, 8, 12 weeks or 6, 10,14 weeks (Zanzibar)


1,812,0001,700,000

43,739,00068

1081,35021%

2009 2008129 129

100% 100%

2% 1%

27% 32%

71% 67%

60% 49%

81% 81%

…

2009

9-59 m

90%


172

Thailand





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 99% 99% 98% 99% 80% 68%

DTP1 99% 99% 99% 99% 99% 98% 98% 97% 83% 73%

DTP3 99% 99% 98% 98% 98% 97% 96% 92% 62% 49%

HepB3 98% 98% 96% 96% 96% 95% 93% … … …

Hib3 … … … … … … … … … …

MCV 98% 98% 96% 96% 96% 94% 91% 80% 26% …

Pol3 99% 99% 98% 98% 98% 97% 96% 92% 61% 19%

PAB 91% 91% 89% 88% 88% 85% 87% 75% 41% 25%




at 80% or above





BCG birth

DTwP 1.5-2, 4-5 years


HepB birth

Influenza >65 years (subnational);high-risk groups

JE 1.5-2 years (2 doses);2.5-3 years

Measles 9-12 months

MenACWY pilgrims (subnational)

MMR school entrance

OPV 2, 4, 6 months

Td 1st contact; +1, +6 months(schoolchilden grade 6;

pregnancy)


977,000

970,000

67,764,000

12

14

7,640

100%

…………

2009 2008926 926

… …… …… …… …

… …

… …


173

The former Yugoslav Republic of Macedonia








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 98% 94% 95% 92% 99% 97% 95% … … …

DTP1 98% 95% 95% 95% 98% 98% 98% … … …

DTP3 96% 95% 95% 93% 97% 95% 95% … … …

HepB3 95% 97% 96% 89% 53% … … … … …

Hib3 82% 13% … … … … … … … …

MCV 96% 98% 96% 94% 96% 97% 97% … … …

Pol3 96% 96% 96% 92% 98% 96% 95% … … …

PAB … … … … … … … … … …

BCG birth; 7, 14 years

DTwP 4, 5, 6, 18 months; 4 years


Hib 3, 4, 6, 18 months

HPV 12 years; +2, +6 months(females)


OPV 4, 5.5, 7, 20 months; 7, 14 years


Td 7, 14 years

TT 18 years

22,00022,000

2,042,0001011

8,830100%

2009 200831 31

100% 100%

0% 0%

0% 0%

100% 100%

97% 100%

… 0%

97%

2009

13 m-26 y

…


174

Timor-Leste





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 71% 85% 74% 72% 70% … … … … …

DTP1 76% 85% 76% 75% 64% … … … … …

DTP3 72% 79% 70% 67% 55% … … … … …

HepB3 72% 79% … … … … … … … …

Hib3 … … … … … … … … … …

MCV 70% 73% 63% 64% 48% … … … … …

Pol3 78% 79% 70% 66% 55% … … … … …

PAB 81% 66% 59% 63% 59% … … … … …




at 80% or above





BCG birth


Measles 9 months



Vitamin A 6, 12, 18, 24, 30, 36 months

46,000

43,000

1,134,000

48

56

4,700

100%

…2009

9-59 m76%

2009 200813 13

100% 100%0% 0%

54% 54%46% 46%

23% 31%

100% 92%


175

Togo








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 91% 92% 91% 96% 96% 84% 83% 99% 54% …

DTP1 93% 92% 94% 91% 91% 80% 74% 90% 48% …

DTP3 89% 89% 88% 87% 82% 64% 58% 77% 24% …

HepB3 89% 24% … … … … … … … …

Hib3 89% 24% … … … … … … … …

MCV 84% 77% 80% 83% 70% 58% 53% 73% 27% …

Pol3 89% 88% 78% 87% 80% 63% 59% 76% 23% …

PAB 81% 81% 82% 81% 81% 63% 52% 47% … …

BCG birth



Measles 9 months



Vitamin A 6, 10, 14 weeks; 9 months; post-partum


215,000200,000

6,619,0006498

85010%

2009 200835 35

100% 100%

0% 0%

17% 14%

83% 86%

37% 17%

94% 91%

…

2008

9-59 m

98%


176

Tonga





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 99% 99% 99% 99% 99% 99%

DTP1 98% 98% 98% 98% 98% 98% 98% 97% 97% 65%

DTP3 99% 99% 99% 99% 99% 95% 95% 94% 92% 40%

HepB3 99% 98% 99% 99% 99% 97% 91% 94% … …

Hib3 99% 99% 99% 99% 99% … … … … …

MCV 99% 99% 99% 99% 99% 95% 94% 86% 81% …

Pol3 99% 99% 99% 99% 99% 95% 93% 93% 81% 20%

PAB … … … … … … … … … …




at 80% or above



BCG birth

DTwP 18 months; 5-6 years

DTwPHib 6, 10, 14 weeks


MR 12, 18 months

OPV 6, 10, 14 weeks

Td 15-19 years; pregnancy

3,000

3,000

104,000

17

19

4,580

95%

99%2001

12-59 m…

2009 20086 6

100% 100%0% 0%0% 0%

100% 100%

100% 100%

100% 100%




177

Trinidad and Tobago








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … …

DTP1 95% 91% 90% 93% 98% 90% 96% 94% 91% 51%

DTP3 90% 90% 88% 92% 95% 90% 89% 82% 75% 26%

HepB3 90% 90% 89% 89% 95% … … … … …

Hib3 90% 90% 88% 89% 95% 74% … … … …

MCV 94% 91% 91% 89% 93% 90% 84% 70% 32% …

Pol3 90% 91% 90% 89% 95% 90% 90% 87% 74% 38%

PAB … … … … … … … … … …

DT 3, 4, 6, 18 months; 4-5 years(pertussis contraindication)

DTwP 18, 48-60 months


HepB >10 years (3 doses)

Hib 3, 4, 6 months (high-risk groups)


IPV 2, 4, 5, 18 months: 4-5 years(immunocompromised)

MMR 1, 4-5 years

OPV 2, 4, 6, 18 months; 4-5 years


Td ≥10 years

Yellow fever 1, 11 years

20,00019,000

1,339,0003135

25,100100%

2009 20089 9

100% 100%

0% 0%

0% 11%

100% 89%

78% 56%

100% 100%

80%

…

…

…


178

Tunisia





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 98% 99% 99% 99% 98% 95% 97% 96% 90% …

DTP1 99% 99% 99% 99% 99% 98% 97% 97% 88% …

DTP3 99% 99% 98% 99% 98% 97% 94% 93% 70% …

HepB3 99% 99% 98% 99% 97% 94% … … … …

Hib3 … … … … 80% … … … … …

MCV 98% 98% 98% 98% 96% 95% 91% 93% 65% …

Pol3 99% 99% 98% 99% 98% 97% 94% 93% 70% …

PAB 96% 96% 96% 89% 90% 68% 58% 40% 8% 2%




at 80% or above



BCG birth




OPV 2, 3, 6, 18 months; 6, 12, 18 years


Td 7, 12, 18 years; CBAW

165,000

162,000

10,272,000

18

21

7,820

100%

98%2005

13-18 y91%

2009 2008225 225

100% 100%0% 0%0% 0%

100% 100%

95% 95%

100% 100%




179

T urkey








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 96% 96% 94% 88% 88% 89% 90% 93% 76% …

DTP1 97% 97% 98% 92% 92% 92% 86% 94% 78% 67%

DTP3 96% 96% 96% 90% 90% 85% 67% 84% 55% 42%

HepB3 92% 92% 96% 82% 85% 71% … … … …

Hib3 96% 96% 76% … … … … … … …

MCV 97% 97% 96% 98% 91% 87% 65% 78% 61% 27%

Pol3 96% 96% 96% 90% 90% 85% 67% 84% 55% 63%

PAB 71% 71% 70% 68% 62% 50% 42% 20% … …

BCG 2 months



MMR 1, 6 years



Td 6, 14 years

1,346,0001,311,000

74,816,0001920

13,730

…

2009 200881 81

100% 100%

0% 0%

0% 0%

100% 100%

98% 99%

100% 99%

88%

2003

6-14 y

97%


180

Turkmenistan





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 99% 99% 93% … … …

DTP1 99% 99% 99% 99% 99% 98% 97% … … …

DTP3 96% 96% 98% 98% 99% 97% 93% … … …

HepB3 97% 96% 98% 98% 99% … … … … …

Hib3 … … … … … … … … … …

MCV 99% 99% 99% 99% 99% 97% 92% … … …

Pol3 97% 96% 98% 98% 99% 98% 96% … … …

PAB … … … … … … … … … …




at 80% or above



BCG 2-3 days; 14 years

DT 6 years




OPV 2-3 days; 2, 3, 4, 18 months

Td 15, 25 years

111,000

105,000

5,110,000

42

45

6,990

…

99%………

2009 200864 61

100% 100%0% 0%0% 0%

100% 100%

100% 100%

100% 100%




181

Tuvalu








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 99% 99% 88% 96% 90% 99%

DTP1 99% 99% 99% 99% 99% 91% 95% 99% 76% 61%

DTP3 89% 99% 97% 97% 93% 82% 87% 99% 52% 36%

HepB3 92% 99% 97% 97% 79% 81% 49% … … …

Hib3 84% … … … … … … … … …

MCV 90% 93% 95% 84% 62% 81% 94% 95% 92% …

Pol3 99% 99% 97% 97% 99% 82% 85% 84% 97% 23%

PAB … … … … … … … … … …

BCG birth


DTwPHibHep 6, 10, 14 weeks (subnational)

HepB birth

MR 12, 18 months

OPV 6, 10, 14 weeks

TT 1st contact; +1, + 6 months; +1 year

…

…

10,000

29

35

…

0%

2009 20088 8

… 100%

… 0%

… 0%

… 100%

100% 100%

100% 100%

84%

2001

12-59 m

…


182

Uganda





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 90% 90% 90% 90% 90% 82% 83% 75% 37% …

DTP1 90% 90% 90% 90% 90% 80% 81% 72% 36% …

DTP3 64% 64% 64% 64% 64% 52% 59% 45% 14% …

HepB3 64% 64% 64% 64% 64% … … … … …

Hib3 64% 64% 64% 64% 64% … … … … …

MCV 68% 68% 68% 68% 68% 57% 57% 52% 17% …

Pol3 59% 59% 59% 59% 59% 55% 58% 45% 13% …

PAB 89% 85% 85% 83% 85% 70% 82% 41% 12% …




at 80% or above



BCG birth


HPV 10-12 years; +1, +5 months (females, subnational)

Measles 9 months


TT CBAW (15-49 years); +4, +6 weeks; +1, +1 year

Vitamin A 6, 12, 18, 24, 30, 36 months

1,502,000

1,394,000

32,710,000

79

128

1,190

13%

…2009

unknown104%

2009 200880 80

100% 99%4% 10%

38% 39%59% 50%

26% 24%

46% 45%




183

Ukraine








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 95% 95% 98% 97% 96% 99% 95% … … …

DTP1 94% 94% 98% 99% 98% 99% 98% … … …

DTP3 90% 90% 98% 98% 96% 99% 98% … … …

HepB3 84% 84% 92% 96% 97% 4% … … … …

Hib3 81% 81% 46% 11% … … … … … …

MCV 94% 94% 97% 98% 96% 99% 97% … … …

Pol3 91% 91% 98% 99% 95% 99% 97% … … …

PAB … … … … … … … … … …

BCG 3 days; 7, 14 years

Dip 23 years

DT 6 years

DTaP 18 months

DTaPHibIPV 3 months

DTwPHib 4, 5 months


Hib 4, 5, 18 months

IPV 3, 4 months

MMR 1, 6 years

Mumps 15 years

OPV 5, 18 months; 6, 14 years

Rubella 15 years

Td 14, 18 years

TT 60 years

468,000

462,000

45,708,000

13

15

6,190

…

2009 2008… 490

… …

… …

… …

… …

… …

… …

…

2008

15-29 y

…


184

United Arab Emirates





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 98% 98% 98% 98% 98% 98% 98% 96% 60% 15%

DTP1 98% 98% 98% 98% 98% 97% 96% 95% 91% 32%

DTP3 92% 92% 92% 92% 94% 94% 90% 85% 76% 11%

HepB3 92% 92% 92% 92% 92% 92% 90% … … …

Hib3 92% 92% 92% 92% 94% 92% … … … …

MCV 92% 92% 92% 92% 92% 94% 90% 80% 60% 34%

Pol3 94% 94% 94% 94% 94% 94% 90% 85% 74% 11%

PAB … … … … … … … … … …




at 80% or above



BCG birthDT 6 yearsDTwP 18 monthsDTwPHibHep 2, 4, 6 monthsHib 18 monthsInfluenza seasonal

(high-risk groups)Measles 9 monthsMenACWY pilgrimsMMR 15 months; 6 years




Td 15 years

Typhoid food handlers

Varicella high-risk groups


63,000

62,000

4,599,000

7

7

…

100%

…2001

9 m-18 y94%

2009 2008… 9… 100%… 0%… 0%… 100%

… 100%

… 100%




185

United Kingdom








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … …

DTP1 97% 97% 97% 97% 97% 97% 97% 94% 85% 66%

DTP3 93% 92% 92% 92% 91% 92% 94% 84% 65% 41%

HepB3 … … … … … … … … … …

Hib3 93% 92% 92% 92% 92% 92% 94% … … …

MCV 86% 86% 86% 85% 82% 88% 92% 87% 68% 53%

Pol3 93% 92% 92% 92% 92% 92% 96% 92% 95% 81%

PAB … … … … … … … … … …



DTaPIPV 3-5 years

HepB birth; 1, 2, 6 months(high-risk groups)

HibMenC 1 year

HPV 12-13 (3 doses) and17-18 years (females)

Influenza ≥65 years; +annual booster (high-risk groups)

MenACWY 3-24 or 6-24 months(pilgrims)

MenC_conj 3, 4 months



Pneumo_ps ≥65 years; high-risk groups

TdIPV 13-18 years

Varicella 1, 2 months; high-risk groups

749,000

745,000

61,565,000

5

6

37,360

…

2009 2008173 173

100% 95%

0% 0%

4% 4%

96% 92%

22% 23%

… …

79%

…

…

…


186

United States of America





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG … … … … … … … … … …

DTP1 98% 98% 98% 98% 98% 98% 98% 96% 98% 98%

DTP3 95% 95% 95% 95% 96% 94% 95% 90% 96% 96%

HepB3 92% 92% 92% 92% 92% 90% 68% … … …

Hib3 93% 93% 93% 93% 94% 93% 91% … … …

MCV 92% 92% 92% 92% 93% 91% 88% 90% 97% 86%

Pol3 93% 93% 93% 93% 92% 90% 88% 85% 96% 95%

PAB … … … … … … … … … …




at 80% or above



DTaP 2, 4, 6, 15-18 months; 4-6 years (or other combination vaccine)

HepA 12-23 months (2 doses);high-risk groups

HepB birth; 1-2, 6-18 monthsHib 2, 4, 6, 12-15 monthsHPV 11-12 years (females, 3 doses)Influenza 6-59 months; >50 years;

high-risk groupsIPV 2, 4, 6-18 months; 4-6 years

MenC_conj 11-12 years; high-risk groupsMMR 12-15 months; 4-6 yearsPneumo_conj 2, 4, 6, 12-15 months;

high-risk groupsPneumo_ps ≥2 years; high-risk groupsRotavirus 2, 4, 6 or 2, 4 monthsTdap 11-12 yearsVaricella 12-18 months; 4-6 years;

high-risk groups

4,413,000

4,387,000

314,659,000

7

8

46,730…

…………

2009 2008… …… …… …… …… …

… …

… …




187

Uruguay








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 99% 99% 99% 99% 99% 99% 99% 92% 56%

DTP1 99% 98% 98% 99% 99% 92% 97% 98% 84% 77%

DTP3 95% 94% 94% 95% 96% 90% 91% 97% 63% 53%

HepB3 95% 94% 94% 95% 96% 92% … … … …

Hib3 95% 94% 94% 95% 96% 88% … … … …

MCV 94% 95% 96% 94% 95% 89% 90% 97% 59% 50%

Pol3 95% 94% 94% 95% 96% 92% 91% 97% 58% 59%

PAB … … … … … … … … … …

BCG birth

DT pertussis contraindication

DTwP 5 years


HepA 15, 21 months

HepB 12 years; +1, +6 months

Influenza 6-59 months; >65 years;high-risk groups

MMR 1, 5 years




Rabies high-risk groups;post-exposure

Td 12 years; +every 10 yearsas booster

Varicella 1 year

50,000

49,000

3,361,000

11

13

12,910

…

2009 2008275 275

100% 100%

0% 0%

0% 0%

100% 100%

100% 100%

100% 100%

…

2003

1-4 y

94%


188

Uzbekistan





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 99% 96% 99% 99% 93% 98% 99% … … …

DTP1 98% 98% 98% 96% 99% 98% 96% … … …

DTP3 98% 98% 96% 96% 99% 99% 87% … … …

HepB3 98% 91% 99% 98% 99% … … … … …

Hib3 98% … … … … … … … … …

MCV 95% 98% 98% 98% 99% 99% 91% … … …

Pol3 99% 98% 98% 94% 99% 99% 99% … … …

PAB … … … … … … … … … …




at 80% or above



BCG birth; 7, 14 years

DTwP 16 months


HepB birth


MenA high-risk groups

MMR 1, 6 years

OPV 3 days; 2, 3, 4, 16 months; 7 years

Td 7, 16 years

Typhoid high-risk groups

558,000

532,000

27,488,000

32

36

2,890

58%

8%………

2009 2008199 199

100% 100%0% 0%0% 0%

100% 100%

89% 91%

100% 75%




189

Vanuatu








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 81% 81% 81% 81% 81% 79% 67% 96% 83% …

DTP1 78% 78% 78% 78% 79% 85% 90% 91% 55% …

DTP3 68% 68% 68% 68% 68% 71% 73% 76% 30% …

HepB3 59% 59% 59% 59% 61% 70% 66% … … …

Hib3 … … … … … … … … … …

MCV 52% 52% 52% 52% 53% 61% 60% 66% 26% …

Pol3 67% 67% 67% 67% 67% 67% 74% 78% 27% …

PAB 73% 73% 73% 88% 84% 86% 33% 47% 19% …

BCG birth




Measles 1 year

OPV 6, 10, 14 weeks; 6, 12 years

Td 6, 7 years


7,000

7,000

240,000

14

16

4,280

100%

2009 20086 6

100% 100%

0% …

33% 100%

67% …

33% …

0% 0%

…

2006

1-12 y

99%


190

Venezuela, Bolivarian Republic of





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 87% 90% 82% 83% 95% 99% 91% 82% 89% 72%

DTP1 83% 79% 69% 78% 98% 92% 87% 84% 73% 79%

DTP3 83% 50% 65% 71% 87% 77% 68% 63% 49% 56%

HepB3 83% 50% 65% 71% 88% 5% … … … …

Hib3 83% 50% 65% 71% 87% 2% … … … …

MCV 83% 93% 56% 55% 76% 84% 47% 61% 56% 50%

Pol3 73% 76% 67% 73% 80% 86% 85% 72% 59% 95%

PAB 50% 52% 51% 49% 51% … … … … …




at 80% or above



BCG birth

DT 1st contact; +1, +6 months;+1, +1 year

DTwP 5 years


HepB 1st contact; +2,+4 months

Influenza 6, 7 months; adults (seasonally)

MMR 1, 5 years


Pneumo_ps ≥60 years; +5 years


Td 1st contact; +1, +6 months; +1, +1 year

Yellow fever 1 year

600,000

590,000

28,583,000

15

18

12,370

100%

6%20092-5 y23%

2009 2008367 367

100% 100%9% …

44% …47% 0%

30% 0%

72% …




191

Viet Nam








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 97% 92% 94% 95% 95% 98% 96% 90% 50% …

DTP1 97% 97% 92% 94% 98% 97% 97% 96% 67% …

DTP3 96% 93% 92% 94% 95% 96% 93% 88% 42% …

HepB3 94% 87% 67% 93% 94% … … … … …

Hib3 … … … … … … … … … …

MCV 97% 92% 83% 93% 95% 97% 95% 88% 19% …

Pol3 97% 93% 92% 94% 94% 96% 94% 88% 62% …

PAB 87% 84% 86% 87% 86% 86% 80% 24% … …

BCG birth

DTwP 2, 3, 4 months


JE 1 year; +2 weeks; +2 years(subnational)


OPV 2, 3, 4 months

TT pregnancy; +1, +6 months; +1, +1 year

Typhoid 2 years (subnational)

Vitamin A 6-11, 12-17, 18-23, 24-29,30-36 months

1,485,000

1,457,000

88,069,000

20

24

2,850

80%

2009 2008690 684

100% 100%

1% 1%

2% 2%

97% 97%

94% 96%

96% 96%

96%

…

…

…


192

Yemen





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 58% 60% 64% 67% 66% 87% 60% 95% 20% 9%

DTP1 77% 78% 79% 77% 78% 71% 69% 94% 33% 18%

DTP3 66% 67% 67% 65% 65% 61% 44% 84% 12% 1%

HepB3 66% 67% 67% 65% 66% 12% … … … …

Hib3 67% 68% 68% 66% 55% … … … … …

MCV 58% 62% 63% 57% 65% 62% 40% 69% 13% 2%

Pol3 65% 66% 66% 64% 65% 61% 44% 84% 12% 1%

PAB 66% 63% 52% 56% 59% 54% 30% 17% 3% …




at 80% or above



BCG birth






861,000

813,000

23,580,000

51

66

2,340

35%

44%2009

9-59 m96%

2009 2008333 333

100% 100%6% 3%

26% 31%68% 66%

6% 11%

68% 65%




193

Zambia








at 80% or above





2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 92% 92% 92% 92% 92% 94% 97% 97% 92% …

DTP1 92% 92% 92% 92% 92% 94% 97% 97% 86% …

DTP3 81% 81% 81% 81% 82% 85% 86% 91% 66% …

HepB3 80% 80% 80% 80% 82% … … … … …

Hib3 81% 81% 81% 81% 82% … … … … …

MCV 85% 85% 85% 85% 85% 85% 86% 90% 58% …

Pol3 83% 83% 83% 83% 84% 85% 84% 90% 61% …

PAB 90% 90% 89% 90% 91% 78% 85% 62% … …

BCG birth


Measles 9 months

OPV 6, 10, 14 weeks

TT 1st contact pregnancy; +1, +1,+6 months; +1, +1 year

Vitamin A 6, 12, 18, 24, 30, 36 months

549,000

500,000

12,935,000

86

141

1,280

95%

2009 200872 72

100% 97%

1% 1%

13% 19%

86% 76%

56% 44%

63% …

…

2007

9-59 m

109%


194

Zimbabwe





2009

2009 2008 2007 2006 2005 2000 1995 1990 1985 1980

BCG 91% 91% 86% 81% 76% 85% 96% 91% 76% …

DTP1 87% 89% 85% 81% 77% 85% 96% 96% 84% …

DTP3 73% 75% 72% 68% 65% 79% 88% 88% 63% …

HepB3 73% 75% 71% 68% 64% 78% 1% … … …

Hib3 73% 75% … … … … … … … …

MCV 76% 70% 69% 67% 66% 75% 87% 87% 78% …

Pol3 69% 75% 72% 70% 67% 79% 88% 89% 63% …

PAB 76% 76% 78% 78% 77% 76% 42% 57% 44% …




at 80% or above



BCG birth

DT 5 years

DTwP 18 months


Measles 9 months



Vitamin A 6, 18, 24, 30, 36, 42 months; post-partum

379,000

359,000

12,523,000

56

90

…

0%

…2009

9-59 m92%

2009 200860 62

98% 97%3% 13%

52% 53%45% 31%

22% 5%

20% 45%




195

GLOSSARY OF ACRONYMS

Note: Compound acronyms denote vaccine combinations.‘DTPHibHepIPV’, for example, denotes DTP, Hib, HepB and IPVvaccines combined.

AMC advanced market commitmentaP acellular pertussis vaccine

BCG bacille Calmette-Guérin (vaccine against tuberculosis)

CBAW childbearing-aged women; refers to ages 15-45 unless otherwise noted

Dip diphtheria toxoid vaccine

DT diphtheria toxoidDTaP diphtheria and tetanus toxoid with acellular

pertussis vaccineDTP diphtheria and tetanus toxoid with pertussis

vaccineDTP1 first dose of diphtheria and tetanus toxoid with

pertussis vaccine

DTP3 third dose of diphtheria and tetanus toxoid with pertussis vaccine

DTwP diphtheria and tetanus toxoid with whole-cell pertussis vaccine

EPI Expanded Programme on Immunization

GAVI Global Alliance for Vaccines and Immunisation

GNI gross national income (US$)

HepA hepatitis A vaccine

HepB hepatitis B vaccine

HepB3 third dose of hepatitis B vaccine

Hib Haemophilus influenzae type b vaccine

Hib3 third dose of Haemophilus influenzae type b vaccine

HPV human papilloma virus vaccineIPV inactivated polio vaccineJE Japanese encephalitis

MCV measles-containing vaccineMCV2 second dose of measles-containing vaccineMenA meningococcal A vaccine; this monovalent vaccine

protects against meningitis serogroup A

MenAC meningococcal AC vaccine; this bivalent vaccine protects against meningitis serogroups A and C

MenACWY meningococcal ACWY vaccine; this quadrivalent vaccine protects against meningitis serogroups A, C, Y and W-135

MenBC meningococcal BC vaccine; this bivalent vaccine protects against meningitis serogroups B and C

MenC meningococcal C vaccine; this monovalent vaccine protects against meningitis serogroup C

MenC_conj meningococcal C conjugate vaccine


ImthHethin

Thpr

MMAd

196

Glossary of acronyms, continued

MM measles and mumps vaccine

MMR measles-mumps-rubella vaccine

MMRV measles-mumps-rubella-varicella vaccine

MR measles and rubella vaccine

OPV oral polio vaccine

PAB protected at birth against tetanus

Pneumo_conj pneumococcal conjugate vaccine

Pneumo_ps pneumococcal polisaccharide vaccine

Pol3 third dose of poliomyelitis vaccine

PPP purchasing power parity

Pw whole-cell pertussis vaccine

TBD to be determined

TBE tick-borne encephalitis vaccine

Td tetanus toxoid with reduced amount of diphtheriatoxoid

Tdap tetanus toxoid vaccine (full dose) with acellularpertussis vaccine (reduced dose)

TT tetanus toxoid

UNICEF United Nations Children's Fund

WHO World Health Organization


Immunization Summary for 2009 data – jointly produced bythe United Nations Children’s Fund (UNICEF) and the WorldHealth Organization (WHO) – presents detailed statistics onthe performance of national and local immunization systemsin 194 countries and territories.

The attached CD-ROM complements the print version andprovides such reports and forms as:

• Excel worksheets containing WHO/UNICEFcoverage estimates with data for all years since 1980, plus reported data that include district-level performance indicators, supply and safety indicators, survey data and national immunizationschedules for 2008-2009.

• Samples of the WHO/UNICEF Joint Reporting Form on Immunization in English, French and Spanish.

• National Immunization Coverage Final Report (PDF) for each country or territory.

• Full-text version of Immunization Summary: A Statistical Reference containing data through 2009.

Minimum technical requirements:Microsoft® Office (Microsoft® Excel and Word)Adobe® Acrobat® (for PDF downloads)

197


rev3878 UNICEF BACK CVRS.indd 2 1/20/11 2:26 AM

Further information on the publication can be obtained from:

UNICEF Statistics and Monitoring SectionDivision of Policy and Practice3 United Nations PlazaNew York, NY 10017, [email protected]: +1-212-326-7000

World Health Organization (WHO)20 Avenue AppiaCH-1211 Geneva 27, [email protected]: +41-22-791-2111

© The United Nations Children’s Fund (UNICEF) January 2011


IMMUNIZATION SUMMARY - UNICEF DATA · IMMUNIZATION SUMMARY A statistical reference containing data...

Documents

Transcript of IMMUNIZATION SUMMARY - UNICEF DATA · IMMUNIZATION SUMMARY A statistical reference containing data...